Nothing Special   »   [go: up one dir, main page]

WO1998007864A1 - Recombinant toxin fragments - Google Patents

Recombinant toxin fragments Download PDF

Info

Publication number
WO1998007864A1
WO1998007864A1 PCT/GB1997/002273 GB9702273W WO9807864A1 WO 1998007864 A1 WO1998007864 A1 WO 1998007864A1 GB 9702273 W GB9702273 W GB 9702273W WO 9807864 A1 WO9807864 A1 WO 9807864A1
Authority
WO
WIPO (PCT)
Prior art keywords
asn
leu
lys
glu
asp
Prior art date
Application number
PCT/GB1997/002273
Other languages
French (fr)
Inventor
Clifford Charles Shone
Conrad Padraig Quinn
Keith Alan Foster
Original Assignee
Microbiological Research Authority Camr (Centre For Applied Microbiology & Research)
The Speywood Laboratory Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU43895/97A priority Critical patent/AU723397B2/en
Priority to AT97942094T priority patent/ATE294238T1/en
Priority to DK97942094T priority patent/DK0939818T3/en
Priority to EP97942094A priority patent/EP0939818B1/en
Priority to JP1998510524A priority patent/JP4273250B6/en
Priority to DE69733146T priority patent/DE69733146T2/en
Priority to CA2264191A priority patent/CA2264191C/en
Application filed by Microbiological Research Authority Camr (Centre For Applied Microbiology & Research), The Speywood Laboratory Limited filed Critical Microbiological Research Authority Camr (Centre For Applied Microbiology & Research)
Publication of WO1998007864A1 publication Critical patent/WO1998007864A1/en
Priority to US09/255,829 priority patent/US6461617B1/en
Priority to US10/241,596 priority patent/US7192596B2/en
Priority to US11/077,550 priority patent/US7674470B2/en
Priority to US11/644,010 priority patent/US20070248626A1/en
Priority to US11/717,713 priority patent/US7897158B2/en
Priority to US12/174,896 priority patent/US8454976B2/en
Priority to US12/360,470 priority patent/US8017134B2/en
Priority to US12/369,341 priority patent/US8012491B2/en
Priority to US12/399,542 priority patent/US8012479B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Definitions

  • This invention relates to recombinant toxin fragments, to DNA encoding these fragments and to their uses such as in a vaccine and for in vitro and in vivo purposes
  • the clostndial neurotoxins are potent inhibitors of calcium-dependent neurotransmitter secretion in neuronal cells. They are currently considered to mediate this activity through a specific endoproteolytic cleavage of at least one of three vesicle or pre-synaptic membrane associated proteins VAMP, syntaxin or SNAP-25 which are central to the vesicle docking and membrane fusion events of neurotransmitter secretion.
  • the neuronal cell targeting of tetanus and botulinum neurotoxins is considered to be a receptor mediated event following which the toxins become internalised and subsequently traffic to the appropriate intracellular compartment where they effect their endopeptidase activity.
  • the clostndial neurotoxins share a common architecture of a catalytic L-chain (LC, ca 50 kDa) disulphide linked to a receptor binding and translocating H-chain (HC, ca 1 00 kDa) .
  • LC catalytic L-chain
  • HC receptor binding and translocating H-chain
  • the HC polypeptide is considered to comprise all or part of two distinct functional domains.
  • the carboxy-terminal half of the HC (ca 50 kDa), termed the H c domain, is involved in the high affinity, neurospecific binding of the neurotoxin to cell surface receptors on the target neuron, whilst the amino-termmal half, termed the H N domain (ca 50 kDa), is considered to mediate the translocation of at least some portion of the neurotoxin across cellular membranes such that the functional activity of the LC is expressed within the target cell.
  • the H N domain also has the property, under conditions of low pH, of forming ion-permeabie channels in lipid membranes, this may in some manner relate to its translocation function.
  • BoNT/A botulinum neurotoxin type A
  • these domains are considered to reside within ammo acid residues 872-1296 for the H c , ammo acid residues 449-871 for the H N and residues 1 -448 for the LC.
  • Digestion with trypsin effectively degrades the H c domain of the BoNT/A to generate a non-toxic fragment designated LH N , which is no longer able to bind to and enter neurons (Fig . 1 ) .
  • the LH N fragment so produced also has the property of enhanced solubility compared to both the parent holotoxin and the isolated LC.
  • -a metalloprotease exhibiting high substrate specificity for vesicle and/or plasma - membrane associated proteins involved in the exocytotic process.
  • it cleaves one or more of SNAP-25, VAMP (synaptobrevin / cellubrevin) and syntaxin.
  • the domain responsible for translocation of the endopeptidase activity following binding of neurotoxin to its specific cell surface receptor via the binding domain, into the target cell.
  • synaptotagmin may be the receptor for botulinum neurotoxin type B. It is probable that each of the neurotoxins has a different receptor.
  • the present invention seeks to overcome or at least ameliorate problems associated with production and handling of clostridial toxin.
  • the invention provides a polypeptide comprising first and second domains, wherein said first domain is adapted to cleave one or more vesicle or plasma-membrane associated proteins essential to neuronal exocytosis and wherein said second domain is adapted (i) to translocate the polypeptide into the cell or (ii) to increase the solubility of the polypeptide compared to the solubility of the first domain on its own or (iii) both to translocate the polypeptide into the cell and to increase the solubility of the polypeptide compared to the solubility of the first domain on its own, said polypeptide being free of clostridial neurotoxin and free of any clostridial neurotoxin precursor that can be converted into toxin by proteolytic action.
  • the invention may thus provide a single polypeptide chain containing a domain equivalent to a clostridial toxin light chain and a domain providing the functional aspects of the H N of a clostridial toxin heavy chain, whilst lacking the functional aspects of a clostridial toxin H c domain.
  • the functional property or properties of the H of a clostridial toxin heavy chain that are required to be exhibited by the second domain of the polypeptide of the invention are either (i) translocation of the polypeptide into a cell, or (ii) increasing solubility of the polypeptide compared to solubility of the first domain on its own or (iii) both (i) and (ii) .
  • References hereafter to a H N domain or to the functions of a H N domain are references to this property or properties.
  • the second domain is not required to exhibit other properties of the H N domain of a clostridial toxin heavy chain.
  • a polypeptide of the invention can thus be soluble but lack the translocation function of a native toxin-this is of use in providing an immunogen for vaccinating or assisting to vaccinate an individual against challenge by toxin
  • a polypeptide designated LH 423 /A elicited neutralising antibodies against type A neurotoxin In a specific embodiment of the invention described in an example below a polypeptide designated LH 423 /A elicited neutralising antibodies against type A neurotoxin.
  • a polypeptide of the invention can likewise thus be relatively insoluble but retain the translocation function of a native toxin - this is of use if solubility is imparted to a composition made up of that polypeptide and one or more other components by one or more of said other components.
  • the first domain of the polypeptide of the invention cleaves one or more vesicle or plasma-membrane associated proteins essential to the specific cellular process of exocytosis, and cleavage of these proteins results in inhibition of exocytosis, typically in a non-cytotoxic manner.
  • the cell or cells affected are not restricted to a particular type or subgroup but can include both neuronal and non-neuronal cells.
  • the activity of clostridial neurotoxins in inhibiting exocytosis has., indeed, been observed almost universally in eukaryotic cells expressing a relevant cell surface receptor, including such diverse cells as from Aplysia (sea slug), Drosophila (fruit fly) and mammalian nerve cells, and the activity of the first domain is to be understood as including a corresponding range of cells.
  • the polypeptide of the invention may be obtained by expression of a recombinant nucleic acid, preferably a DNA, and is a single polypeptide, that is to say not cleaved into separate light and heavy chain domains.
  • the polypeptide is thus available in convenient and large quantities using recombinant techniques.
  • said first domain preferably comprises a clostridial toxin light chain or a fragment or variant of a clostridial toxin light chain .
  • the fragment is optionally an N-terminal, or C-terminal fragment of the light chain, or is an internal fragment, so long as it substantially retains the ability to cleave the vesicle or plasma-membrane associated protein essential to exocytosis.
  • the minimal domains necessary for the activity of the light chain of clostridial toxins are described in J. Biol. Chem., Vol.267, No. 21 , July 1 992, pages 1 4721 - 14729.
  • the variant has a different peptide sequence from the light chain or from the fragment, though it too is capable of cleaving the vesicle or plasma-membrane associated protein. It is conveniently obtained by insertion, deletion and/or substitution of a light chain or fragment thereof.
  • a variant sequence comprises (i) an N-terminal extension to a clostridial toxin light chain or fragment (ii) a clostridial toxin light chain or fragment modified by alteration of at least one amino acid (iii) a C-terminal extension to a clostridial toxin light chain or fragment, or (iv) combinations of 2 or more of (i)-(iii) .
  • the variant contains an amino acid sequence modified so that (a) there is no protease sensitive region between the LC and H N components of the polypeptide, or (b) the protease sensitive region is specific for a particular protease.
  • This latter embodiment is of use if it is desired to activate the endopeptidase activity of the light chain in a particular environment o ⁇ cell.
  • the polypeptides of the invention are activated prior to administration.
  • the first domain preferably exhibits endopeptidase activity specific for a substrate selected from one or more of SNAP-25, synaptobrevin/VAMP and syntaxin.
  • the clostridial toxin is preferably botulinum toxin or tetanus toxin.
  • the toxin light chain and the portion of the toxin heavy chain are of botulinum toxin type A.
  • the toxin light chain and the portion of the toxin heavy chain are of botulinum toxin type B.
  • the polypeptide optionally comprises a light chain or fragment or variant of one toxin type and a heavy chain or fragment or variant of another toxin type.
  • said second domain preferably comprises a clostridial toxin heavy chain H N portion or a fragment or variant of a clostridial toxin heavy chain H N portion .
  • the fragment is optionally an N-terminal or C-terminal or internal fragment, so long as it retains the function of the H N domain
  • Teachings of regions within the H N responsible for its function are provided for example in Biochemistry 1 995, 34, pages 1 51 75- 1 51 81 and Eur. J Biochem, 1 989, 1 85, pages 1 97-203.
  • the variant has a different sequence from the H N domain or fragment, though it too retains the function of the H N domain It is conveniently obtained by insertion, deletion and/or substitution of a H N domain or fragment thereof.
  • it comprises (i) an N-terminal extension to a H N domain or fragment, (ii) a C-terminal extension to a H N domain or fragment, (iii) a modification to a H N domain or fragment by alteration of at least one ammo acid, or (iv) combinations of 2 or more of (i)-(i ⁇ i) .
  • the clostridial toxin is preferably botulinum toxin or tetanus toxin.
  • the invention also provides a polypeptide comprising a clostridial neurotoxin light chain and a N-terminal fragment of a clostridial neurotoxin heavy chain, the fragment preferably comprising at least 423 of the N-terminal ammo acids of the heavy chain of botulinum toxin type A, 41 7 of the N-terminal amino acids of the heavy chain of botulinum toxin type B or the equivalent number of N-terminal am o acids of the heavy chain of other types of clostridial toxin such that the fragment possesses an equivalent alignment of homologous ammo acid residues.
  • polypeptides of the invention are thus not composed of two or more polypeptides, linked for example by di-sulphide bridges into composite molecules. Instead, these polypeptides are single chains and are not active or their activity is significantly reduced in an in vitro assay of neurotoxin endopeptidase activity.
  • polypeptides may be susceptible to be converted into a form exhibiting endopeptidase activity by the action of a proteolytic agent, such as trypsin In this way it is possible to control the endopeptidase activity of the toxin light chain.
  • a proteolytic agent such as trypsin
  • polypeptide lacking a portion designated H c of a clostridial toxin heavy chain This portion, seen in the naturally produced toxin, is responsible for binding of toxin to cell surface receptors prior to interna sation of the toxin .
  • This specific embodiment is therefore adapted so that it can not be converted into active toxin, for example by the action of a proteolytic enzyme
  • the invention thus also provides a polypeptide comprising a clostndial toxin light chain and a fragment of a clostndial toxin heavy chain, said fragment being not capable of binding to those cell surface receptors involved in the intoxicating action of clostndial toxin, and it is preferred that such a polypeptide lacks an intact portion designated H c of a clostridial toxin heavy chain.
  • compositions containing a polypeptide comprising a clostridial toxin light chain and a portion designated H N of a clostndial toxin heavy chain, and wherein the composition is free of clostndial toxin and free of any clostridial toxin precursor that may be converted into clostridial toxin by the action of a proteolytic enzyme.
  • these compositions include those containing toxin light chain and H N sequences of botulinum toxin types A, B, C, , D, E, F and G.
  • polypeptides of the invention are conveniently adapted to bind to, or include, a ligand for targeting to desired cells.
  • the polypeptide optionally comprises a sequence that binds to, for example, an immunoglobu n.
  • a suitable sequence is a tandem repeat synthetic IgG binding domain derived from domain B of Staphylococcal protein A. Choice of immunoglobuhn specificity then determines the target for a polypeptide - immunoglobuhn complex.
  • the - o - polypeptide comprises a non-clostridial sequence that binds to a cell surface receptor, suitable sequences including insulin-like growth factor-1 (IGF-1 ) which binds to its specific receptor on particular cell types and the 1 4 amino acid residue sequence from the carboxy-terminus of cholera toxin A subunit which is able to bind the cholera toxin B subunit and thence to GM 1 gangliosides.
  • IGF-1 insulin-like growth factor-1
  • a polypeptide according to the invention thus, optionally, further comprises a third domain adapted for binding of the polypeptide to a cell.
  • the invention provides a fusion protein comprising a fusion of (a) a polypeptide of the invention as described above with (b) a second polypeptide adapted for binding to a chromatography matrix so as to enable purification of the fusion protein using said chromatography matrix. It is convenient for the second polypeptide to be adapted to bind to an affinity matrix, such as a glutathione Sepharose, enabling rapid separation and purification of the fusion protein from an impure source, such as a cell extract or supernatant.
  • an affinity matrix such as a glutathione Sepharose
  • GST glutathione-S-transferase
  • a third aspect of the invention provides a composition comprising a derivative of a clostridial toxin, said derivative retaining at least 10% of the endopeptidase activity of the clostridial toxin, said derivative further being non-toxic in vivo due to its inability to bind to cell surface receptors, and wherein the composition is free of any component, such as toxin or a further toxin derivative, that is toxic in vivo.
  • the activity of the derivative preferably approaches that of natural toxin, and is thus preferably at least 30% and most preferably at least 60% of natural toxin.
  • the overall endopeptidase activity of the composition will, of course, also be determined by the amount of the derivative that is present. While it is known to treat naturally produced clostridial toxin to remove the H domain, this treatment does not totally remove toxicity of the preparation, instead some residual toxin activity remains. Natural toxin treated in this way is therefore still not entirely safe.
  • composition of the invention derived by treatment of a pure source of polypeptide advantageously is free of toxicity, and can conveniently be used as a positive control in a toxin assay, as a vaccine against clostridial toxin or for other purposes where it is essential that there is no residual toxicity in the composition.
  • the invention enables production of the polypeptides and fusion proteins of the invention by recombinant means.
  • a fourth aspect of the invention provides a nucleic acid encoding a polypeptide or a fusion protein according to any of the aspects of the invention described above.
  • a DNA sequence provided to code for the polypeptide or fusion protein is not derived from native clostridial sequences, but is an artificially derived sequence not preexisting in nature.
  • a specific DNA (SEQ ID NO: 1 ) described in more detail below encodes a polypeptide or a fusion protein comprising nucleotides encoding residues 1 -871 of a botulinum toxin type A.
  • Said polypeptide comprises the light chain domain and the first 423 amino acid residues of the amino terminal portion of a botulinum toxin type A heavy chain.
  • This recombinant product is designated LH 423 /A (SEQ ID NO: 2) .
  • a DNA sequence which codes for the polypeptide or fusion protein is derived from native clostridial sequences but codes for a polypeptide or fusion protein not found in nature.
  • a specific DNA (SEQ ID NO: 1 9) described in more detail below encodes a polypeptide or a fusion protein and comprises nucleotides encoding residues 1 - 1 1 71 of a botulinum toxin type B. Said polypeptide comprises the light chain domain and the first 728 am o acid residues of the ammo terminal protein of a botulinum type B heavy chain. This recombinant product is designated LH 728 /B (SEQ ID NO: 20) .
  • the invention thus also provides a method of manufacture of a polypeptide comprising expressing in a host cell a DNA according to the third aspect of the invention.
  • the host cell is suitably not able to cleave a polypeptide or fusion protein of the invention so as to separate light and heavy toxin chains; for example, a non-clostridial host.
  • the invention further provides a method of manufacture of a polypeptide comprising expressing in a host cell a DNA encoding a fusion protein as described above, purifying the fusion protein by elution through a chromatography column adapted to retain the fusion protein, eluting through said chromatography column a ligand adapted to displace the fusion protein and recovering the fusion protein. Production of substantially pure fusion protein is thus made possible. Likewise, the fusion protein is readily cleaved to yield a polypeptide of the invention, again in substantially pure form, as the second polypeptide may conveniently be removed using the same type of chromatography column.
  • the LH N /A derived from dichain native toxin requires extended digestion with trypsin to remove the C-terminal 1 /2 of the heavy chain, the H c domain.
  • the loss of this domain effectively renders the toxin inactive in vivo by preventing its interaction with host target cells.
  • There is, however, a residual toxic activity which may indicate a contaminating, trypsin insensitive, form of the whole type A neurotoxin.
  • the recombinant preparations of the invention are the product of a discreet, defined gene coding sequence and can not be contaminated by full length toxin protein.
  • the product as recovered from E. coli, and from other recombinant expression hosts is an inactive single chain peptide or if expression hosts produce a processed, active polypeptide it is not a toxin. Endopeptidase activity of LH 423 /A, as assessed by the current in vitro peptide cleavage assay, is wholly dependent on activation of the recombinant molecule between residues 430 and 454 by trypsin.
  • proteolytic enzymes that cleave between these two residues are generally also suitable for activation of the recombinant molecule Trypsin cleaves the peptide bond C-terminal to Argmine or C-terminal to Lysme and is suitable as these residues are found in the 430-454 region and are exposed (see
  • the recombinant polypeptides of the invention are potential therapeutic agents for targeting to cells expressing the relevant substrate but which are not implicated in effecting botulism.
  • An example might be where secretion of neurotransmitter is inappropriate or undesirable or alternatively where a neuronal cell is hyperactive in terms of regulated secretion of substances other than neurotransmitter.
  • the function of the H c domain of the native toxin could be replaced by an alternative targeting sequence providing, for example, a cell receptor hgand and/or translocation domain.
  • recombinant polypeptides of the invention will be as a reagent component for synthesis of therapeutic molecules, such as disclosed in WO-A-94/21 300.
  • the recombinant product will also find application as a non-toxic standard for the assessment and development of in vitro assays for detection of functional botulinum or tetanus neurotoxins either in foodstuffs or in environmental samples, for example as disclosed in EP-A-07631 31 .
  • a further option is addition, to the C-terminal end of a polypeptide of the invention, of a peptide sequence which allows specific chemical conjugation to targeting gands of both protein and non-protein origin.
  • an alternative targeting hgand is added to the N- terminus of polypeptides of the invention.
  • Recombinant LH N derivatives have been designated that have specific protease cleavage sites engineered at the C-termmus of the LC at the putative trypsin sensitive region and also at the extreme C- terminus of the complete protein product. These sites will enhance the activational specificity of the recombinant product such that the dichain species can only be activated by proteolytic cleavage of a more predictable nature than use of trypsin.
  • the LH N enzymatically produced from native BoNT/A is an efficient immunogen and thus the recombinant form with its total divorce from any full length neurotoxin represents a vaccine component.
  • the recombinant product may serve as a basal reagent for creating defined protein modifications in support of any of the above areas.
  • Recombinant constructs are assigned distinguishing names on the basis of their amino acid sequence length and their Light Chain (L-chain, L) and Heavy Chain (H- chain, H) content as these relate to translated DNA sequences in the public domain or specifically to SEQ ID NO: 2 and SEQ ID NO: 20.
  • the ' LH' designation is followed by 7X ' where 'X' denotes the corresponding clostridial toxin serotype or class, e.g . 'A' for botulinum neurotoxin type A or 'TeTx' for tetanus toxin.
  • Sequence variants from that of the native toxin polypeptide are given in parenthesis in standard format, namely the residue position number prefixed by the residue of the native sequence and suffixed by the residue of the variant.
  • Subscript number prefixes indicate an amino-terminal (N-terminal) extension, or where negative a deletion, to the translated sequence.
  • subscript number suffixes indicate a carboxy terminal (C-terminal) extension or where negative numbers are used, a deletion.
  • Specific sequence inserts such as protease cleavage sites are indicated using abbreviations, e.g. Factor Xa is abbreviated to FXa.
  • L- chain C-terminal suffixes and H-chain N-terminal prefixes are separated by a 7 to indicate the predicted junction between the L and H-chains.
  • Abbreviations for engineered ligand sequences are prefixed or suffixed to the clostridial L-chain or H- chain corresponding to their position in the translation product.
  • LH ⁇ 4 2 overcomes this nomenclature, LH ⁇ 4 2 devis3/'A SEQ ID NO: 2, containing the entire L-chain and 423 ammo acids of the H-chain of botulinum neurotoxin type A;
  • 2L-FXa 2H 2 3 A a further variant containing a two amino acid extension to the N-terminus of the L-chain, and a Factor Xa cleavage sequence at the C-terminus of the L-chain which, after cleavage of the molecule with Factor Xa leaves a two ammo acid N-terminal extension to the H- chain component; and
  • Fig. 1 shows a schematic representation of the domain structure of botulinum neurotoxin type A (BoNT/A);
  • Fig. 2 shows a schematic representation of assembly of the gene for an embodiment of the invention designated LH 423 /A;
  • Fig. 3 is a graph comparing activity of native toxin, trypsin generated
  • “native” LH N /A and an embodiment of the invention designated 2 LH 423 /A (Q 2 E,N 26 K,A 27 Y) in an in vitro peptide cleavage assay;
  • Fig. 4 is a comparison of the first 33 amino acids in published sequences of native toxin and embodiments of the invention.
  • Fig. 5 shows the transition region of an embodiment of the invention designated L/ 4 H 423 /A illustrating insertion of four amino acids at the N-terminus of the H N sequence; amino acids coded for by the Eco 47 III restriction endonuclease cleavage site are marked and the H N sequence then begins ALN...;
  • Fig . 6 shows the transition region of an embodiment of the invention designated L FXa/3 H 423 /A illustrating insertion of a Factor Xa cleavage site at the C-terminus of the L-chain, and three additional amino acids coded for at the N-terminus of the H- sequence; the N-terminal amino acid of the cleavage-activated H N will be cysteine;
  • Fig. 7 shows the C-terminal portion of the amino acid sequence of an embodiment of the invention designated L FXa/3 H 423 /A-IGF-1 , a fusion protein; the IGF-1 sequence begins at position G 882 ;
  • Fig. 8 shows the C-terminal portion of the amino acid sequence of an embodiment of the invention designated L FXa/3 H 423 /A-CtxA14, a fusion protein; the C-terminal CtxA sequence begins at position Q 882 ;
  • Fig.9 shows the C-termi ⁇ al portion of the amino acid sequence ofan embodiment of the invention designated L FXa/3 H 423 /A-ZZ, a fusion protein; the C-terminal ZZ sequence begins at position A 890 immediately after a genenase recognition site (underlined);
  • FIGS. 1 0 & 1 1 show schematic representations of manipulations of Figs. 1 0 & 1 1 polypeptides of the invention
  • Fig. 1 0 shows LH 423 /A with N-terminal addition of an affinity purification peptide (in this case GST) and C-terminal addition of an Ig binding domain
  • protease cleavage sites R1 , R2 and R3 enable selective enzymatic separation of domains
  • FIG. 1 1 shows specific examples of protease cleavage sites R1 , R2 and R3 and a C-terminal fusion peptide sequence
  • Fig. 12 shows the trypsin sensitive activation region of a polypeptide of the invention
  • Fig. 13 shows Western blot analysis of recombinant LH 107 /B expressed from E.coli; panel A was probed with anti- BoNT/B antiserum; Lane 1 , molecular weight standards; lanes 2 & 3, native BoNT/B; lane 4, immunopurified LH 107 /B; panel B was probed with anti-T7 peptide tag antiserum; lane 1 , molecular weight standards; lanes 2 & 3, positive control E.coli T7 expression; lane 4 immunopurified LH 107 /B.
  • N-terminal portion is shown in Fig. 4.
  • a 261 6 base pair, double stranded gene sequence (SEQ ID NO: 1 ) has been assembled from a combination of synthetic , chromosomal and polymerase-chain-reaction generated DNA ( Figure 2) .
  • the gene codes for a polypeptide of 871 amino acid residues corresponding to the entire light-chain (LC, 448 amino acids) and 423 residues of the amino terminus of the heavy-chain (H c ) of botulinum neurotoxin type A. This recombinant product is designated the LH 423 /A fragment (SEQ ID NO: 2).
  • the first 91 8 base pairs of the recombinant gene were synthesised by concatenation of short oligonucleotides to generate a coding sequence with an E. coli codon bias. Both DNA strands in this region were completely synthesised as short overlapping oligonucleotides which were phosphorylated, annealed and ligated to generate the full synthetic region ending with a unique Kpn ⁇ restriction site.
  • the remainder of the LH 423 /A coding sequence was PCR amplified from total chromosomal DNA from Clostridium botulinum and annealed to the synthetic portion of the gene.
  • the internal PCR amplified product sequences were then deleted and replaced with the native, fully sequenced, regions from clones of C. botulinum chromosomal origin to generate the final gene construct.
  • the final composition is synthetic DNA (bases 1 -913), polymerase amplified DNA (bases 914-1 1 38 and 1 976-261 6) and the remainder is of C. botulinum chromosomal origin (bases 1 1 39- 1 975) .
  • the assembled gene was then fully sequenced and cloned into a variety of E. coli plasmid vectors for expression analysis.
  • the DNA is expressed in E. coli as a single nucleic acid transcript producing a soluble single chain polypeptide of 99,951 Daltons predicted molecular weight.
  • the gene is currently expressed in E. coli as a fusion to the commercially available coding sequence of glutathione S-transferase (GST) of Schistosoma japonicum but any of an extensive range of recombinant gene expression vectors such as pEZZ1 8, pTrc99, pFLAG or the pMAL series may be equally effective as might expression in other prokaryotic or eukaryotic hosts such as the Gram positive bacilli, the yeast P. pastoris or in insect or mammalian ceils under appropriate conditions.
  • GST glutathione S-transferase
  • E. coli harbouring the expression construct is grown in Luria-Bertani broth (L-broth pH 7.0, containing 10 g/l bacto-tryptone, 5 g/l bacto-yeast extract and 10 g/l sodium chloride) at 37 ° C until the cell density (biomass) has an optical absorbance of 0.4- 0.6 at 600 nm and the cells are in mid-logarithmic growth phase.
  • Expression of the gene is then induced by addition of isopropylthio- ?-D-galactosidase (IPTG) to a final concentration of 0.5 mM. Recombinant gene expression is allowed to proceed for 90 min at a reduced temperature of 25°C.
  • the cells are then harvested by centrifugation, are resuspended in a buffer solution containing 10 mM Na 2 HP0 4 , 0.5 M NaCI, 10 mM EGTA, 0.25% Tween, pH 7.0 and then frozen at -20°C.
  • a buffer solution containing 10 mM Na 2 HP0 4 , 0.5 M NaCI, 10 mM EGTA, 0.25% Tween, pH 7.0 and then frozen at -20°C.
  • the cell extract is then cleared of debris by centrifugation and the cleared supernatant fluid containing soluble recombinant fusion protein (GST- LH 423 /A) is stored at -20°C pending purification.
  • GST- LH 423 /A soluble recombinant fusion protein
  • the recombinant GST- LH 423 /A is purified by adsorption onto a commercially prepared affinity matrix of glutathione Sepharose and subsequent elution with reduced glutathione.
  • the GST affinity purification marker is then removed by proteolytic cleavage and reabsorption to glutathione Sepharose; recombinant LH 423 /A is recovered in the non-adsorbed material.
  • LH 423 /A Q 2 E,N 26 K,A 27 Y
  • SEQ ID NO: 26 A variant of the molecule, LH 423 /A (Q 2 E,N 26 K,A 27 Y) (SEQ ID NO: 26) has been produced in which three amino acid residues have been modified within the light chain of LH 423 /A producing a polypeptide containing a light chain sequence different to that of the published amino acid sequence of the light chain of BoNT/A .
  • Two further variants of the gene sequence that have been expressed and the corresponding products purified are 23 LH 423 /A (Q 2 E,N 26 K,A 27 Y) (SEQ ID NO: 4) which has a 23 amino acid N-terminal extension as compared to the predicted native L-chain of BoNT/A and 2 LH 423 /A (Q 2 E,N 26 K,A 27 Y) (SEQ ID NO: 6) which has a 2 amino acid N-terminal extension ( Figure 4) .
  • a gene has been produced which contains a Eco 47 III restriction site between nucleotides 1 344 and 1 345 of the gene sequence given in (SEQ ID NO: 1 ) .
  • This modification provides a restriction site at the position in the gene representing the interface of the heavy and light chains in native neurotoxin, and provides the capability to make insertions at this point using standard restriction enzyme methodologies known to those skilled in the art. It will also be obvious to those skilled in the art that any one of a number of restriction sites could be so employed, and that the fco 47 III insertion simply exemplifies this approach. Similarly, it would be obvious for one skilled in the art that insertion of a restriction site in the manner described could be performed on any gene of the invention.
  • L /4 H 423 /A SEQ ID NO: 10
  • L /4 H 423 /A SEQ ID NO: 10
  • amino acids 448 and 449 of LH 423 /A amino acids 448 and 449 of LH 423 /A at a position equivalent to the amino terminus of the heavy chain of native BoNT/A.
  • a variant of the gene has been expressed, L FXa/3 H 423 /A (SEQ ID NO- 12), in which a specific proteolytic cleavage site was incorporated at the carboxy-terminal end of the light chain domain, specifically after residue 448 of L /4 H 423 /A.
  • the cleavage site incorporated was for Factor Xa protease and was coded for by modification of SEQ ID NO: 1 . It will be apparent to one skilled in the art that a cleavage site for another specified protease could be similarly incorporated, and that any gene sequence coding for the required cleavage site could be employed . Modification of the gene sequence in this manner to code for a defined protease site could be performed on any gene of the invention.
  • Variants of L FXa/3 H 423 /A have been constructed in which a third domain is present at the carboxy-terminal end of the polypeptide which incorporates a specific binding activity into the polypeptide.
  • L FXa/3 H 423 /A-ZZ (SEQ ID NO: 1 8) , in which the carboxy-terminal domain is a tandem repeating synthetic IgG binding domain.
  • This variant also exemplifies another modification applicable to the current invention, namely the inclusion in the gene of a sequence coding for a protease cleavage site located between the end of the clostridial heavy chain sequence and the sequence coding for the binding gand. Specifically in this example a sequence is inserted at nucleotides 2650 to 2666 coding for a genenase cleavage site. Expression of this gene produces a polypeptide which has the desired protease sensitivity at the interface between the domain providing H N function and the binding domain. Such a modification enables selective removal of the C-terminal binding domain by treatment of the polypeptide with the relevant protease.
  • binding domains could be incorporated into the polypeptide sequences of this invention and that the above examples are merely to exemplify the concept. Similarly, such binding domains can be incorporated into any of the polypeptide sequences that are the basis of this invention. Further, it should be noted that such binding domains could be incorporated at any appropriate location within the polypeptide molecules of the invention.
  • DNA of the invention further comprising a desired restriction endonuclease site at a desired location and by a polypeptide of the invention further comprising a desired protease cleavage site at a desired location.
  • the restriction endonuclease site may be introduced so as to facilitate further manipulation of the DNA in manufacture of an expression vector for expressing a polypeptide of the invention; it may be introduced as a consequence of a previous step in manufacture of the DNA; it may be introduced by way of modification by insertion, substitution or deletion of a known sequence.
  • the consequence of modification of the DNA may be that the amino acid sequence is unchanged, or may be that the amino acid sequence is changed, for example resulting in introduction of a desired protease cleavage site, either way the polypeptide retains its first and second domains having the properties required by the invention.
  • Figure 10 is a diagrammatic representation of an expression product exemplifying features described in this example. Specifically, it illustrates a single polypeptide incorporating a domain equivalent to the light chain of botulinum neurotoxin type A and a domain equivalent to the H N domain of the heavy chain of botulinum neurotoxin type A with a N-terminal extension providing an affinity purification domain, namely GST, and a C-terminal extension providing a ligand binding domain, namely an IgG binding domain.
  • the domains of the polypeptide are spatially separated by specific protease cleavage sites enabling selective enzymatic separation of domains as exemplified in the Figure. This concept is more specifically depicted in Figure 1 1 where the various protease sensitivities are defined for the purpose of example.
  • the LC of botulinum neurotoxin type A exerts a zinc-dependent endopeptidase activity on the synaptic vesicle associated protein SNAP-25 which it cleaves in a specific manner at a single peptide bond.
  • the 2 LH 423 /A (Q 2 E,N 26 K,A 27 Y) (SEQ ID NO: 6) cleaves a synthetic SNAP-25 substrate in vitro under the same conditions as the native toxin ( Figure 3) .
  • the modification of the polypeptide sequence of 2 LH 423 /A (Q 2 E,N 26 K,A 27 Y) relative to the native sequence and within the minimal functional LC domains does not prevent the functional activity of the LC domains.
  • This activity is dependent on proteolytic modification of the recombinant GST- 2 LH 423 /A (Q 2 E,N 26 K,A 27 Y) to convert the single chain polypeptide product to a disulphide linked dichain species. This is currently done using the proteolytic enzyme trypsin.
  • the recombinant product 100-600 ⁇ g/ml is incubated at 37 °C for 10-50 minutes with trypsin ( 10 ⁇ g/ml) in a solution containing 140 mM NaCI, 2.7 mM KCI, 10 mM Na 2 HP0 4 , 1 .8 mM KH 2 P0 4 , pH 7.3.
  • the reaction is terminated by addition of a 100-fold molar excess of trypsin inhibitor.
  • the activation by trypsin generates a disulphide linked dichain species as determined by polyacrylamide gel electrophoresis and immunoblotting analysis using polyclonal anti-botulinum neurotoxin type A antiserum.
  • 2 LH 423 /A is more stable in the presence of trypsin and more active in the in vitro peptide cleavage assay than is 23 LH 423 /A. Both variants, however, are fully functional in the in vitro peptide cleavage assay. This demonstrates that the recombinant molecule will tolerate N-terminal amino acid extensions and this may be expanded to other chemical or organic moieties as would be obvious to those skilled in the art.
  • a number of gene sequences have been assembled coding for polypeptides corresponding to the entire light-chain and varying numbers of residues from the amino terminal end of the heavy chain of botulinum neurotoxin type B.
  • the gene sequences assembled were obtained from a combination of chromosomal and polymerase-chain-reaction generated DNA, and therefore have the nucleotide sequence of the equivalent regions of the natural genes, thus exemplifying the principle that the substance of this disclosure can be based upon natural as well as a synthetic gene sequences.
  • A- gene has been assembled coding for a polypeptide of 1 171 amino acids corresponding to the entire light-chain (443 amino acids) and 728 residues from the amino terminus of the heavy chain of neurotoxin type B. Expression of this gene produces a polypeptide, LH 728 /B (SEQ ID NO: 20), which lacks the specific neuronal binding activity of full length BoNT/B.
  • a gene has also been assembled coding for a variant polypeptide, LH 417 /B (SEQ ID NO: 22), which possesses an amino acid sequence at its carboxy terminus equivalent by ammo acid homology to that at the carboxy-terminus of the heavy chain fragment in native LH N /A .
  • a gene has also been assembled coding for a variant polypeptide, LH, 07 /B (SEQ ID NO: 24) , which expresses at its carboxy-terminus a short sequence from the ammo terminus of the heavy chain of BoNT/B sufficient to maintain solubility of the expressed polypeptide.
  • a variant of the coding sequence for the first 274 bases of the gene shown in SEQ ID NO. 21 has been produced which whilst being a non-native nucleotide sequence still codes for the native polypeptide.
  • oligonucleotides representing the first (5') 268 nucleotides of the native sequence for botulinum toxin type B were synthesised.
  • 23 oligonucleotides representing internal sequence nucleotides 691 -1641 of the native sequence for botulinum toxin type B were synthesised.
  • the oligonucleotides ranged from 57-73 nucleotides in length. Overlapping regions, 1 7-20 nucleotides, were designed to give melting temperatures in the range 52-56°C.
  • terminal restriction endonuclease sites of the synthetic products were constructed to facilitate insertion of these products into the exact corresponding region of the native sequence.
  • the 268 bp 5' synthetic sequence has been incorporated into the gene shown in SEQ ID NO: 21 in place of the original first 268 bases (and is shown in SEQ ID NO: 27) . Similarly the sequence could be inserted into other genes of the examples.
  • SEQ ID NO: 28 Another variant sequence equivalent to nucleotides 691 to 1 641 of SEQ ID NO: 21 , and employing non-native codon usage whilst coding for a native polypeptide sequence, has been constructed using the internal synthetic sequence.
  • This sequence (SEQ ID NO: 28) can be incorporated, alone or in combination with other variant sequences, in place of the equivalent coding sequence in any of the genes of the example.
  • An exemplification of the utility of this invention is as a non-toxic and effective immunogen.
  • the non-toxic nature of the recombinant, single chain material was demonstrated by intraperitoneal administration in mice of GST- 2 LH 423 /A.
  • the polypeptide was prepared and purified as described above.
  • the amount of immunoreactive material in the final preparation was determined by enzyme linked immunosorbent assay (ELISA) using a monoclonal antibody (BA1 1 ) reactive against a conformation dependent epitope on the native LH N /A.
  • the recombinant material was serially diluted in phosphate buffered saline (PBS; NaCI 8 g/l, KCI 0.2 g/l, Na 2 HP0 4 1 .
  • PBS phosphate buffered saline
  • mice 1 5 g/l, KH 2 P0 4 0.2 g/l, pH 7.4) and 0.5 ml volumes injected into 3 groups of 4 mice such that each group of mice received 1 0, 5 and 1 micrograms of material respectively. Mice were observed for 4 days and no deaths were seen.
  • Antisera which were botulinum neurotoxin reactive at a dilution of 1 :2000 were used for evaluation of neutralising efficacy in mice.
  • 0.1 ml of antiserum was diluted into 2.5 ml of gelatine phosphate buffer (GPB; Na 2 HP0 4 anhydrous 10 g/l, gelatin (Difco) 2 g/l, pH 6.5- 6.6) containing a dilution range from 0.5 ⁇ g (5X10 6 g) to 5 picograms (5X 10 12 g) .
  • GPB gelatine phosphate buffer
  • nucleic acid sequence (SEQ ID NO: 23) coding for the polypeptide LH 107 /B (SEQ ID NO: 24) was inserted into the commercially available plasmid pET28a (Novogen, Madison, Wl, USA) .
  • the nucleic acid was expressed in E.
  • coli BL21 (DE3) (New England BioLabs, Beverley, MA, USA) as a fusion protein with a N-terminal T7 fusion peptide, under IPTG induction at 1 mM for 90 minutes at 37 °C. Cultures were harvested and recombinant protein extracted as described previously for LH 423 /A.
  • Recombinant protein was recovered and purified from bacterial paste lysates by immunoaffinity adsorption to an immobilised anti-T7 peptide monoclonal antibody using a T7 tag purification kit (New England bioLabs, Beverley, MA, USA) . Purified recombinant protein was analysed by gradient (4-20%) denaturing SDS- polyacrylamide gel electrophoresis (Novex, San Diego, CA, USA) and western blotting using poiyclonal anti-botulinum neurotoxin type antiserum or anti-T7 antiserum. Western blotting reagents were from Novex, immunostained proteins were visualised using the Enhanced Chemi-Luminescence system (ECL) from Amersham. The expression of an anti-T7 antibody and anti-botulinum neurotoxin type B antiserum reactive recombinant product is demonstrated in Figure 1 3.
  • ECL Enhanced Chemi-Luminescence system
  • the recombinant product was soluble and retained that part of the light chain responsible for endopeptidase activity.
  • the invention thus provides recombinant polypeptides useful inter alia as immunogens, enzyme standards and components for synthesis of molecules as described in WO-A-94/21 300.
  • MOLECULE TYPE DNA (genomic) ( IX ) FEATURE :
  • ATC CAG TTT GAG TGC AAG AGC TTT GGC CAC GAA GTG TTG AAC CTG ACG 528 lie Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175
  • AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA 1296 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Ar ⁇ 420 425 430
  • MOLECULE TYPE DNA (genomic)
  • GGA GTG ACC AAA TTA TTC GAG CGT ATT TAT TCC ACT GAC CTG GGC CGT 384 Gly Val Thr Lys Leu Phe Glu Arg He Tyr Ser Thr Asp Leu Gly Arg 115 120 125
  • GAT CTA AAT AAA GGA GAA GAA ATT ACA TCT GAT ACT AAT ATA GAA GCA 1536 Asp Leu Asn Lys Gly Glu Glu He Thr Ser Asp Thr Asn He Glu Ala 500 505 510
  • AGT GAC ATT ATA GGC CAA TTA GAA CTT ATG CCT AAT ATA GAA AGA TTT 168 0 Ser Asp He He Gly Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe 545 550 555 560
  • Lys Tyr Gly Gin Met Gin Pro Val Lys Ala Phe Lys He His Asn Lys 50 55 60
  • Lys Lys Met Lys Glu Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala 755 760 765
  • GCA AAA CAA GTT CCA GTT TCA TAT TAT GAT TCA ACA TAT TTA AGT ACA 240 Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80
  • AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA 1296 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430
  • GAT TTA ATA CAA CAA TAT TAT TTA ACC TTT AAT TTT GAT AAT GAA CCT 1536 Asp Leu He Gin Gin Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro 500 505 510
  • Glu Asn lie Ser He Glu Asn Leu Ser Ser Asp He He Gly Gin Leu 515 520 525
  • MOLECULE TYPE DNA (genomic)
  • AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA 129 6 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430
  • MOLECULE TYPE DNA (genomic)
  • AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA 1296 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430
  • GAT CTA AAT AAA GGA GAA GAA ATT ACA TCT GAT ACT AAT ATA GAA GCA 1488 Asp Leu Asn Lys Gly Glu Glu He Thr Ser Asp Thr Asn He Glu Ala 485 490 495
  • AGT GAC ATT ATA GGC CAA TTA GAA CTT ATG CCT AAT ATA GAA AGA TTT 1632 Ser Asp He He Gly Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe 530 535 540
  • Lys Lys Met Lys Glu Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala 740 745 750
  • MOLECULE TYPE DNA (genomic)
  • AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA 1296 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430
  • GAT CTA AAT AAA GGA GAA GAA ATT ACA TCT GAT ACT AAT ATA GAA GCA 1488 Asp Leu Asn Lys Gly Glu Glu He Thr Ser Asp Thr Asn He Glu Ala 485 490 495
  • AGT GAC ATT ATA GGC CAA TTA GAA CTT ATG CCT AAT ATA GAA AGA TTT 1632 Ser Asp He He Gly Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe 530 535 540 CCT AAT GGA AAA AAG TAT GAG TTA GAT AAA TAT ACT ATG TTC CAT TAT 1680 Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lvs Tyr Thr Met Phe His Tyr 545 550 " 555 560

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A polypeptide has first and second domains which enable the polypeptide to be translocated into a target cell or which increase the solubility of the polypeptide, or both, and further enable the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.

Description

RECOMBINANT TOXIN FRAGMENTS
This invention relates to recombinant toxin fragments, to DNA encoding these fragments and to their uses such as in a vaccine and for in vitro and in vivo purposes
The clostndial neurotoxins are potent inhibitors of calcium-dependent neurotransmitter secretion in neuronal cells. They are currently considered to mediate this activity through a specific endoproteolytic cleavage of at least one of three vesicle or pre-synaptic membrane associated proteins VAMP, syntaxin or SNAP-25 which are central to the vesicle docking and membrane fusion events of neurotransmitter secretion. The neuronal cell targeting of tetanus and botulinum neurotoxins is considered to be a receptor mediated event following which the toxins become internalised and subsequently traffic to the appropriate intracellular compartment where they effect their endopeptidase activity.
The clostndial neurotoxins share a common architecture of a catalytic L-chain (LC, ca 50 kDa) disulphide linked to a receptor binding and translocating H-chain (HC, ca 1 00 kDa) . The HC polypeptide is considered to comprise all or part of two distinct functional domains. The carboxy-terminal half of the HC (ca 50 kDa), termed the Hc domain, is involved in the high affinity, neurospecific binding of the neurotoxin to cell surface receptors on the target neuron, whilst the amino-termmal half, termed the HN domain (ca 50 kDa), is considered to mediate the translocation of at least some portion of the neurotoxin across cellular membranes such that the functional activity of the LC is expressed within the target cell. The HN domain also has the property, under conditions of low pH, of forming ion-permeabie channels in lipid membranes, this may in some manner relate to its translocation function.
For botulinum neurotoxin type A (BoNT/A) these domains are considered to reside within ammo acid residues 872-1296 for the Hc, ammo acid residues 449-871 for the HN and residues 1 -448 for the LC. Digestion with trypsin effectively degrades the Hc domain of the BoNT/A to generate a non-toxic fragment designated LHN, which is no longer able to bind to and enter neurons (Fig . 1 ) . The LHN fragment so produced also has the property of enhanced solubility compared to both the parent holotoxin and the isolated LC.
It is therefore possible to provide functional definitions of the domains within the neurotoxin molecule, as follows:
(A) clostridial neurotoxin light chain:
-a metalloprotease exhibiting high substrate specificity for vesicle and/or plasma - membrane associated proteins involved in the exocytotic process. In particular, it cleaves one or more of SNAP-25, VAMP (synaptobrevin / cellubrevin) and syntaxin.
(B) clostridial neurotoxin heavy chain HN domain:
-a portion of the heavy chain which enables translocation of that portion of the neurotoxin molecule such that a functional expression of light chain activity occurs within a target cell.
-the domain responsible for translocation of the endopeptidase activity, following binding of neurotoxin to its specific cell surface receptor via the binding domain, into the target cell.
-the domain responsible for formation of ion-permeable pores in lipid membranes under conditions of low pH.
-the domain responsible for increasing the solubility of the entire polypeptide compared to the solubility of light chain alone.
(C) clostridial neurotoxin heavy chain Hc domain.
-a portion of the heavy chain which is responsible for binding of the native holotoxin to cell surface receptor(s) involved in the intoxicating action of clostridial toxin prior to internaiisation of the toxin into the cell.
The identity of the cellular recognition markers for these toxins is currently not understood and no specific receptor species have yet been identified although Kozaki et al. have reported that synaptotagmin may be the receptor for botulinum neurotoxin type B. It is probable that each of the neurotoxins has a different receptor.
It is desirable to have positive controls for toxin assays, to develop clostridial toxin vaccines and to develop therapeutic agents incorporating desirable properties of clostridial toxin.
However, due to its extreme toxicity, the handling of native toxin is hazardous.
The present invention seeks to overcome or at least ameliorate problems associated with production and handling of clostridial toxin.
Accordingly, the invention provides a polypeptide comprising first and second domains, wherein said first domain is adapted to cleave one or more vesicle or plasma-membrane associated proteins essential to neuronal exocytosis and wherein said second domain is adapted (i) to translocate the polypeptide into the cell or (ii) to increase the solubility of the polypeptide compared to the solubility of the first domain on its own or (iii) both to translocate the polypeptide into the cell and to increase the solubility of the polypeptide compared to the solubility of the first domain on its own, said polypeptide being free of clostridial neurotoxin and free of any clostridial neurotoxin precursor that can be converted into toxin by proteolytic action. Accordingly, the invention may thus provide a single polypeptide chain containing a domain equivalent to a clostridial toxin light chain and a domain providing the functional aspects of the HN of a clostridial toxin heavy chain, whilst lacking the functional aspects of a clostridial toxin Hc domain. For the purposes of the invention, the functional property or properties of the H of a clostridial toxin heavy chain that are required to be exhibited by the second domain of the polypeptide of the invention are either (i) translocation of the polypeptide into a cell, or (ii) increasing solubility of the polypeptide compared to solubility of the first domain on its own or (iii) both (i) and (ii) . References hereafter to a HN domain or to the functions of a HN domain are references to this property or properties. The second domain is not required to exhibit other properties of the HN domain of a clostridial toxin heavy chain.
A polypeptide of the invention can thus be soluble but lack the translocation function of a native toxin-this is of use in providing an immunogen for vaccinating or assisting to vaccinate an individual against challenge by toxin In a specific embodiment of the invention described in an example below a polypeptide designated LH423/A elicited neutralising antibodies against type A neurotoxin. A polypeptide of the invention can likewise thus be relatively insoluble but retain the translocation function of a native toxin - this is of use if solubility is imparted to a composition made up of that polypeptide and one or more other components by one or more of said other components.
The first domain of the polypeptide of the invention cleaves one or more vesicle or plasma-membrane associated proteins essential to the specific cellular process of exocytosis, and cleavage of these proteins results in inhibition of exocytosis, typically in a non-cytotoxic manner. The cell or cells affected are not restricted to a particular type or subgroup but can include both neuronal and non-neuronal cells. The activity of clostridial neurotoxins in inhibiting exocytosis has., indeed, been observed almost universally in eukaryotic cells expressing a relevant cell surface receptor, including such diverse cells as from Aplysia (sea slug), Drosophila (fruit fly) and mammalian nerve cells, and the activity of the first domain is to be understood as including a corresponding range of cells.
The polypeptide of the invention may be obtained by expression of a recombinant nucleic acid, preferably a DNA, and is a single polypeptide, that is to say not cleaved into separate light and heavy chain domains. The polypeptide is thus available in convenient and large quantities using recombinant techniques.
In a polypeptide according to the invention, said first domain preferably comprises a clostridial toxin light chain or a fragment or variant of a clostridial toxin light chain . The fragment is optionally an N-terminal, or C-terminal fragment of the light chain, or is an internal fragment, so long as it substantially retains the ability to cleave the vesicle or plasma-membrane associated protein essential to exocytosis. The minimal domains necessary for the activity of the light chain of clostridial toxins are described in J. Biol. Chem., Vol.267, No. 21 , July 1 992, pages 1 4721 - 14729. The variant has a different peptide sequence from the light chain or from the fragment, though it too is capable of cleaving the vesicle or plasma-membrane associated protein. It is conveniently obtained by insertion, deletion and/or substitution of a light chain or fragment thereof. In embodiments of the invention described below a variant sequence comprises (i) an N-terminal extension to a clostridial toxin light chain or fragment (ii) a clostridial toxin light chain or fragment modified by alteration of at least one amino acid (iii) a C-terminal extension to a clostridial toxin light chain or fragment, or (iv) combinations of 2 or more of (i)-(iii) .
In further embodiments of the invention, the variant contains an amino acid sequence modified so that (a) there is no protease sensitive region between the LC and HN components of the polypeptide, or (b) the protease sensitive region is specific for a particular protease. This latter embodiment is of use if it is desired to activate the endopeptidase activity of the light chain in a particular environment oχ cell. Though, in general, the polypeptides of the invention are activated prior to administration.
The first domain preferably exhibits endopeptidase activity specific for a substrate selected from one or more of SNAP-25, synaptobrevin/VAMP and syntaxin. The clostridial toxin is preferably botulinum toxin or tetanus toxin.
In an embodiment of the invention described in an example below, the toxin light chain and the portion of the toxin heavy chain are of botulinum toxin type A. In a further embodiment of the invention described in an example below, the toxin light chain and the portion of the toxin heavy chain are of botulinum toxin type B. The polypeptide optionally comprises a light chain or fragment or variant of one toxin type and a heavy chain or fragment or variant of another toxin type.
In a polypeptide according to the invention said second domain preferably comprises a clostridial toxin heavy chain HN portion or a fragment or variant of a clostridial toxin heavy chain HN portion . The fragment is optionally an N-terminal or C-terminal or internal fragment, so long as it retains the function of the HN domain Teachings of regions within the HN responsible for its function are provided for example in Biochemistry 1 995, 34, pages 1 51 75- 1 51 81 and Eur. J Biochem, 1 989, 1 85, pages 1 97-203. The variant has a different sequence from the HN domain or fragment, though it too retains the function of the HN domain It is conveniently obtained by insertion, deletion and/or substitution of a HN domain or fragment thereof. In embodiments of the invention, described below, it comprises (i) an N-terminal extension to a HN domain or fragment, (ii) a C-terminal extension to a HN domain or fragment, (iii) a modification to a HN domain or fragment by alteration of at least one ammo acid, or (iv) combinations of 2 or more of (i)-(iιi) . The clostridial toxin is preferably botulinum toxin or tetanus toxin.
The invention also provides a polypeptide comprising a clostridial neurotoxin light chain and a N-terminal fragment of a clostridial neurotoxin heavy chain, the fragment preferably comprising at least 423 of the N-terminal ammo acids of the heavy chain of botulinum toxin type A, 41 7 of the N-terminal amino acids of the heavy chain of botulinum toxin type B or the equivalent number of N-terminal am o acids of the heavy chain of other types of clostridial toxin such that the fragment possesses an equivalent alignment of homologous ammo acid residues.
These polypeptides of the invention are thus not composed of two or more polypeptides, linked for example by di-sulphide bridges into composite molecules. Instead, these polypeptides are single chains and are not active or their activity is significantly reduced in an in vitro assay of neurotoxin endopeptidase activity.
Further, the polypeptides may be susceptible to be converted into a form exhibiting endopeptidase activity by the action of a proteolytic agent, such as trypsin In this way it is possible to control the endopeptidase activity of the toxin light chain.
In a specific embodiment of the invention described in an example below, there is provided a polypeptide lacking a portion designated Hc of a clostridial toxin heavy chain This portion, seen in the naturally produced toxin, is responsible for binding of toxin to cell surface receptors prior to interna sation of the toxin . This specific embodiment is therefore adapted so that it can not be converted into active toxin, for example by the action of a proteolytic enzyme The invention thus also provides a polypeptide comprising a clostndial toxin light chain and a fragment of a clostndial toxin heavy chain, said fragment being not capable of binding to those cell surface receptors involved in the intoxicating action of clostndial toxin, and it is preferred that such a polypeptide lacks an intact portion designated Hc of a clostridial toxin heavy chain.
In further embodiments of the invention there are provided compositions containing a polypeptide comprising a clostridial toxin light chain and a portion designated HN of a clostndial toxin heavy chain, and wherein the composition is free of clostndial toxin and free of any clostridial toxin precursor that may be converted into clostridial toxin by the action of a proteolytic enzyme. Examples of these compositions include those containing toxin light chain and HN sequences of botulinum toxin types A, B, C, , D, E, F and G.
The polypeptides of the invention are conveniently adapted to bind to, or include, a ligand for targeting to desired cells. The polypeptide optionally comprises a sequence that binds to, for example, an immunoglobu n. A suitable sequence is a tandem repeat synthetic IgG binding domain derived from domain B of Staphylococcal protein A. Choice of immunoglobuhn specificity then determines the target for a polypeptide - immunoglobuhn complex. Alternatively, the - o - polypeptide comprises a non-clostridial sequence that binds to a cell surface receptor, suitable sequences including insulin-like growth factor-1 (IGF-1 ) which binds to its specific receptor on particular cell types and the 1 4 amino acid residue sequence from the carboxy-terminus of cholera toxin A subunit which is able to bind the cholera toxin B subunit and thence to GM 1 gangliosides. A polypeptide according to the invention thus, optionally, further comprises a third domain adapted for binding of the polypeptide to a cell.
In a second aspect the invention provides a fusion protein comprising a fusion of (a) a polypeptide of the invention as described above with (b) a second polypeptide adapted for binding to a chromatography matrix so as to enable purification of the fusion protein using said chromatography matrix. It is convenient for the second polypeptide to be adapted to bind to an affinity matrix, such as a glutathione Sepharose, enabling rapid separation and purification of the fusion protein from an impure source, such as a cell extract or supernatant.
One possible second purification polypeptide is glutathione-S-transferase (GST), and others will be apparent to a person of skill in the art, being chosen so as to enable purification on a chromatography column according to conventional techniques.
As noted above, by proteolytic treatment, for example using trypsin, of a polypeptide of the invention it is possible to induce endopeptidase activity in the treated polypeptide. A third aspect of the invention provides a composition comprising a derivative of a clostridial toxin, said derivative retaining at least 10% of the endopeptidase activity of the clostridial toxin, said derivative further being non-toxic in vivo due to its inability to bind to cell surface receptors, and wherein the composition is free of any component, such as toxin or a further toxin derivative, that is toxic in vivo. The activity of the derivative preferably approaches that of natural toxin, and is thus preferably at least 30% and most preferably at least 60% of natural toxin. The overall endopeptidase activity of the composition will, of course, also be determined by the amount of the derivative that is present. While it is known to treat naturally produced clostridial toxin to remove the H domain, this treatment does not totally remove toxicity of the preparation, instead some residual toxin activity remains. Natural toxin treated in this way is therefore still not entirely safe. The composition of the invention, derived by treatment of a pure source of polypeptide advantageously is free of toxicity, and can conveniently be used as a positive control in a toxin assay, as a vaccine against clostridial toxin or for other purposes where it is essential that there is no residual toxicity in the composition.
The invention enables production of the polypeptides and fusion proteins of the invention by recombinant means.
A fourth aspect of the invention provides a nucleic acid encoding a polypeptide or a fusion protein according to any of the aspects of the invention described above.
In one embodiment of this aspect of the invention, a DNA sequence provided to code for the polypeptide or fusion protein is not derived from native clostridial sequences, but is an artificially derived sequence not preexisting in nature.
A specific DNA (SEQ ID NO: 1 ) described in more detail below encodes a polypeptide or a fusion protein comprising nucleotides encoding residues 1 -871 of a botulinum toxin type A. Said polypeptide comprises the light chain domain and the first 423 amino acid residues of the amino terminal portion of a botulinum toxin type A heavy chain. This recombinant product is designated LH423/A (SEQ ID NO: 2) .
In a second embodiment of this aspect of the invention a DNA sequence which codes for the polypeptide or fusion protein is derived from native clostridial sequences but codes for a polypeptide or fusion protein not found in nature.
A specific DNA (SEQ ID NO: 1 9) described in more detail below encodes a polypeptide or a fusion protein and comprises nucleotides encoding residues 1 - 1 1 71 of a botulinum toxin type B. Said polypeptide comprises the light chain domain and the first 728 am o acid residues of the ammo terminal protein of a botulinum type B heavy chain. This recombinant product is designated LH728/B (SEQ ID NO: 20) .
The invention thus also provides a method of manufacture of a polypeptide comprising expressing in a host cell a DNA according to the third aspect of the invention. The host cell is suitably not able to cleave a polypeptide or fusion protein of the invention so as to separate light and heavy toxin chains; for example, a non-clostridial host.
The invention further provides a method of manufacture of a polypeptide comprising expressing in a host cell a DNA encoding a fusion protein as described above, purifying the fusion protein by elution through a chromatography column adapted to retain the fusion protein, eluting through said chromatography column a ligand adapted to displace the fusion protein and recovering the fusion protein. Production of substantially pure fusion protein is thus made possible. Likewise, the fusion protein is readily cleaved to yield a polypeptide of the invention, again in substantially pure form, as the second polypeptide may conveniently be removed using the same type of chromatography column.
The LHN/A derived from dichain native toxin requires extended digestion with trypsin to remove the C-terminal 1 /2 of the heavy chain, the Hc domain. The loss of this domain effectively renders the toxin inactive in vivo by preventing its interaction with host target cells. There is, however, a residual toxic activity which may indicate a contaminating, trypsin insensitive, form of the whole type A neurotoxin.
In contrast, the recombinant preparations of the invention are the product of a discreet, defined gene coding sequence and can not be contaminated by full length toxin protein. Furthermore, the product as recovered from E. coli, and from other recombinant expression hosts, is an inactive single chain peptide or if expression hosts produce a processed, active polypeptide it is not a toxin. Endopeptidase activity of LH423/A, as assessed by the current in vitro peptide cleavage assay, is wholly dependent on activation of the recombinant molecule between residues 430 and 454 by trypsin. Other proteolytic enzymes that cleave between these two residues are generally also suitable for activation of the recombinant molecule Trypsin cleaves the peptide bond C-terminal to Argmine or C-terminal to Lysme and is suitable as these residues are found in the 430-454 region and are exposed (see
The recombinant polypeptides of the invention are potential therapeutic agents for targeting to cells expressing the relevant substrate but which are not implicated in effecting botulism. An example might be where secretion of neurotransmitter is inappropriate or undesirable or alternatively where a neuronal cell is hyperactive in terms of regulated secretion of substances other than neurotransmitter. In such an example the function of the Hc domain of the native toxin could be replaced by an alternative targeting sequence providing, for example, a cell receptor hgand and/or translocation domain.
One application of the recombinant polypeptides of the invention will be as a reagent component for synthesis of therapeutic molecules, such as disclosed in WO-A-94/21 300. The recombinant product will also find application as a non-toxic standard for the assessment and development of in vitro assays for detection of functional botulinum or tetanus neurotoxins either in foodstuffs or in environmental samples, for example as disclosed in EP-A-07631 31 .
A further option is addition, to the C-terminal end of a polypeptide of the invention, of a peptide sequence which allows specific chemical conjugation to targeting gands of both protein and non-protein origin.
In yet a further embodiment an alternative targeting hgand is added to the N- terminus of polypeptides of the invention. Recombinant LHN derivatives have been designated that have specific protease cleavage sites engineered at the C-termmus of the LC at the putative trypsin sensitive region and also at the extreme C- terminus of the complete protein product. These sites will enhance the activational specificity of the recombinant product such that the dichain species can only be activated by proteolytic cleavage of a more predictable nature than use of trypsin.
The LHN enzymatically produced from native BoNT/A is an efficient immunogen and thus the recombinant form with its total divorce from any full length neurotoxin represents a vaccine component. The recombinant product may serve as a basal reagent for creating defined protein modifications in support of any of the above areas.
Recombinant constructs are assigned distinguishing names on the basis of their amino acid sequence length and their Light Chain (L-chain, L) and Heavy Chain (H- chain, H) content as these relate to translated DNA sequences in the public domain or specifically to SEQ ID NO: 2 and SEQ ID NO: 20. The ' LH' designation is followed by 7X' where 'X' denotes the corresponding clostridial toxin serotype or class, e.g . 'A' for botulinum neurotoxin type A or 'TeTx' for tetanus toxin. Sequence variants from that of the native toxin polypeptide are given in parenthesis in standard format, namely the residue position number prefixed by the residue of the native sequence and suffixed by the residue of the variant.
Subscript number prefixes indicate an amino-terminal (N-terminal) extension, or where negative a deletion, to the translated sequence. Similarly, subscript number suffixes indicate a carboxy terminal (C-terminal) extension or where negative numbers are used, a deletion. Specific sequence inserts such as protease cleavage sites are indicated using abbreviations, e.g. Factor Xa is abbreviated to FXa. L- chain C-terminal suffixes and H-chain N-terminal prefixes are separated by a 7 to indicate the predicted junction between the L and H-chains. Abbreviations for engineered ligand sequences are prefixed or suffixed to the clostridial L-chain or H- chain corresponding to their position in the translation product.
Following this nomenclature, LHΛ 42„3/'A SEQ ID NO: 2, containing the entire L-chain and 423 ammo acids of the H-chain of botulinum neurotoxin type A;
,LHΛ2„3/'A a variant of this molecule, containing a two ammo acid extension to the N-terminus of the L-chain,
-/2H 23/A a further variant in which the molecule contains a two ammo acid extension on the N-termmus of both the L- chain and the H-chain;
2L-FXa 2H 23 A a further variant containing a two amino acid extension to the N-terminus of the L-chain, and a Factor Xa cleavage sequence at the C-terminus of the L-chain which, after cleavage of the molecule with Factor Xa leaves a two ammo acid N-terminal extension to the H- chain component; and
2LFXa/2H423/A-IGF- 1 = a variant of this molecule which has a further C-terminal extension to the H-chain, in this example the insulin-like growth factor 1 (IGF-1 ) sequence.
There now follows description of specific embodiments of the invention, illustrated by drawings in which:
Fig. 1 shows a schematic representation of the domain structure of botulinum neurotoxin type A (BoNT/A);
Fig. 2 shows a schematic representation of assembly of the gene for an embodiment of the invention designated LH423/A; Fig. 3 is a graph comparing activity of native toxin, trypsin generated
"native" LHN/A and an embodiment of the invention designated 2LH423/A (Q2E,N26K,A27Y) in an in vitro peptide cleavage assay;
Fig. 4 is a comparison of the first 33 amino acids in published sequences of native toxin and embodiments of the invention;
Fig. 5 shows the transition region of an embodiment of the invention designated L/4H423/A illustrating insertion of four amino acids at the N-terminus of the HN sequence; amino acids coded for by the Eco 47 III restriction endonuclease cleavage site are marked and the HN sequence then begins ALN...;
Fig . 6 shows the transition region of an embodiment of the invention designated LFXa/3H423/A illustrating insertion of a Factor Xa cleavage site at the C-terminus of the L-chain, and three additional amino acids coded for at the N-terminus of the H- sequence; the N-terminal amino acid of the cleavage-activated HN will be cysteine;
Fig. 7 shows the C-terminal portion of the amino acid sequence of an embodiment of the invention designated LFXa/3H423/A-IGF-1 , a fusion protein; the IGF-1 sequence begins at position G882;
Fig. 8 shows the C-terminal portion of the amino acid sequence of an embodiment of the invention designated LFXa/3H423/A-CtxA14, a fusion protein; the C-terminal CtxA sequence begins at position Q882;
Fig.9 shows the C-termiπal portion of the amino acid sequence ofan embodiment of the invention designated LFXa/3H423/A-ZZ, a fusion protein; the C-terminal ZZ sequence begins at position A890 immediately after a genenase recognition site (underlined);
show schematic representations of manipulations of Figs. 1 0 & 1 1 polypeptides of the invention; Fig. 1 0 shows LH423/A with N-terminal addition of an affinity purification peptide (in this case GST) and C-terminal addition of an Ig binding domain; protease cleavage sites R1 , R2 and R3 enable selective enzymatic separation of domains; Fig. 1 1 shows specific examples of protease cleavage sites R1 , R2 and R3 and a C-terminal fusion peptide sequence;
Fig. 12 shows the trypsin sensitive activation region of a polypeptide of the invention;
Fig. 13 shows Western blot analysis of recombinant LH107/B expressed from E.coli; panel A was probed with anti- BoNT/B antiserum; Lane 1 , molecular weight standards; lanes 2 & 3, native BoNT/B; lane 4, immunopurified LH107/B; panel B was probed with anti-T7 peptide tag antiserum; lane 1 , molecular weight standards; lanes 2 & 3, positive control E.coli T7 expression; lane 4 immunopurified LH107/B.
The sequence listing that accompanies this application contains the following sequences:-
SEQ ID NO: Sequence
1 DNA coding for LH423/A 2 LH423/A
3 DNA coding for 23LH423/A (Q2E,N26K,A27Y) , of which an
N-terminal portion is shown in Fig. 4.
4 23LH423/A (Q2E,N26K,A27Y)
5 DNA coding for 2LH423/A (Q2E,N26K,A27Y) , of which an N- terminal portion is shown in Fig .4
6 2LH423/A (Q2E,N26K,A27Y)
7 DNA coding for native BoNT/A according to Binz et al
8 native BoNT/A according to Binz et al
9 DNA coding for L/4H423/A
10 L/4H423/A
1 1 DNA coding for LFXa/3H423/A
1 2 LFXa/3H423/A
1 3 DNA coding for LFXa/3H423/A-IGF-1
1 4 FXa/3H423/A-IGF-1
1 5 DNA coding for LFXa/3H423/A-CtxA14
1 6 LFXa/3H423/A-CtxA14
1 7 DNA coding for LFXa/3H423/A-ZZ
1 8 LFXa/3H423/A-ZZ
1 9 DNA coding for LH728/B
20 LH728/B
21 DNA coding for LH417/B
22 LH417/B
23 DNA coding for LH107/B
24 LH107/B
25 DNA coding for LH423/A (Q2E,N26K,A27Y)
26 LH423/A (Q2E,N26K,A27Y)
27 DNA coding for LH417/B wherein the first 274 bases are modified to have an E. coli codon bias 28 DNA coding for LH417/B wherein bases 691 - 1 641 of the native BoNT/B sequence have been replaced by a degenerate DNA coding for amino acid residues 231 -547 of the native BoNT/B polypeptide
Example 1
A 261 6 base pair, double stranded gene sequence (SEQ ID NO: 1 ) has been assembled from a combination of synthetic , chromosomal and polymerase-chain-reaction generated DNA (Figure 2) . The gene codes for a polypeptide of 871 amino acid residues corresponding to the entire light-chain (LC, 448 amino acids) and 423 residues of the amino terminus of the heavy-chain (Hc) of botulinum neurotoxin type A. This recombinant product is designated the LH423/A fragment (SEQ ID NO: 2).
Construction of the recombinant product
The first 91 8 base pairs of the recombinant gene were synthesised by concatenation of short oligonucleotides to generate a coding sequence with an E. coli codon bias. Both DNA strands in this region were completely synthesised as short overlapping oligonucleotides which were phosphorylated, annealed and ligated to generate the full synthetic region ending with a unique Kpn\ restriction site. The remainder of the LH423/A coding sequence was PCR amplified from total chromosomal DNA from Clostridium botulinum and annealed to the synthetic portion of the gene.
The internal PCR amplified product sequences were then deleted and replaced with the native, fully sequenced, regions from clones of C. botulinum chromosomal origin to generate the final gene construct. The final composition is synthetic DNA (bases 1 -913), polymerase amplified DNA (bases 914-1 1 38 and 1 976-261 6) and the remainder is of C. botulinum chromosomal origin (bases 1 1 39- 1 975) . The assembled gene was then fully sequenced and cloned into a variety of E. coli plasmid vectors for expression analysis.
Expression of the recombinant gene and recovery of protein product
The DNA is expressed in E. coli as a single nucleic acid transcript producing a soluble single chain polypeptide of 99,951 Daltons predicted molecular weight. The gene is currently expressed in E. coli as a fusion to the commercially available coding sequence of glutathione S-transferase (GST) of Schistosoma japonicum but any of an extensive range of recombinant gene expression vectors such as pEZZ1 8, pTrc99, pFLAG or the pMAL series may be equally effective as might expression in other prokaryotic or eukaryotic hosts such as the Gram positive bacilli, the yeast P. pastoris or in insect or mammalian ceils under appropriate conditions.
Currently, E. coli harbouring the expression construct is grown in Luria-Bertani broth (L-broth pH 7.0, containing 10 g/l bacto-tryptone, 5 g/l bacto-yeast extract and 10 g/l sodium chloride) at 37 ° C until the cell density (biomass) has an optical absorbance of 0.4- 0.6 at 600 nm and the cells are in mid-logarithmic growth phase. Expression of the gene is then induced by addition of isopropylthio- ?-D-galactosidase (IPTG) to a final concentration of 0.5 mM. Recombinant gene expression is allowed to proceed for 90 min at a reduced temperature of 25°C. The cells are then harvested by centrifugation, are resuspended in a buffer solution containing 10 mM Na2HP04, 0.5 M NaCI, 10 mM EGTA, 0.25% Tween, pH 7.0 and then frozen at -20°C. For extraction of the recombinant protein the cells arβ-disrupted by sonication. The cell extract is then cleared of debris by centrifugation and the cleared supernatant fluid containing soluble recombinant fusion protein (GST- LH423/A) is stored at -20°C pending purification. A proportion of recombinant material is not released by the sonication procedure and this probably reflects insolubility or inclusion body formation. Currently we do not extract this material for analysis but if desired this could be readily achieved using methods known to those skilled in the art. The recombinant GST- LH423/A is purified by adsorption onto a commercially prepared affinity matrix of glutathione Sepharose and subsequent elution with reduced glutathione. The GST affinity purification marker is then removed by proteolytic cleavage and reabsorption to glutathione Sepharose; recombinant LH423/A is recovered in the non-adsorbed material.
Construct variants
A variant of the molecule, LH423/A (Q2E,N26K,A27Y) (SEQ ID NO: 26) has been produced in which three amino acid residues have been modified within the light chain of LH423/A producing a polypeptide containing a light chain sequence different to that of the published amino acid sequence of the light chain of BoNT/A .
Two further variants of the gene sequence that have been expressed and the corresponding products purified are 23LH423/A (Q2E,N26K,A27Y) (SEQ ID NO: 4) which has a 23 amino acid N-terminal extension as compared to the predicted native L-chain of BoNT/A and 2LH423/A (Q2E,N26K,A27Y) (SEQ ID NO: 6) which has a 2 amino acid N-terminal extension (Figure 4) .
In yet another variant a gene has been produced which contains a Eco 47 III restriction site between nucleotides 1 344 and 1 345 of the gene sequence given in (SEQ ID NO: 1 ) . This modification provides a restriction site at the position in the gene representing the interface of the heavy and light chains in native neurotoxin, and provides the capability to make insertions at this point using standard restriction enzyme methodologies known to those skilled in the art. It will also be obvious to those skilled in the art that any one of a number of restriction sites could be so employed, and that the fco 47 III insertion simply exemplifies this approach. Similarly, it would be obvious for one skilled in the art that insertion of a restriction site in the manner described could be performed on any gene of the invention. The gene described, when expressed, codes for a polypeptide, L/4H423/A (SEQ ID NO: 10), which contains an additional four amino acids between amino acids 448 and 449 of LH423/A at a position equivalent to the amino terminus of the heavy chain of native BoNT/A.
A variant of the gene has been expressed, LFXa/3H423/A (SEQ ID NO- 12), in which a specific proteolytic cleavage site was incorporated at the carboxy-terminal end of the light chain domain, specifically after residue 448 of L/4H423/A. The cleavage site incorporated was for Factor Xa protease and was coded for by modification of SEQ ID NO: 1 . It will be apparent to one skilled in the art that a cleavage site for another specified protease could be similarly incorporated, and that any gene sequence coding for the required cleavage site could be employed . Modification of the gene sequence in this manner to code for a defined protease site could be performed on any gene of the invention.
Variants of LFXa/3H423/A have been constructed in which a third domain is present at the carboxy-terminal end of the polypeptide which incorporates a specific binding activity into the polypeptide.
Specific examples described are:
0 ) LFχa 3 23/A-| G F-1 <SEQ I D N 0 : 1 4> < ,n which the carboxy-terminal domain has a sequence equivalent to that of insulin-like growth factor-1 (IGF-1 ) and is able to bind to the insulin-like growth factor receptor with high affinity;
(2) LFXa/3H423/A-CtxA1 4 (SEQ ID NO: 1 6) , in which the carboxy-terminal domain has a sequence equivalent to that of the 14 amino acids from the carboxy-terminus of the A-subunit of cholera toxin (CtxA) and is thereby able to interact with the cholera toxin B-subunit pentamer; and
(3) LFXa/3H423/A-ZZ (SEQ ID NO: 1 8) , in which the carboxy-terminal domain is a tandem repeating synthetic IgG binding domain. This variant also exemplifies another modification applicable to the current invention, namely the inclusion in the gene of a sequence coding for a protease cleavage site located between the end of the clostridial heavy chain sequence and the sequence coding for the binding gand. Specifically in this example a sequence is inserted at nucleotides 2650 to 2666 coding for a genenase cleavage site. Expression of this gene produces a polypeptide which has the desired protease sensitivity at the interface between the domain providing HN function and the binding domain. Such a modification enables selective removal of the C-terminal binding domain by treatment of the polypeptide with the relevant protease.
It will be apparent that any one of a number of such binding domains could be incorporated into the polypeptide sequences of this invention and that the above examples are merely to exemplify the concept. Similarly, such binding domains can be incorporated into any of the polypeptide sequences that are the basis of this invention. Further, it should be noted that such binding domains could be incorporated at any appropriate location within the polypeptide molecules of the invention.
Further embodiments of the invention are thus illustrated by a DNA of the invention further comprising a desired restriction endonuclease site at a desired location and by a polypeptide of the invention further comprising a desired protease cleavage site at a desired location.
The restriction endonuclease site may be introduced so as to facilitate further manipulation of the DNA in manufacture of an expression vector for expressing a polypeptide of the invention; it may be introduced as a consequence of a previous step in manufacture of the DNA; it may be introduced by way of modification by insertion, substitution or deletion of a known sequence. The consequence of modification of the DNA may be that the amino acid sequence is unchanged, or may be that the amino acid sequence is changed, for example resulting in introduction of a desired protease cleavage site, either way the polypeptide retains its first and second domains having the properties required by the invention.
Figure 10 is a diagrammatic representation of an expression product exemplifying features described in this example. Specifically, it illustrates a single polypeptide incorporating a domain equivalent to the light chain of botulinum neurotoxin type A and a domain equivalent to the HN domain of the heavy chain of botulinum neurotoxin type A with a N-terminal extension providing an affinity purification domain, namely GST, and a C-terminal extension providing a ligand binding domain, namely an IgG binding domain. The domains of the polypeptide are spatially separated by specific protease cleavage sites enabling selective enzymatic separation of domains as exemplified in the Figure. This concept is more specifically depicted in Figure 1 1 where the various protease sensitivities are defined for the purpose of example.
Assay of product activity
The LC of botulinum neurotoxin type A exerts a zinc-dependent endopeptidase activity on the synaptic vesicle associated protein SNAP-25 which it cleaves in a specific manner at a single peptide bond. The 2LH423/A (Q2E,N26K,A27Y) (SEQ ID NO: 6) cleaves a synthetic SNAP-25 substrate in vitro under the same conditions as the native toxin (Figure 3) . Thus, the modification of the polypeptide sequence of 2LH423/A (Q2E,N26K,A27Y) relative to the native sequence and within the minimal functional LC domains does not prevent the functional activity of the LC domains.
This activity is dependent on proteolytic modification of the recombinant GST-2LH423/A (Q2E,N26K,A27Y) to convert the single chain polypeptide product to a disulphide linked dichain species. This is currently done using the proteolytic enzyme trypsin. The recombinant product ( 100-600 μg/ml) is incubated at 37 °C for 10-50 minutes with trypsin ( 10 μg/ml) in a solution containing 140 mM NaCI, 2.7 mM KCI, 10 mM Na2HP04, 1 .8 mM KH2P04, pH 7.3. The reaction is terminated by addition of a 100-fold molar excess of trypsin inhibitor. The activation by trypsin generates a disulphide linked dichain species as determined by polyacrylamide gel electrophoresis and immunoblotting analysis using polyclonal anti-botulinum neurotoxin type A antiserum.
2LH423/A is more stable in the presence of trypsin and more active in the in vitro peptide cleavage assay than is 23LH423/A. Both variants, however, are fully functional in the in vitro peptide cleavage assay. This demonstrates that the recombinant molecule will tolerate N-terminal amino acid extensions and this may be expanded to other chemical or organic moieties as would be obvious to those skilled in the art.
Example 2
As a further exemplification of this invention a number of gene sequences have been assembled coding for polypeptides corresponding to the entire light-chain and varying numbers of residues from the amino terminal end of the heavy chain of botulinum neurotoxin type B. In this exemplification of the disclosure the gene sequences assembled were obtained from a combination of chromosomal and polymerase-chain-reaction generated DNA, and therefore have the nucleotide sequence of the equivalent regions of the natural genes, thus exemplifying the principle that the substance of this disclosure can be based upon natural as well as a synthetic gene sequences.
The gene sequences relating to this example were all assembled and expressed using methodologies as detailed in Sambrook J, Fritsch E F & Maniatis T ( 1 989) Molecular Cloning: A Laboratory Manual (2nd Edition), Ford N, Nolan C, Ferguson M & Ockler M (eds), Cold Spring Harbor Laboratory Press, New York, and known to those skilled in the art.
A- gene has been assembled coding for a polypeptide of 1 171 amino acids corresponding to the entire light-chain (443 amino acids) and 728 residues from the amino terminus of the heavy chain of neurotoxin type B. Expression of this gene produces a polypeptide, LH728/B (SEQ ID NO: 20), which lacks the specific neuronal binding activity of full length BoNT/B.
A gene has also been assembled coding for a variant polypeptide, LH417/B (SEQ ID NO: 22), which possesses an amino acid sequence at its carboxy terminus equivalent by ammo acid homology to that at the carboxy-terminus of the heavy chain fragment in native LHN/A .
A gene has also been assembled coding for a variant polypeptide, LH,07/B (SEQ ID NO: 24) , which expresses at its carboxy-terminus a short sequence from the ammo terminus of the heavy chain of BoNT/B sufficient to maintain solubility of the expressed polypeptide.
Construct Variants
A variant of the coding sequence for the first 274 bases of the gene shown in SEQ ID NO. 21 has been produced which whilst being a non-native nucleotide sequence still codes for the native polypeptide.
Two double stranded, a 268 base pair and a 951 base pair, gene sequences have been created using an overlapping primer PCR strategy. The nucleotide bias of these sequences was designed to have an E. coli codon usage bias.
For the first sequence, six oligonucleotides representing the first (5') 268 nucleotides of the native sequence for botulinum toxin type B were synthesised. For the second sequence 23 oligonucleotides representing internal sequence nucleotides 691 -1641 of the native sequence for botulinum toxin type B were synthesised. The oligonucleotides ranged from 57-73 nucleotides in length. Overlapping regions, 1 7-20 nucleotides, were designed to give melting temperatures in the range 52-56°C. In addition, terminal restriction endonuclease sites of the synthetic products were constructed to facilitate insertion of these products into the exact corresponding region of the native sequence. The 268 bp 5' synthetic sequence has been incorporated into the gene shown in SEQ ID NO: 21 in place of the original first 268 bases (and is shown in SEQ ID NO: 27) . Similarly the sequence could be inserted into other genes of the examples.
Another variant sequence equivalent to nucleotides 691 to 1 641 of SEQ ID NO: 21 , and employing non-native codon usage whilst coding for a native polypeptide sequence, has been constructed using the internal synthetic sequence. This sequence (SEQ ID NO: 28) can be incorporated, alone or in combination with other variant sequences, in place of the equivalent coding sequence in any of the genes of the example.
Example 3
An exemplification of the utility of this invention is as a non-toxic and effective immunogen. The non-toxic nature of the recombinant, single chain material was demonstrated by intraperitoneal administration in mice of GST-2LH423/A. The polypeptide was prepared and purified as described above. The amount of immunoreactive material in the final preparation was determined by enzyme linked immunosorbent assay (ELISA) using a monoclonal antibody (BA1 1 ) reactive against a conformation dependent epitope on the native LHN/A. The recombinant material was serially diluted in phosphate buffered saline (PBS; NaCI 8 g/l, KCI 0.2 g/l, Na2HP04 1 . 1 5 g/l, KH2P04 0.2 g/l, pH 7.4) and 0.5 ml volumes injected into 3 groups of 4 mice such that each group of mice received 1 0, 5 and 1 micrograms of material respectively. Mice were observed for 4 days and no deaths were seen.
For immunisation, 20 μg of GST-2LH423/A in a 1 .0 ml volume of water-in-oil emulsion ( 1 : 1 vohvol) using Freund's complete (primary injections only) or Freund's incomplete adjuvant was administered into guinea pigs via two sub-cutaneous dorsal injections. Three injections at 10 day intervals were given (day 1 , day 10 and day 20) and antiserum collected on day 30. The antisera were shown by ELISA to be immunoreactive against native botulinum neurotoxin type A and to its derivative LHN/A. Antisera which were botulinum neurotoxin reactive at a dilution of 1 :2000 were used for evaluation of neutralising efficacy in mice. For neutralisation assays 0.1 ml of antiserum was diluted into 2.5 ml of gelatine phosphate buffer (GPB; Na2HP04 anhydrous 10 g/l, gelatin (Difco) 2 g/l, pH 6.5- 6.6) containing a dilution range from 0.5 μg (5X10 6 g) to 5 picograms (5X 10 12 g) . Aliquots of 0.5 ml were injected into mice intraperitoneally and deaths recorded over a 4 day period. The results are shown in Table 1 and Table 2. It can clearly be seen that 0.5 ml of 1 :40 diluted anti- GST-2LH423/A antiserum can protect mice against intraperitoneal challenge with botulinum neurotoxin in the range 5 pg - 50 ng ( 1 - 1 0,000 mouse LD50; 1 mouse LD50 = 5 pg) .
TABLE 1 . Neutralisation of botulinum neurotoxin in mice by guinea pig anti-GST-2LH423/A antiserum.
Botulinum Toxin/mouse
Survivors 0.5μg O.CO5μg 0.0005/ g 0.5ng O.OOδng 5pg Control
On Day (no toxin)
1 4 4 4 4 4 4
2 4 4 4 4 4 4 3 4 4 4 4 4 4 4 4 4 4 4 4 4
TABLE 2. Neutralisation of botulinum neurotoxin in mice by non-immune guinea pig antiserum.
Botulinum Toxin/mouse
Survivors 0.5/ g O.OOδμg O.OOOδμg O.δng O.OOδng 5pg Control On Day (no toxin)
1 2 4 2 0 4 3 4 4 4
Example 4
Expression of recombinant LH107/B in E. coli.
As an exemplification of the expression of a nucleic acid coding for a LHN of a clostridial neurotoxin of a serotype other than botulinum neurotoxin type A, the nucleic acid sequence (SEQ ID NO: 23) coding for the polypeptide LH107/B (SEQ ID NO: 24) was inserted into the commercially available plasmid pET28a (Novogen, Madison, Wl, USA) . The nucleic acid was expressed in E. coli BL21 (DE3) (New England BioLabs, Beverley, MA, USA) as a fusion protein with a N-terminal T7 fusion peptide, under IPTG induction at 1 mM for 90 minutes at 37 °C. Cultures were harvested and recombinant protein extracted as described previously for LH423/A.
Recombinant protein was recovered and purified from bacterial paste lysates by immunoaffinity adsorption to an immobilised anti-T7 peptide monoclonal antibody using a T7 tag purification kit (New England bioLabs, Beverley, MA, USA) . Purified recombinant protein was analysed by gradient (4-20%) denaturing SDS- polyacrylamide gel electrophoresis (Novex, San Diego, CA, USA) and western blotting using poiyclonal anti-botulinum neurotoxin type antiserum or anti-T7 antiserum. Western blotting reagents were from Novex, immunostained proteins were visualised using the Enhanced Chemi-Luminescence system (ECL) from Amersham. The expression of an anti-T7 antibody and anti-botulinum neurotoxin type B antiserum reactive recombinant product is demonstrated in Figure 1 3.
The recombinant product was soluble and retained that part of the light chain responsible for endopeptidase activity.
The invention thus provides recombinant polypeptides useful inter alia as immunogens, enzyme standards and components for synthesis of molecules as described in WO-A-94/21 300.
SEQUENCE LISTING
(1) GENERAL INFORMATION.
(l) APPLICANT:
(A) NAME: MICROBIOLOGICAL RESEARCH AUTHORITY
(B) STREET: Centre For Applied Microbiology And Research,
Porton Down
(C) CITY: Salisbury
(D) STATE: Wiltshire
(E) COUNTRY. UK
(F) POSTAL CODE (ZIP) . SP4 OJG
(A) NAME ■ THE SPEYWOOD LABORATORY LIMITED
(B) STREET- 14 Kensington Square
(C) CITY: London
(E) COUNTRY. UK
(F) POSTAL CODE (ZIP) ■ W8 5HH
(A) NAME- FOSTER; Keith Alan
(B) STREET- Centre For Applied Microbiology And Research,
Porton Down
(C) CITY: Salisbury
(D) STATE: Wiltshire
(E) COUNTRY: UK
(F) POSTAL CODE (ZIP) . SP4 OJG
(A) NAME: QUINN; Conrad Padraig
(B) STREET: Centre For Applied Microbiology And Research,
Porton Down
(C) CITY: Salisbury
(D) STATE: Wiltshire
(E) COUNTRY: UK
(F) POSTAL CODE (ZIP) : SP4 OJG
(A) NAME. SHONE; Clifford Charles
(B) STREET: Centre For Applied Microbiology And Research,
Porton Down
(C) CITY: Salisbury
(D) STATE: Wiltshire (E). COUNTRY: UK
(F) POSTAL CODE (ZIP) : SP4 OJG
(ii) TITLE OF INVENTION: Recombinant Toxin Fragments (iii) NUMBER OF SEQUENCES: 28
(iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPU ER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: Patentln Release #1.0, Version #1.30 (EPO)
(2) INFORMATION FOR SEQ ID NO: 1 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2616 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic) ( IX ) FEATURE :
(A) NAME/KEY: CDS
(B) LOCATION: 1..2616
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 1:
ATG CAG TTC GTG AAC AAG CAG TTC AAC TAT AAG GAC CCT GTA AAC GGT 48 Met Gin Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15
GTT GAC ATT GCC TAC ATC AAA ATT CCA AAC GCC GGC CAG ATG CAG CCG 96 Val Asp lie Ala Tyr lie Lys lie Pro Asn Ala Gly Gin Met Gin Pro 20 25 30
GTG AAG GCT TTC AAG ATT CAT AAC AAA ATC TGG GTT ATT CCG GAA CGC 144 Val Lys Ala Phe Lys lie His Asn Lys lie Trp Val lie Pro Glu Arg 35 40 45
GAT ACA TTT ACG AAC CCG GAA GAA GGA GAC TTG AAC CCG CCG CCG GAA 192 Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60
GCA AAG CAG GTG CCA GTT TCA TAC TAC GAT TCA ACC TAT CTG AGC ACA 240 Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80
GAC AAC GAG AAG GAT AAC TAC CTG AAG GGA GTG ACC AAA TTA TTC GAG 288 Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95
CGT ATT TAT TCC ACT GAC CTG GGC CGT ATG CTG CTG ACC TCA ATC GTC 336 Arg lie Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser lie Val 100 105 110
CGC GGA ATC CCA TTT TGG GGT GGC AGT ACC ATT GAC ACG GAG TTG AAG 384 Arg Gly lie Pro Phe Trp Gly Gly Ser Thr lie Asp Thr Glu Leu Lys 115 120 125
GTT ATT GAC ACT AAC TGC ATT AAC GTG ATC CAA CCA GAC GGT AGC TAC 432 Val lie Asp Thr Asn Cys lie Asn Val lie Gin Pro Asp Gly Ser Tyr 130 135 140
AGA TCT GAA GAA CTT AAC CTC GTA ATC ATC GGG CCC TCC GCG GAC ATT 480 Arg Ser Glu Glu Leu Asn Leu Val lie lie Gly Pro Ser Ala Asp lie 145 150 155 160
ATC CAG TTT GAG TGC AAG AGC TTT GGC CAC GAA GTG TTG AAC CTG ACG 528 lie Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175
CGT AAC GGT TAC GGC TCT ACT CAG TAC ATT CGT TTC AGC CCA GAC TTC 576 Arg Asn Gly Tyr Gly Ser Thr Gin Tyr lie Arg Phe Ser Pro Asp Phe 180 185 190
ACG TTC GGT TTC GAG GAG AGC CTG GAG GTT GAT ACC AAC CCG CTG TTG 624 Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205
GGT GCA GGC AAG TTC GCA ACT GAT CCA GCG GTG ACC CTG GCA CAC GAG 672 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220
CTG ATC CAC GCC GGT CAT CGT CTG TAT GGC ATT GCG ATT AAC CCG AAC 720 Leu lie His Ala Gly His Arg Leu Tyr Gly lie Ala lie Asn Pro Asn 225 230 235 240 CGC GTG TTC AAG GTT AAC ACC AAC GCC TAC TAC GAG ATG AGT GGT TTA 7GR Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255
GAA GTA AGC TTC GAG GAA CTG CGC ACG TTC GGT GGC CAT GAT GCG AAG aifi Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270
TTT ATC GAC AGC TTG CAG GAG AAC GAG TTC CGT CTG TAC TAC TAC AAC 864 Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285
AAG TTT AAA GAT ATT GCA AGT ACA CTG AAC AAG GCT AAG TCC ATT GTG 91? Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300
GGT ACC ACT GCT TCA TTA CAG TAT ATG AAA AAT GTT TTT AAA GAG AAA 960 Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lvs 305 310 315 3^0
TAT CTC CTA TCT GAA GAT ACA TCT GGA AAA TTT TCG GTA GAT AAA TTA 1008 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335
AAA TTT GAT AAG TTA TAC AAA ATG TTA ACA GAG ATT TAC ACA GAG GAT 1056 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350
AAT TTT GTT AAG TTT TTT AAA GTA CTT AAC AGA AAA ACA TAT TTG AAT 1104 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365
TTT GAT AAA GCC GTA TTT AAG ATA AAT ATA GTA CCT AAG GTA AAT TAC 1152 Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tvr 370 375 380
ACA ATA TAT GAT GGA TTT AAT TTA AGA AAT ACA AAT TTA GCA GCA AAC 1200 Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400
TTT AAT GGT CAA AAT ACA GAA ATT AAT AAT ATG AAT TTT ACT AAA CTA 1248 Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415
AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA 1296 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arα 420 425 430
GGG ATA ATA ACT TCT AAA ACT AAA TCA TTA GAT AAA GGA TAC AAT AAG 1344 Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lvs 435 440 445 *
GCA TTA AAT GAT TTA TGT ATC AAA GTT AAT AAT TGG GAC TTG TTT TTT 1392 Ala Leu Asn Asp Leu Cys He Lys Val Asn Asn Trp Asp Leu Phe Phe 450 455 460
AGT CCT TCA GAA GAT AAT TTT ACT AAT GAT CTA AAT AAA GGA GAA GAA 1440 Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu 465 470 475 480
ATT ACA TCT GAT ACT AAT ATA GAA GCA GCA GAA GAA AAT ATT AGT TTA 1488 He Thr Ser Asp Thr Asn He Glu Ala Ala Glu Glu Asn He Ser Leu 485 490 495
GAT TTA ATA CAA CAA TAT TAT TTA ACC TTT AAT TTT GAT AAT GAA CCT 1536 Asp Leu He Gin Gin Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro 500 505 510 GAA AAT ATT TCA ATA GAA AAT CTT TCA AGT GAC ATT ATA GGC CAA TTA 1584 Glu Asn He Ser He Glu Asn Leu Ser Ser Asp He He Gly Gin Leu 515 520 525
GAA CTT ATG CCT AAT ATA GAA AGA TTT CCT AAT GGA AAA AAG TAT GAG 1632 Glu Leu Met Pro Asn He Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu 530 535 540
TTA GAT AAA TAT ACT ATG TTC CAT TAT CTT CGT GCT CAA GAA TTT GAA 1680 Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gin Glu Phe Glu 545 550 555 560
CAT GGT AAA TCT AGG ATT GCT TTA ACA AAT TCT GTT AAC GAA GCA TTA 1728 His Gly Lys Ser Arg He Ala Leu Thr Asn Ser Val Asn Glu Ala Leu 565 570 575
TTA AAT CCT AGT CGT GTT TAT ACA TTT TTT TCT TCA GAC TAT GTA AAG 1776 Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys 580 585 590
AAA GTT AAT AAA GCT ACG GAG GCA GCT ATG TTT TTA GGC TGG GTA GAA 1824 Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu 595 600 605
CAA TTA GTA TAT GAT TTT ACC GAT GAA ACT AGC GAA GTA AGT ACT ACG 1872 Gin Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr 610 615 620
GAT AAA ATT GCG GAT ATA ACT ATA ATT ATT CCA TAT ATA GGA CCT GCT 1920 Asp Lys He Ala Asp He Thr He He He Pro Tyr He Gly Pro Ala 625 630 635 640
TTA AAT ATA GGT AAT ATG TTA TAT AAA GAT GAT TTT GTA GGT GCT TTA 1968 Leu Asn He Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu 645 650 655
ATA TTT TCA GGA GCT GTT ATT CTG TTA GAA TTT ATA CCA GAG ATT GCA 2016 He Phe Ser Gly Ala Val He Leu Leu Glu Phe He Pro Glu He Ala 660 665 670
ATA CCT GTA TTA GGT ACT TTT GCA CTT GTA TCA TAT ATT GCG AAT AAG 2064 He Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr He Ala Asn Lys 675 680 685
GTT CTA ACC GTT CAA ACA ATA GAT AAT GCT TTA AGT AAA AGA AAT GAA 2112 Val Leu Thr Val Gin Thr He Asp Asn Ala Leu Ser Lys Arg Asn Glu 690 695 700
AAA TGG GAT GAG GTC TAT AAA TAT ATA GTA ACA AAT TGG TTA GCA AAG 2160 Lys Trp Asp Glu Val Tyr Lys Tyr He Val Thr Asn Trp Leu Ala Lys 705 710 715 720
GTT AAT ACA CAG ATT GAT CTA ATA AGA AAA AAA ATG AAA GAA GCT TTA 2208 Val Asn Thr Gin He Asp Leu He Arg Lys Lys Met Lys Glu Ala Leu 725 730 735
GAA AAT CAA GCA GAA GCA ACA AAG GCT ATA ATA AAC TAT CAG TAT AAT 2256 Glu Asn Gin Ala Glu Ala Thr Lys Ala He He Asn Tyr Gin Tyr Asn 740 745 750
CAA TAT ACT GAG GAA GAG AAA AAT AAT ATT AAT TTT AAT ATT GAT GAT 2304 Gin Tyr Thr Glu Glu Glu Lys Asn Asn He Asn Phe Asn He Asp Asp 755 760 765
TTA AGT TCG AAA CTT AAT GAG TCT ATA AAT AAA GCT ATG ATT AAT ATA 2352 Leu Ser Ser Lys Leu Asn Glu Ser He Asn Lys Ala Met He Asn He 770 775 780 AAT AAA TTT TTG AAT CAA TGC TCT GTT TCA TAT TTA ATG AAT TCT ATC 2400 Asn Lys Phe Leu Asn Gin Cys Ser Val Ser Tyr Leu Met Asn Ser Met 785 79° 795 800
ATC CCT TAT GGT GTT AAA CGG TTA GAA GAT TTT GAT GCT AGT CTT AAA ■>* * * He Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lvs 80S 810 815
GAT GCA TTA TTA AAG TAT ATA TAT GAT AAT AGA GGA ACT TTA ATT GGT ?* *<: Asp Ala Leu Leu Lys Tyr He Tyr Asp Asn Arg Gly Thr Leu He Gly 620 825 830 V
CAA GTA GAT AGA TTA AAA GAT AAA GTT AAT AAT ACA CTT AGT ACA GAT , , Gin Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp 835 840 845 y
ATA CCT TTT CAG CTT TCC AAA TAC GTA GAT AAT CAA AGA TTA TTA TCT ,„, He Pro Phe Gin Leu Ser Lys Tyr Val Asp Asn Gin Arq Leu Leu Ser 850 855 860
ACA TTT ACT GAA TAT ATT AAG TAA
Thr Phe Thr Glu Tyr He Lys * 2616
865 870
(2) INFORMATION FOR SEQ ID NO 2
(l) SEQUENCE CHARACTERISTICS
(A) LENGTH 872 amino acids
(B) TYPE amino acid (D) TOPOLOGY linear
(ii ) MOLECULE TYPE protein
(xi) SEQUENCE DESCRIPTION SEQ ID NO 2
Met Gin Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15
Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30
Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro Glu Arg 35 40 45
Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60
Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80
Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95
Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 100 105 110
Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lys 115 120 125
Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tyr 130 135 140
Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160
He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175 Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro Asp Phe 180 185 190
Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205
Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220
Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240
Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255
Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270
Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285
Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300
Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320
Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335
Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350
Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365
Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tyr 370 375 380
Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400
Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415
Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430
Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445
Ala Leu Asn Asp Leu Cys He Lys Val Asn Asn Trp Asp Leu Phe Phe 450 455 460
Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu 465 470 475 480
He Thr Ser Asp Thr Asn He Glu Ala Ala Glu Glu Asn He Ser Leu 485 490 495
Asp Leu He Gin Gin Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro 500 505 510
Glu Asn He Ser He Glu Asn Leu Ser Ser Asp He He Gly Gin Leu 515 520 525 Glu Leu Met Pro Asn He Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu 530 535 540
Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gin Glu Phe Glu 545 550 555 560
His Gly Lys Ser Arg He Ala Leu Thr Asn Ser Val Asn Glu Ala Leu 565 570 575
Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys 580 585 590
Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu 595 600 605
Gin Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr 610 615 620
Asp Lys He Ala Asp He Thr He He He Pro Tyr He Gly Pro Ala 625 630 635 640
Leu Asn He Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu 645 650 655
He Phe Ser Gly Ala Val He Leu Leu Glu Phe He Pro Glu He Ala 660 665 670
He Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr He Ala Asn Lys 675 680 685
Val Leu Thr Val Gin Thr He Asp Asn Ala Leu Ser Lys Arg Asn Glu 690 695 700
Lys Trp Asp Glu Val Tyr Lys Tyr He Val Thr Asn Trp Leu Ala Lys 705 710 715 720
Val Asn Thr Gin He Asp Leu He Arg Lys Lys Met Lys Glu Ala Leu 725 730 735
Glu Asn Gin Ala Glu Ala Thr Lys Ala He He Asn Tyr Gin Tyr Asn 740 745 750
Gin Tyr Thr Glu Glu Glu Lys Asn Asn He Asn Phe Asn He Asp Asp 755 760 765
Leu Ser Ser Lys Leu Asn Glu Ser He Asn Lys Ala Met He Asn He 770 775 780
Asn Lys Phe Leu Asn Gin Cys Ser Val Ser Tyr Leu Met Asn Ser Met 785 790 795 800
He Pro Tyr Gly Val Lys Arg Leu Glu Asp PKe Asp Ala Ser Leu Lys 805 810 815
Asp Ala Leu Leu Lys Tyr He Tyr Asp Asn Arg Gly Thr Leu He Gly 820 825 830
Gin Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp 835 840 845
He Pro Phe Gin Leu Ser Lys Tyr Val Asp Asn Gin Arg Leu Leu Ser 850 855 860
Thr Phe Thr Glu Tyr He Lys * 865 870
(2) INFORMATION FOR SEQ ID NO : 3: (l) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2685 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY, linear
(11) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..2685
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 3
GGA TCC CCA GGA ATT CAT ATG ACG TCG ACG CGT CTG CAG AAG CTT CTA 48 Gly Ser Pro Gly He His Met Thr Ser Thr Arg Leu Gin Lys Leu Leu 1 10 15
GAA TTC GAG CTC CCG GGT ACC ATG GAG TTC GTG AAC AAG CAG TTC AAC 96 Glu Phe Glu Leu Pro Gly Thr Met Glu Phe Val Asn Lvs Gin Phe Asn 20 25 ' 30
TAT AAG GAC CCT GTA AAC GGT GTT GAC ATT GCC TAC ATC AAA ATT CCA 144 Tyr Lys Asp Pro Val Asn Gly Val Asp He Ala Tyr He Lvs He Pro 35 40 45
AAG TAC GGC CAG ATG CAG CCG GTG AAG GCT TTC AAG ATT CAT AAC AAA 192 Lys Tyr Gly Gin Met Gin Pro Val Lys Ala Phe Lys He His Asn Lys 50 55 60
ATC TGG GTT ATT CCG GAA CGC GAT ACA TTT ACG AAC CCG GAA GAA GGA 240 He Trp Val He Pro Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly 65 70 75 80
GAC TTG AAC CCG CCG CCG GAA GCA AAG CAG GTG CCA GTT TCA TAC TAC 288 Asp Leu Asn Pro Pro Pro Glu Ala Lys Gin Val Pro Val Ser Tyr Tyr 85 90 95
GAT TCA ACC TAT CTG AGC ACA GAC AAC GAG AAG GAT AAC TAC CTG AAG 336 Asp Ser Thr Tyr Leu Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys 100 105 110
GGA GTG ACC AAA TTA TTC GAG CGT ATT TAT TCC ACT GAC CTG GGC CGT 384 Gly Val Thr Lys Leu Phe Glu Arg He Tyr Ser Thr Asp Leu Gly Arg 115 120 125
ATG CTG CTG ACC TCA ATC GTC CGC GGA ATC CCA TTT TGG GGT GGC AGT 432 Met Leu Leu Thr Ser He Val Arg Gly He Pro Phe Trp Gly Gly Ser 130 135 140
ACC ATT GAC ACG GAG TTG AAG GTT ATT GAC ACT AAC TGC ATT AAC GTG 480 Thr He Asp Thr Glu Leu Lys Val He Asp Thr Asn Cys He Asn Val 145 150 155 160
ATC CAA CCA GAC GGT AGC TAC AGA TCT GAA GAA CTT AAC CTC GTA ATC 528 He Gin Pro Asp Gly Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val He 165 170 175
ATC GGG CCC TCC GCG GAC ATT ATC CAG TTT GAG TGC AAG AGC TTT GGC 576 He Gly Pro Ser Ala Asp He He Gin Phe Glu Cys Lys Ser Phe Gly 180 185 190
CAC GAA GTG TTG AAC CTG ACG CGT AAC GGT TAC GGC TCT ACT CAG TAC 624 His Glu Val Leu Asn Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gin Tyr 195 200 205 ATT CGT TTC AGC CCA GAC TTC ACG TTC GGT TTC GAG GAG AGC CTG GAG 672 He Arg Phe Ser Pro Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu 210 215 220
GTT GAT ACC AAC CCG CTG TTG GGT GCA GGC AAG TTC GCA ACT GAT CCA 720 Val Asp Thr Asn Pro Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro 225 230 235 240
GCG GTG ACC CTG GCA CAC GAG CTG ATC CAC GCC GGT CAT CGT CTG TAT 768 Ala Val Thr Leu Ala His Glu Leu He His Ala Glv His Arg Leu Tyr 245 250 ' 255
GGC ATT GCG ATT AAC CCG AAC CGC GTG TTC AAG GTT AAC ACC AAC GCC 816 Gly He Ala He Asn Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala 260 265 270
TAC TAC GAG ATG AGT GGT TTA GAA GTA AGC TTC GAG GAA CTG CGC ACG 864 Tyr Tyr Glu Met Ser Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr 275 280 285
TTC GGT GGC CAT GAT GCG AAG TTT ATC GAC AGC TTG CAG GAG AAC GAG 912 Phe Gly Gly His Asp Ala Lys Phe He Asp Ser Leu Gin Glu Asn Glu 290 295 300
TTC CGT CTG TAC TAC TAC AAC AAG TTT AAA GAT ATT GCA AGT ACA CTG 960 Phe Arg Leu Tyr Tyr Tyr Asn Lys Phe Lys Asp He Ala Ser Thr Leu 305 310 315 320
AAC AAG GCT AAG TCC ATT GTG GGT ACC ACT GCT TCA TTA CAG TAT ATG 1008 Asn Lys Ala Lys Ser He Val Gly Thr Thr Ala Ser Leu Gin Tyr Met 325 330 335
AAA AAT GTT TTT AAA GAG AAA TAT CTC CTA TCT GAA GAT ACA TCT GGA 1056 Lys Asn Val Phe Lys Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly 340 345 350
AAA TTT TCG GTA GAT AAA TTA AAA TTT GAT AAG TTA TAC AAA ATG TTA 1104 Lys Phe Ser Val Asp Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu 355 360 365
ACA GAG ATT TAC ACA GAG GAT AAT TTT GTT AAG TTT TTT AAA GTA CTT 1152 Thr Glu He Tyr Thr Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu 370 375 380
AAC AGA AAA ACA TAT TTG AAT TTT GAT AAA GCC GTA TTT AAG ATA AAT 1200 Asn Arg Lys Thr Tyr Leu Asn Phe Asp Lys Ala Val Phe Lys He Asn 385 390 395 400
ATA GTA CCT AAG GTA AAT TAC ACA ATA TAT GAT GGA TTT AAT TTA AGA 1248 He Val Pro Lys Val Asn Tyr Thr He Tyr Asp Gly Phe Asn Leu Arg 405 410 415
AAT ACA AAT TTA GCA GCA AAC TTT AAT GGT CAA AAT ACA GAA ATT AAT 1296 Asn Thr Asn Leu Ala Ala Asn Phe Asn Gly Gin Asn Thr Glu He Asn 420 425 430
AAT ATG AAT TTT ACT AAA CTA AAA AAT TTT ACT GGA TTG TTT GAA TTT 1344 Asn Met Asn Phe Thr Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe 435 440 445
TAT AAG TTG CTA TGT GTA AGA GGG ATA ATA ACT TCT AAA ACT AAA TCA 1392 Tyr Lys Leu Leu Cys Val Arg Gly He He Thr Ser Lys Thr Lys Ser 450 455 460
TTA GAT AAA GGA TAC AAT AAG GCA TTA AAT GAT TTA TGT ATC AAA GTT 1440 Leu Asp Lys Gly Tyr Asn Lys Ala Leu Asn Asp Leu Cys He Lys Val 465 470 475 480 AAT AAT TGG GAC TTG TTT TTT AGT CCT TCA GAA GAT AAT TTT ACT AAT 1488 Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu ASD Asn Phe Thr Asn 485 490 * 495
GAT CTA AAT AAA GGA GAA GAA ATT ACA TCT GAT ACT AAT ATA GAA GCA 1536 Asp Leu Asn Lys Gly Glu Glu He Thr Ser Asp Thr Asn He Glu Ala 500 505 510
GCA GAA GAA AAT ATT AGT TTA GAT TTA ATA CAA CAA TAT TAT TTA ACC 1584 Ala Glu Glu Asn He Ser Leu Asp Leu He Gin Gin Tyr Tyr Leu Thr 515 520 525
TTT AAT TTT GAT AAT GAA CCT GAA AAT ATT TCA ATA GAA AAT CTT TCA 1632 Phe Asn Phe Asp Asn Glu Pro Glu Asn He Ser He Glu Asn Leu Ser 530 535 540
AGT GAC ATT ATA GGC CAA TTA GAA CTT ATG CCT AAT ATA GAA AGA TTT 1680 Ser Asp He He Gly Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe 545 550 555 560
CCT AAT GGA AAA AAG TAT GAG TTA GAT AAA TAT ACT ATG TTC CAT TAT 1728 Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lvs Tyr Thr Met Phe His Tyr 565 570 575
CTT CGT GCT CAA GAA TTT GAA CAT GGT AAA TCT AGG ATT GCT TTA ACA 1776 Leu Arg Ala Gin Glu Phe Glu His Gly Lvs Ser Arg He Ala Leu Thr 580 585 590
AAT TCT GTT AAC GAA GCA TTA TTA AAT CCT AGT CGT GTT TAT ACA TTT 1824 Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe 595 600 605
TTT TCT TCA GAC TAT GTA AAG AAA GTT AAT AAA GCT ACG GAG GCA GCT 1872 Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala 610 615 620
ATG TTT TTA GGC TGG GTA GAA CAA TTA GTA TAT GAT TTT ACC GAT GAA 1920 Met Phe Leu Gly Trp Val Glu Gin Leu Val Tyr Asp Phe Thr Asp Glu 625 630 635 640
ACT AGC GAA GTA AGT ACT ACG GAT AAA ATT GCG GAT ATA ACT ATA ATT 1968 Thr Ser Glu Val Ser Thr Thr Asp Lys He Ala Asp He Thr He He 645 650 655
ATT CCA TAT ATA GGA CCT GCT TTA AAT ATA GGT AAT ATG TTA TAT AAA 2016 He Pro Tyr He Gly Pro Ala Leu Asn He Gly Asn Met Leu Tyr Lys 660 665 670
GAT GAT TTT GTA GGT GCT TTA ATA TTT TCA GGA GCT GTT ATT CTG TTA 2064 Asp Asp Phe Val Gly Ala Leu He Phe Ser Gly Ala Val He Leu Leu 675 680 685
GAA TTT ATA CCA GAG ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT 2112 Glu Phe He Pro Glu He Ala He Pro Val Leu Gly Thr Phe Ala Leu 690 695 700
GTA TCA TAT ATT GCG AAT AAG GTT CTA ACC GTT CAA ACA ATA GAT AAT 2160 Val Ser Tyr He Ala Asn Lys Val Leu Thr Val Gin Thr He Asp Asn 705 710 715 720
GCT TTA AGT AAA AGA AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA 2208 Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr He 725 730 735
GTA ACA AAT TGG TTA GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA 2256 Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gin He Asp Leu He Arg 740 745 750 AAA AAA ATG AAA GAA GCT TTA GAA AAT CAA GCA GAA GCA ACA AAG GCT 2304 Lys Lys Met Lys Glu Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala 755 760 765
ATA ATA AAC TAT CAG TAT AAT CAA TAT ACT GAG GAA GAG AAA AAT AAT 2352 He He Asn Tyr Gin Tyr Asn Gin Tyr Thr Glu Glu Glu Lys Asn Asn 770 775 780
ATT AAT TTT AAT ATT GAT GAT TTA AGT TCG AAA CTT AAT GAG TCT ATA 2400 He Asn Phe Asn He Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser He 785 790 795 800
AAT AAA GCT ATG ATT AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT 2448 Asn Lvs Ala Met He Asn He Asn Lys Phe Leu Asn Gin Cys Ser Val 805 810 815
TCA TAT TTA ATG AAT TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA 2496 Ser Tyr Leu Met Asn Ser Met He Pro Tyr Gly Val Lys Arg Leu Glu 820 825 830
GAT TTT GAT GCT AGT CTT AAA GAT GCA TTA TTA AAG TAT ATA TAT GAT 2544 Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr He Tyr Asp 835 840 845
AAT AGA GGA ACT TTA ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT 2592 Asn Arg Gly Thr Leu He Gly Gin Val Asp Arg Leu Lys Asp Lys Val 850 855 860
AAT AAT ACA CTT AGT ACA GAT ATA CCT TTT CAG CTT TCC AAA TAC GTA 2640 Asn Asn Thr Leu Ser Thr Asp He Pro Phe Gin Leu Ser Lys Tyr Val 865 870 875 880
GAT AAT CAA AGA TTA TTA TCT ACA TTT ACT GAA TAT ATT AAG TAA 2685
Asp Asn Gin Arg Leu Leu Ser Thr Phe Thr Glu Tyr He Lys * 885 890 895
(2) INFORMATION FOR SEQ ID NO : 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 895 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
Gly Ser Pro Gly He His Met Thr Ser Thr Arg Leu Gin Lys Leu Leu 1 5 10 15
Glu Phe Glu Leu Pro Gly Thr Met Glu Phe Val Asn Lys Gin Phe Asn 20 25 30 -
Tyr Lys Asp Pro Val Asn Gly Val Asp He Ala Tyr He Lys He Pro 35 40 45
Lys Tyr Gly Gin Met Gin Pro Val Lys Ala Phe Lys He His Asn Lys 50 55 60
He Trp Val He Pro Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly 65 70 75 80
Asp Leu Asn Pro Pro Pro Glu Ala Lys Gin Val Pro Val Ser Tyr Tyr 85 90 95
Asp Ser Thr Tyr Leu Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys 100 105 * 110 Gly Val Thr Lys Leu Phe Glu Arg He Tyr Ser Thr Asp Leu Gly Arq 115 120 125
Met Leu Leu Thr Ser He Val Arg Gly He Pro Phe Trp Gly Gly Ser 130 135 140
Thr He Asp Thr Glu Leu Lys Val He Asp Thr Asn Cys He Asn Val 145 150 155 ' 160
He Gin Pro Asp Gly Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val He 165 170 175
He Gly Pro Ser Ala Asp He He Gin Phe Glu Cys Lys Ser Phe Gly 180 185 ' 190
His Glu Val Leu Asn Leu Thr Arg Asn Gly Tyr Glv Ser Thr Gin Tyr 195 200 * ' 205
He Arg Phe Ser Pro Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu 210 215 220
Val Asp Thr Asn Pro Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro 225 230 235 240
Ala Val Thr Leu Ala His Glu Leu He His Ala Gly His Arg Leu Tyr 245 250 255
Gly He Ala He Asn Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala 260 265 270
Tyr Tyr Glu Met Ser Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr 275 280 285
Phe Gly Gly His Asp Ala Lys Phe He Asp Ser Leu Gin Glu Asn Glu 290 295 300
Phe Arg Leu Tyr Tyr Tyr Asn Lys Phe Lys Asp He Ala Ser Thr Leu 305 310 315 320
Asn Lys Ala Lys Ser He Val Gly Thr Thr Ala Ser Leu Gin Tyr Met 325 330 335
Lys Asn Val Phe Lys Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly 3.40 345 350
Lys Phe Ser Val Asp Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu 355 360 365
Thr Glu He Tyr Thr Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu 370 375 380
Asn Arg Lys Thr Tyr Leu Asn Phe Asp Lys Ala Val Phe Lys He Asn 385 390 395 400
He Val Pro Lys Val Asn Tyr Thr He Tyr Asp Gly Phe Asn Leu Arg 405 410 415
Asn Thr Asn Leu Ala Ala Asn Phe Asn Gly Gin Asn Thr Glu He Asn 420 425 430
Asn Met Asn Phe Thr Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe 435 440 445
Tyr Lys Leu Leu Cys Val Arg Gly He He Thr Ser Lys Thr Lys Ser 450 455 460 Leu Asp Lys Gly Tyr Asn Lys Ala Leu Asn Asp Leu Cys He Lvs Val 465 470 475 - 480
Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn 485 490 495
Asp Leu Asn Lys Gly Glu Glu He Thr Ser Asp Thr Asn He Glu Ala 500 505 510
Ala Glu Glu Asn He Ser Leu Asp Leu He Gin Gin Tyr Tyr Leu Thr 515 520 525
Phe Asn Phe Asp Asn Glu Pro Glu Asn He Ser He Glu Asn Leu Ser 530 535 540
Ser Asp He He Gly Gin Leu Glu Leu Met Pro Asn He Glu Arα Ph<= 545 550 555 9 5gJ
Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr 565 570 575
Leu Arg Ala Gin Glu Phe Glu His Gly Lys Ser Arg He Ala Leu Thr 580 585 590
Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe 595 600 605
Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala 610 615 620
Met Phe Leu Gly Trp Val Glu Gin Leu Val Tyr Asp Phe Thr Asp Glu 25 630 635 640
Thr Ser Glu Val Ser Thr Thr Asp Lys He Ala Asp He Thr He He 6 5 650 655
He Pro Tyr He Gly Pro Ala Leu Asn He Gly Asn Met Leu Tyr Lys 660 665 670
Asp Asp Phe Val Gly Ala Leu He Phe Ser Gly Ala Val He Leu Leu 675 680 685
Glu Phe He Pro Glu He Ala He Pro Val Leu Gly Thr Phe Ala Leu 690 695 700
Val Ser Tyr He Ala Asn Lys Val Leu Thr Val Gin Thr He Asp Asn 705 710 715 * 720
Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tvr He 725 730 735
Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gin He Asp Leu He Arq 740 745 750
Lys Lys Met Lys Glu Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala 755 760 765
He He Asn Tyr Gin Tyr Asn Gin Tyr Thr Glu Glu Glu Lys Asn Asn 770 775 780
He Asn Phe Asn He Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser He 785 790 795 800 sn Lys Ala Met He Asn He Asn Lys Phe Leu Asn Gin Cys Ser Val 805 810 815 Ser Tyr Leu Met Asn Ser Met He Pro Tyr Gly Val Lys Arg Leu Glu 820 825 830
Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr He Tyr Asp 835 B40 845
Asn Arg Gly Thr Leu He Gly Gin Val Asp Arg Leu Lys Asp Lys Val 850 855 860
Asn Asn Thr Leu Ser Thr Asp He Pro Phe Gin Leu Ser Lys Tyr Val 865 B70 875 ' 880
Asp Asn Gin Arg Leu Leu Ser Thr Phe Thr Glu Tyr He Lys * 885 890 895
(2) INFORMATION FOR SEQ ID NO : 5.
(l) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2622 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS double
(D) TOPOLOGY: linear
(n) MOLECULE TYPE- DNA (genomic)
(ix) FEATURE.
(A) NAME/KEY: CDS
(B) LOCATION: 1..2622
( i ) SEQUENCE DESCRIPTION: SEQ ID NO : 5:
GGA TCC ATG GAG TTC GTG AAC AAG CAG TTC AAC TAT AAG GAC CCT GTA 48 Gly Ser Met Glu Phe Val Asn Lys Gin Phe Asn Tvr Lys Asp Pro Val 1 5 10 ' 15
AAC GGT GTT GAC ATT GCC TAC ATC AAA ATT CCA AAG TAC GGC CAG ATG 96 Asn Gly Val Asp He Ala Tyr He Lys He Pro Lys Tyr Gly Gin Met 20 25 30
CAG CCG GTG AAG GCT TTC AAG ATT CAT AAC AAA ATC TGG GTT ATT CCG 144 Gin Pro Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro 35 40 45
GAA CGC GAT ACA TTT ACG AAC CCG GAA GAA GGA GAC TTG AAC CCG CCG 192 Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro 50 55 60
CCG GAA GCA AAG CAG GTG CCA GTT TCA TAC TAC GAT TCA ACC TAT CTG 240 Pro Glu Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu 65 70 75 80
AGC ACA GAC AAC GAG AAG GAT AAC TAC CTG AAG GGA GTG ACC AAA TTA 288 Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu 85 90 95
TTC GAG CGT ATT TAT TCC ACT GAC CTG GGC CGT ATG CTG CTG ACC TCA 336 Phe Glu Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser 100 105 110
ATC GTC CGC GGA ATC CCA TTT TGG GGT GGC AGT ACC ATT GAC ACG GAG 384 He Val Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu 115 120 125
TTG AAG GTT ATT GAC ACT AAC TGC ATT AAC GTG ATC CAA CCA GAC GGT 432 Leu Lys Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly 130 135 140 AGC TAC AGA TCT GAA GAA CTT AAC CTC GTA ATC ATC GGG CCC TCC rrr 480 Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala 145 15° 155 160
GAC ATT ATC CAG TTT GAG TGC AAG AGC TTT GGC CAC GAA GTG TTG AAC 528 Asp He He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn 165 170 175
CTG ACG CGT AAC GGT TAC GGC TCT ACT CAG TAC ATT CGT TTC AGC CCA 576 Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro 180 185 190
GAC TTC ACG TTC GGT TTC GAG GAG AGC CTG GAG GTT GAT ACC AAC CCG 624 Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro 195 200 205
CTG TTG GGT GCA GGC AAG TTC GCA ACT GAT CCA GCG GTG ACC CTG GCA 672 Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala 210 215 220
CAC GAG CTG ATC CAC GCC GGT CAT CGT CTG TAT GGC ATT GCG ATT AAC 720 His Glu Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn 225 230 235 240
CCG AAC CGC GTG TTC AAG GTT AAC ACC AAC GCC TAC TAC GAG ATG AGT 768 Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser 245 250 255
GGT TTA GAA GTA AGC TTC GAG GAA CTG CGC ACG TTC GGT GGC CAT GAT 816 Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp 260 265 270
GCG AAG TTT ATC GAC AGC TTG CAG GAG AAC GAG TTC CGT CTG TAC TAC 864 Ala Lys Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr 275 280 285
TAC AAC AAG TTT AAA GAT ATT GCA AGT ACA CTG AAC AAG GCT AAG TCC 912 Tyr Asn Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser 290 295 300
ATT GTG GGT ACC ACT GCT TCA TTA CAG TAT ATG AAA AAT GTT TTT AAA 960 He Val Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys 305 310 315 320
GAG AAA TAT CTC CTA TCT GAA GAT ACA TCT GGA AAA TTT TCG GTA GAT 1008 Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp 325 330 335
AAA TTA AAA TTT GAT AAG TTA TAC AAA ATG TTA ACA GAG ATT TAC ACA 1056 Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr 340 345 350
GAG GAT AAT TTT GTT AAG TTT TTT AAA GTA CTT AAC AGA AAA ACA TAT 1104 Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr 355 360 365
TTG AAT TTT GAT AAA GCC GTA TTT AAG ATA AAT ATA GTA CCT AAG GTA 1152 Leu Asn Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val 370 375 380
AAT TAC ACA ATA TAT GAT GGA TTT AAT TTA AGA AAT ACA AAT TTA GCA 1200 Asn Tyr Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala 385 390 395 400
GCA AAC TTT AAT GGT CAA AAT ACA GAA ATT AAT AAT ATG AAT TTT ACT 1248 Ala Asn Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr 405 410 415 AAA CTA AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT 1296 Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys 420 425 * 430
GTA AGA GGG ATA ATA ACT TCT AAA ACT AAA TCA TTA GAT AAA GGA TAC 1344 Val Arg Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr 435 440 445
AAT AAG GCA TTA AAT GAT TTA TGT ATC AAA GTT AAT AAT TGG GAC TTG 1392 Asn Lys Ala Leu Asn Asp Leu Cys He Lys Val Asn Asn Trp Asp Leu 450 455 460
TTT TTT AGT CCT TCA GAA GAT AAT TTT ACT AAT GAT CTA AAT AAA GGA 1440 Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly 465 470 475 ' 480
GAA GAA ATT ACA TCT GAT ACT AAT ATA GAA GCA GCA GAA GAA AAT ATT 1488 Glu Glu He Thr Ser Asp Thr Asn He Glu Ala Ala Glu Glu Asn He 485 490 495
AGT TTA GAT TTA ATA CAA CAA TAT TAT TTA ACC TTT AAT TTT GAT AAT 1536 Ser Leu Asp Leu He Gin Gin Tyr Tyr Leu Thr Phe Asn Phe Asp Asn 500 505 510
GAA CCT GAA AAT ATT TCA ATA GAA AAT CTT TCA AGT GAC ATT ATA GGC 1584 Glu Pro Glu Asn He Ser He Glu Asn Leu Ser Ser ASP He He Gly 515 520 525
CAA TTA GAA CTT ATG CCT AAT ATA GAA AGA TTT CCT AAT GGA AAA AAG 1632 Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe Pro Asn Gly Lys Lvs 530 535 540
TAT GAG TTA GAT AAA TAT ACT ATG TTC CAT TAT CTT CGT GCT CAA GAA 1680 Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gin Glu 545 550 555 560
TTT GAA CAT GGT AAA TCT AGG ATT GCT TTA ACA AAT TCT GTT AAC GAA 1728 Phe Glu His Gly Lys Ser Arg He Ala Leu Thr Asn Ser Val Asn Glu 565 570 575
GCA TTA TTA AAT CCT AGT CGT GTT TAT ACA TTT TTT TCT TCA GAC TAT 1776 Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr 580 585 590
GTA AAG AAA GTT AAT AAA GCT ACG GAG GCA GCT ATG TTT TTA GGC TGG 1824 Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp 595 600 605
GTA GAA CAA TTA GTA TAT GAT TTT ACC GAT GAA ACT AGC GAA GTA AGT 1872 Val Glu Gin Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser 610 615 620
ACT ACG GAT AAA ATT GCG GAT ATA ACT ATA ATT ATT CCA TAT ATA GGA 1920 Thr Thr Asp Lys He Ala Asp He Thr He He He Pro Tyr He Gly 625 630 635 640
CCT GCT TTA AAT ATA GGT AAT ATG TTA TAT AAA GAT GAT TTT GTA GGT 1968 Pro Ala Leu Asn He Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly 645 650 655
GCT TTA ATA TTT TCA GGA GCT GTT ATT CTG TTA GAA TTT ATA CCA GAG 2016 Ala Leu He Phe Ser Gly Ala Val He Leu Leu Glu Phe He Pro Glu 660 665 670
ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT GTA TCA TAT ATT GCG 2064 He Ala He Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr He Ala 675 680 685 AAT AAG GTT CTA ACC GTT CAA ACA ATA GAT AAT GCT TTA AGT AAA AGA 2112 Asn Lys Val Leu Thr Val Gin Thr He Asp Asn Ala Leu Ser Lys Arg 690 695 700
AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA GTA ACA AAT TGG TTA 2160 Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr He Val Thr Asn Trp Leu 705 710 715 720
GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA AAA AAA ATG AAA GAA 2208 Ala Lys Val Asn Thr Gin He Asp Leu He Arg Lys Lys Met Lys Glu 725 730 735
GCT TTA GAA AAT CAA GCA GAA GCA ACA AAG GCT ATA ATA AAC TAT CAG 2256 Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala He He Asn Tyr Gin 740 745 750
TAT AAT CAA TAT ACT GAG GAA GAG AAA AAT AAT ATT AAT TTT AAT ATT 2304 Tyr Asn Gin Tyr Thr Glu Glu Glu Lys Asn Asn He Asn Phe Asn He 755 760 765
GAT GAT TTA AGT TCG AAA CTT AAT GAG TCT ATA AAT AAA GCT ATG ATT 2352 Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser He Asn Lys Ala Met He 770 775 780
AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT TCA TAT TTA ATG AAT 2400 Asn He Asn Lys Phe Leu Asn Gin Cys Ser Val Ser Tvr Leu Met Asn 785 790 795 ' 800
TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA GAT TTT GAT GCT AGT 2448 Ser Met He Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser 805 810 815
CTT AAA GAT GCA TTA TTA AAG TAT ATA TAT GAT AAT AGA GGA ACT TTA 2496 Leu Lys Asp Ala Leu Leu Lys Tyr He Tyr Asp Asn Arg Gly Thr Leu 820 825 830
ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT AAT AAT ACA CTT AGT 2544 He Gly Gin Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser 835 840 845
ACA GAT ATA CCT TTT CAG CTT TCC AAA TAC GTA GAT AAT CAA AGA TTA 2592 Thr Asp He Pro Phe Gin Leu Ser Lys Tyr Val Asp Asn Gin Arg Leu 850 855 860
TTA TCT ACA TTT ACT GAA TAT ATT AAG TAA 2622
Leu Ser Thr Phe Thr Glu Tyr He Lys * 865 870
(2) INFORMATION FOR SEQ ID NO: 6:
(i) SEQUENCE CHARACTERIS ICS:
(A) LENGTH: 874 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 6:
Gly Ser Met Glu Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val 1 5 10 15
Asn Gly Val Asp He Ala Tyr He Lys He Pro Lys Tyr Gly Gin Met 20 25 30
Gin Pro Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro 35 40 45 Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro 50 55 60
Pro Glu Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu 65 70 75 80
Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu 85 90 95
Phe Glu Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser 100 105 110
He Val Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu 115 120 125
Leu Lys Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly 130 135 140
Ser Tvr Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala 145 ' 150 155 160
Asp He He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn 165 170 175
Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro 180 185 190
Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro 195 200 205
Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala 210 215 220
His Glu Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn 225 230 235 240
Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser 245 250 255
Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp 260 265 270
Ala Lys Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr 275 . 280 285
Tyr Asn Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser 290 295 300
He Val Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys 305 310 315 320
Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys-Phe Ser Val Asp 325 330 335
Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr 340 345 350
Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr 355 360 365
Leu Asn Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val 370 375 380
Asn Tyr Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala 385 390 395 400 Ala Asn Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr 405 410 415
Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys 420 425 * 430
Val Arg Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr 435 440 445
Asn Lys Ala Leu Asn Asp Leu Cys He Lys Val Asn Asn Trp Asp Leu 450 455 460
Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn AΞD Leu Asn Lys Gly 465 470 475 " 480
Glu Glu He Thr Ser Asp Thr Asn He Glu Ala Ala Glu Glu Asn He 485 490 495
Ser Leu Asp Leu He Gin Gin Tyr Tyr Leu Thr Phe Asn Phe Asp Asn 500 505 510
Glu Pro Glu Asn He Ser He Glu Asn Leu Ser Ser Asp He He Gly 515 520 525
Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe Pro Asn Gly Lys Lys 530 535 540
Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gin Glu 545 550 555 560
Phe Glu His Gly Lys Ser Arg He Ala Leu Thr Asn Ser Val Asn Glu 565 570 575
Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr 580 585 590
Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp 595 600 605
Val Glu Gin Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser 610 615 620
Thr Thr Asp Lys He Ala Asp He Thr He He He Pro Tyr He Gly 625 630 635 640
Pro Ala Leu Asn He Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly 645 650 655
Ala Leu He Phe Ser Gly Ala Val He Leu Leu Glu Phe He Pro Glu 660 665 670
He Ala He Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr He Ala 675 680 685
Asn Lys Val Leu Thr Val Gin Thr He Asp Asn Ala Leu Ser Lys Arg 690 695 700
Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr He Val Thr Asn Trp Leu 705 710 715 720
Ala Lys Val Asn Thr Gin He Asp Leu He Arg Lys Lys Met Lys Glu 725 730 735
Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala He He Asn Tyr Gin 740 745 750 Tyr Asn Gin Tyr Thr Glu Glu Glu Lys Asn Asn He Asn Phe Asn He 755 760 765
Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser He Asn Lys Ala Met He 770 775 780
Asn He Asn Lys Phe Leu Asn Gin Cys Ser Val Ser Tvr Leu Met Asn 785 790 795 ' 800
Ser Met He Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser 805 810 815
Leu Lys Asp Ala Leu Leu Lys Tyr He Tyr Asp Asn Arg Gly Thr Leu 820 825 830
He Gly Gin Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser 835 840 845
Thr Asp He Pro Phe Gin Leu Ser Lys Tyr Val Asp Asn Gin Arg Leu 850 855 860
Leu Ser Thr Phe Thr Glu Tyr He Lys * 865 870
(2) INFORMATION FOR SEQ ID NO ■ 7
(l) SEQUENCE CHARACTERISTICS:
(A) LENGTH- 2613 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS- double
(D) TOPOLOGY: linear
(ii ) MOLECULE TYPE- DNA (genomic)
(IX) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..2613
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 7:
ATG CCA TTT GTT AAT AAA CAA TTT AAT TAT AAA GAT CCT GTA AAT GGT 46 Met Pro Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15
GTT GAT ATT GCT TAT ATA AAA ATT CCA AAT GCA GGA CAA ATG CAA CCA 96 Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30
GTA AAA GCT TTT AAA ATT CAT AAT AAA ATA TGG GTT ATT CCA GAA AGA 144 Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro Glu Arg 35 40 45
GAT ACA TTT ACA AAT CCT GAA GAA GGA GAT TTA AAT CCA CCA CCA GAA 192 Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60
GCA AAA CAA GTT CCA GTT TCA TAT TAT GAT TCA ACA TAT TTA AGT ACA 240 Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80
GAT AAT GAA AAA GAT AAT TAT TTA AAG GGA GTT ACA AAA TTA TTT GAG 288 Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95 AGA ATT TAT TCA ACT GAT CTT GGA AGA ATG TTG TTA ACA TCA ATA GTA 33fi Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 100 105 HO
AGG GGA ATA CCA TTT TGG GGT GGA AGT ACA ATA GAT ACA GAA TTA AAA 384 Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lvs 115 120 125
GTT ATT GAT ACT AAT TGT ATT AAT GTG ATA CAA CCA GAT GGT AGT TAT 432 Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tyr 130 135 140
AGA TCA GAA GAA CTT AAT CTA GTA ATA ATA GGA CCC TCA GCT GAT ATT 480 Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160
ATA CAG TTT GAA TGT AAA AGC TTT GGA CAT GAA GTT TTG AAT CTT ACG 528 He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175
CGA AAT GGT TAT GGC TCT ACT CAA TAC ATT AGA TTT AGC CCA GAT TTT 576 Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro Asp Phe 180 185 190
ACA TTT GGT TTT GAG GAG TCA CTT GAA GTT GAT ACA AAT CCT CTT TTA 624 Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205
GGT GCA GGC AAA TTT GCT ACA GAT CCA GCA GTA ACA TTA GCA CAT GAA 672 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220
CTT ATA CAT GCT GGA CAT AGA TTA TAT GGA ATA GCA ATT AAT CCA AAT 720 Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240
AGG GTT TTT AAA GTA AAT ACT AAT GCC TAT TAT GAA ATG AGT GGG TTA 768 Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255
GAA GTA AGC TTT GAG GAA CTT AGA ACA TTT GGG GGA CAT GAT GCA AAG 816 Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270
TTT ATA GAT AGT TTA CAG GAA AAC GAA TTT CGT CTA TAT TAT TAT AAT 864 Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285
AAG TTT AAA GAT ATA GCA AGT ACA CTT AAT AAA GCT AAA TCA ATA GTA 912 Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300
GGT ACT ACT GCT TCA TTA CAG TAT ATG AAA AAT GTT TTT AAA GAG AAA 960 Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lvs 05 310 315 320
TAT CTC CTA TCT GAA GAT ACA TCT GGA AAA TTT TCG GTA GAT AAA TTA 1008 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335
AAA TTT GAT AAG TTA TAC AAA ATG TTA ACA GAG ATT TAC ACA GAG GAT 1056 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350
AAT TTT GTT AAG TTT TTT AAA GTA CTT AAC AGA AAA ACA TAT TTG AAT 1104 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365 TTT GAT AAA GCC GTA TTT AAG ATA AAT ATA GTA CCT AAG GTA AAT TAC 1152 Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tyr 370 375 380
ACA ATA TAT GAT GGA TTT AAT TTA AGA AAT ACA AAT TTA GCA GCA AAC 1200 Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400
TTT AAT GGT CAA AAT ACA GAA ATT AAT AAT ATG AAT TTT ACT AAA CTA 1248 Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415
AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA 1296 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430
GGG ATA ATA ACT TCT AAA ACT AAA TCA TTA GAT AAA GGA TAC AAT AAG 1344 Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445
GCA TTA AAT GAT TTA TGT ATC AAA GTT AAT AAT TGG GAC TTG TTT TTT 1392 Ala Leu Asn Asp Leu Cys He Lys Val Asn Asn Trp Asp Leu Phe Phe 450 455 460
AGT CCT TCA GAA GAT AAT TTT ACT AAT GAT CTA AAT AAA GGA GAA GAA 1440 Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu 465 470 475 480
ATT ACA TCT GAT ACT AAT ATA GAA GCA GCA GAA GAA AAT ATT AGT TTA 1488 He Thr Ser Asp Thr Asn He Glu Ala Ala Glu Glu Asn He Ser Leu 485 490 495
GAT TTA ATA CAA CAA TAT TAT TTA ACC TTT AAT TTT GAT AAT GAA CCT 1536 Asp Leu He Gin Gin Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro 500 505 510
GAA AAT ATT TCA ATA GAA AAT CTT TCA AGT GAC ATT ATA GGC CAA TTA 1584 Glu Asn He Ser He Glu Asn Leu Ser Ser Asp He He Gly Gin Leu 515 520 525
GAA CTT ATG CCT AAT ATA GAA AGA TTT CCT AAT GGA AAA AAG TAT GAG 1632 Glu Leu Met Pro Asn He Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu 530 535 540
TTA GAT AAA TAT ACT ATG TTC CAT TAT CTT CGT GCT CAA GAA TTT GAA 1680 Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gin Glu Phe Glu 545 550 555 560
CAT GGT AAA TCT AGG ATT GCT TTA ACA AAT TCT GTT AAC GAA GCA TTA 1728 His Gly Lys Ser Arg He Ala Leu Thr Asn Ser Val Asn Glu Ala Leu 565 570 5JZ5
TTA AAT CCT AGT CGT GTT TAT ACA TTT TTT TCT TCA GAC TAT GTA AAG 1776 Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys 580 585 590
AAA GTT AAT AAA GCT ACG GAG GCA GCT ATG TTT TTA GGC TGG GTA GAA 1824 Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu 595 600 605
CAA TTA GTA TAT GAT TTT ACC GAT GAA ACT AGC GAA GTA AGT ACT ACG 1872 Gin Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr 610 615 620
GAT AAA ATT GCG GAT ATA ACT ATA ATT ATT CCA TAT ATA GGA CCT GCT 1920 Asp Lys He Ala Asp He Thr He He He Pro Tyr He Gly Pro Ala 625 630 635 640 TTA AAT ATA GGT AAT ATG TTA TAT AAA GAT GAT TTT GTA GGT GCT TTA 1968 Leu Asn He Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu 645 650 655
ATA TTT TCA GGA GCT GTT ATT CTG TTA GAA TTT ATA CCA GAG ATT GCA 2016 He Phe Ser Gly Ala Val He Leu Leu Glu Phe He Pro Glu He Ala 660 665 670
ATA CCT GTA TTA GGT ACT TTT GCA CTT GTA TCA TAT ATT GCG AAT AAG 2064 He Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr He Ala Asn Lys 675 680 685
GTT CTA ACC GTT CAA ACA ATA GAT AAT GCT TTA AGT AAA AGA AAT GAA 2112 Val Leu Thr Val Gin Thr He Asp Asn Ala Leu Ser Lys Arg Asn Glu 690 695 700
AAA TGG GAT GAG GTC TAT AAA TAT ATA GTA ACA AAT TGG TTA GCA AAG 2160 Lys Trp Asp Glu Val Tyr Lys Tyr He Val Thr Asn Trp Leu Ala Lys 705 710 715 720
GTT AAT ACA CAG ATT GAT CTA ATA AGA AAA AAA ATG AAA GAA GCT TTA 2208 Val Asn Thr Gin He Asp Leu He Arg Lys Lys Met Lys Glu Ala Leu 725 730 735
GAA AAT CAA GCA GAA GCA ACA AAG GCT ATA ATA AAC TAT CAG TAT AAT 2256 Glu Asn Gin Ala Glu Ala Thr Lys Ala He He Asn Tyr Gin Tyr Asn 740 745 750
CAA TAT ACT GAG GAA GAG AAA AAT AAT ATT AAT TTT AAT ATT GAT GAT 2304 Gin Tyr Thr Glu Glu Glu Lys Asn Asn He Asn Phe Asn He Asp Asp 755 760 765
TTA AGT TCG AAA CTT AAT GAG TCT ATA AAT AAA GCT ATG ATT AAT ATA 2352 Leu Ser Ser Lys Leu Asn Glu Ser He Asn Lys Ala Met He Asn He 770 775 780
AAT AAA TTT TTG AAT CAA TGC TCT GTT TCA TAT TTA ATG AAT TCT ATG 2400 Asn Lys Phe Leu Asn Gin Cys Ser Val Ser Tyr Leu Met Asn Ser Met 785 790 795 800
ATC CCT TAT GGT GTT AAA CGG TTA GAA GAT TTT GAT GCT AGT CTT AAA 2448 He Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys 805 810 815
GAT GCA TTA TTA AAG TAT ATA TAT GAT AAT AGA GGA ACT TTA ATT GGT 2496 Asp Ala Leu Leu Lys Tyr He Tyr Asp Asn Arg Gly Thr Leu He Gly 820 825 830
CAA GTA GAT AGA TTA AAA GAT AAA GTT AAT AAT ACA CTT AGT ACA GAT 2544 Gin Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp 835 840 845
ATA CCT TTT CAG CTT TCC AAA TAC GTA GAT AAT CAA AGA TTA TTA TCT 2592 He Pro Phe Gin Leu Ser Lys Tyr Val Asp Asn Gin Arg Leu Leu Ser 850 855 860
ACA TTT ACT GAA TAT ATT AAG 2613
Thr Phe Thr Glu Tyr He Lys 865 870
(2) INFORMATION FOR SEQ ID NO : 8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 871 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 8:
Met Pro Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15
Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30
Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro Glu Arg 35 40 45
Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60
Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80
Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95
Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 100 105 110
Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lys 115 120 125
Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tyr 130 135 140
Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160
He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175
Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro Asp Phe 180 185 190
Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205
Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 " 215 220
Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240
Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255
Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270
Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285
Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300
Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320
Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350
Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365
Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tyr 370 375 380
Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 39° 395 400
Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lvs Leu 405 410 4i5
Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arα 420 425 4^0 9
Gly He lie Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445 J
Ala Leu Asn Asp Leu Cys He Lys Val Asn Asn Trp ASD Leu Phe Phe 450 455 460
Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu 465 47° 475 480
He Thr Ser Asp Thr Asn He Glu Ala Ala Glu Glu Asn He Ser Leu 485 490 4g5
Asp Leu He Gin Gin Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro 500 505 510
Glu Asn lie Ser He Glu Asn Leu Ser Ser Asp He He Gly Gin Leu 515 520 525
Glu Leu Met Pro Asn He Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu 530 535 540
Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gin Glu Phe Glu 545 550 555 560
His Gly Lys Ser Arg He Ala Leu Thr Asn Ser Val Asn Glu Ala Leu 565 570 575
Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lvs 580 585 590
Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu 595 600 605
Gin Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr 610 615 620
Asp Lys He Ala Asp He Thr He He He Pro Tyr He Gly Pro Ala 625 630 635 640
Leu Asn He Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu 645 650 655
He Phe Ser Gly Ala Val He Leu Leu Glu Phe He Pro Glu He Ala 660 665 670
He Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr He Ala Asn Lys 675 680 685 Val Leu Thr Val Gin Thr He Asp Asn Ala Leu Ser Lys Arg Asn Glu 690 695 700
Lys Trp Asp Glu Val Tyr Lys Tyr He Val Thr Asn Trp Leu Ala Lys 705 710 715 720
Val Asn Thr Gin He Asp Leu He Arg Lys Lys Met Lys Glu Ala Leu 725 730 735
Glu Asn Gin Ala Glu Ala Thr Lys Ala He He Asn Tyr Gin Tyr Asn 740 745 750
Gin Tyr Thr Glu Glu Glu Lys Asn Asn He Asn Phe Asn He Asp Asp 755 760 765
Leu Ser Ser Lys Leu Asn Glu Ser He Asn Lys Ala Met He Asn He 770 775 780
Asn Lys Phe Leu Asn Gin Cys Ser Val Ser Tyr Leu Met Asn Ser Met 785 790 795 800
He Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys 805 810 815
Asp Ala Leu Leu Lys Tyr He Tyr Asp Asn Arg Gly Thr Leu He Gly 820 825 830
Gin Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp 835 840 845
He Pro Phe Gin Leu Ser Lys Tyr Val Asp Asn Gin Arg Leu Leu Ser 850 855 860
Thr Phe Thr Glu Tyr He Lys 865 870
(2) INFORMATION FOR SEQ ID NO : 9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2628 base pairs
(B) TYPE: nucleic acid
( C ) STRANDEDNESS : double
(D) TOPOLOGY : linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATIO :1..2628
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 9:
ATG CAG TTC GTG AAC AAG CAG TTC AAC TAT AAG GAC CCT GTA AAC GGT 48 Met Gin Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15
GTT GAC ATT GCC TAC ATC AAA ATT CCA AAC GCC GGC CAG ATG CAG CCG 96 Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30
GTG AAG GCT TTC AAG ATT CAT AAC AAA ATC TGG GTT ATT CCG GAA CGC 144 Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro Glu Arg 35 40 45
GAT ACA TTT ACG AAC CCG GAA GAA GGA GAC TTG AAC CCG CCG CCG GAA 192 Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60 GCA AAG CAG GTG CCA GTT TCA TAC TAC GAT TCA ACC TAT CTG AGC ACA
Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 5 70 75 80
GAC AAC GAG AAG GAT AAC TAC CTG AAG GGA GTG ACC AAA TTA TTC GAG PAR Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95
CGT ATT TAT TCC ACT GAC CTG GGC CGT ATG CTG CTG ACC TCA ATC GTC 336 Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 100 105 110
CGC GGA ATC CCA TTT TGG GGT GGC AGT ACC ATT GAC ACG GAG TTG AAG 3A4 Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lys 115 120 125
GTT ATT GAC ACT AAC TGC ATT AAC GTG ATC CAA CCA GAC GGT AGC TAC 43? Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tvr 130 135 140 y 7
AGA TCT GAA GAA CTT AAC CTC GTA ATC ATC GGG CCC TCC GCG GAC ATT 480 Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160
ATC CAG TTT GAG TGC AAG AGC TTT GGC CAC GAA GTG TTG AAC CTG ACG 528 He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175
CGT AAC GGT TAC GGC TCT ACT CAG TAC ATT CGT TTC AGC CCA GAC TTC 576 Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro Asp Phe 180 185 190
ACG TTC GGT TTC GAG GAG AGC CTG GAG GTT GAT ACC AAC CCG CTG TTG 624 Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205
GGT GCA GGC AAG TTC GCA ACT GAT CCA GCG GTG ACC CTG GCA CAC GAG 672 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220
CTG ATC CAC GCC GGT CAT CGT CTG TAT GGC ATT GCG ATT AAC CCG AAC 720 Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240
CGC GTG TTC AAG GTT AAC ACC AAC GCC TAC TAC GAG ATG AGT GGT TTA 768 Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255
GAA GTA AGC TTC GAG GAA CTG CGC ACG TTC GGT GGC CAT GAT GCG AAG 816 Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270
TTT ATC GAC AGC TTG CAG GAG AAC GAG TTC CGT CTG TAC TAC TAC AAC 864 Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tvr Asn 275 280 285
AAG TTT AAA GAT ATT GCA AGT ACA CTG AAC AAG GCT AAG TCC ATT GTG 912 Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300
GGT ACC ACT GCT TCA TTA CAG TAT ATG AAA AAT GTT TTT AAA GAG AAA 960 Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320
TAT CTC CTA TCT GAA GAT ACA TCT GGA AAA TTT TCG GTA GAT AAA TTA 1008 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu
325 330 335 AAA TTT GAT AAG TTA TAC AAA ATG TTA ACA GAG ATT TAC ACA GAG GAT 1056 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350
AAT TTT GTT AAG TTT TTT AAA GTA CTT AAC AGA AAA ACA TAT TTG AAT 1104 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365
TTT GAT AAA GCC GTA TTT AAG ATA AAT ATA GTA CCT AAG GTA AAT TAC 1152 Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tyr 370 375 380
ACA ATA TAT GAT GGA TTT AAT TTA AGA AAT ACA AAT TTA GCA GCA AAC 1200 Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400
TTT AAT GGT CAA AAT ACA GAA ATT AAT AAT ATG AAT TTT ACT AAA CTA 1248 Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415
AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA 1296 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430
GGG ATA ATA ACT TCT AAA ACT AAA TCA TTA GAT AAA GGA TAC AAT AAG 1344 Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445
AGC GCT GAT GGG GCA TTA AAT GAT TTA TGT ATC AAA GTT AAT AAT TGG 1392 Ser Ala Asp Gly Ala Leu Asn Asp Leu Cys He Lys Val Asn Asn Trp 450 455 460
GAC TTG TTT TTT AGT CCT TCA GAA GAT AAT TTT ACT AAT GAT CTA AAT 1440 Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn 465 470 475 480
AAA GGA GAA GAA ATT ACA TCT GAT ACT AAT ATA GAA GCA GCA GAA GAA 1488 Lys Gly Glu Glu He Thr Ser Asp Thr Asn He Glu Ala Ala Glu Glu 485 490 495
AAT ATT AGT TTA GAT TTA ATA CAA CAA TAT TAT TTA ACC TTT AAT TTT 1536 Asn He Ser Leu Asp Leu He Gin Gin Tyr Tyr Leu Thr Phe Asn Phe 500 505 510
GAT AAT GAA CCT GAA AAT ATT TCA ATA GAA AAT CTT TCA AGT GAC ATT 1584 Asp Asn Glu Pro Glu Asn He Ser He Glu Asn Leu Ser Ser Asp He 515 520 525
ATA GGC CAA TTA GAA CTT ATG CCT AAT ATA GAA AGA TTT CCT AAT GGA 1632 He Gly Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe Pro Asn Gly 530 535 540
AAA AAG TAT GAG TTA GAT AAA TAT ACT ATG TTC CAT TAT CTT CGT GCT 1680 Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala 545 550 555 560
CAA GAA TTT GAA CAT GGT AAA TCT AGG ATT GCT TTA ACA AAT TCT GTT 1728 Gin Glu Phe Glu His Gly Lys Ser Arg He Ala Leu Thr Asn Ser Val 565 570 575
AAC GAA GCA TTA TTA AAT CCT AGT CGT GTT TAT ACA TTT TTT TCT TCA 1776 Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser 580 585 590
GAC TAT GTA AAG AAA GTT AAT AAA GCT ACG GAG GCA GCT ATG TTT TTA 1824 Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu 595 600 605 - 57 -
GGC TGG GTA GAA CAA TTA GTA TAT GAT TTT ACC GAT GAA ACT ACC .s Gly Trp Val Glu Gin Leu Val Tyr Asp Phe Thr Sp Glϊ τ£ Ser Sϊ ϋlu 615 620
GTA AGT ACT ACG GAT AAA ATT GCG GAT ATA ACT ATA ATT ATT CCA TAT Val Ser Thr Thr Asp Lys He Ala Asp He Thr l J He He Pro ϊyr 1920 6 5 63° 635 640
ATA GGA CCT GCT TTA AAT ATA GGT AAT ATG TTA TAT AAA GAT GAT TTT He Gly Pro Ala Leu Asn He Gly Asn Met Leu Tyr Lys Asp AsJ Phe 1968
650 655
GTA GGT GCT TTA ATA TTT TCA GGA GCT GTT ATT CTG TTA CAA TTT a™ Val Gly Ala Leu He Phe Ser Gly Ala Val lie Leu Ξu Git Hi J£
660 665 670
CCA GAG ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT GTA TCA TAT Pro Glu He Ala He Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr 2064 675 680 685
ATT GCG AAT AAG GTT CTA ACC GTT CAA ACA ATA GAT AAT GCT TTA AGT He Ala Asn Lys Val Leu Thr Val Gin Thr He Asp Asn Ala Leu Ser 211; 690 695 700
AAA AGA AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA GTA ACA AAT Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr He Val Thr Asn 2160 705 710 715 720
TGG TTA GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA AAA AAA ATG Trp Leu Ala Lys Val Asn Thr Gin He Asp Leu He Arg Lys Lys Met 2208 725 730 735
AAA GAA GCT TTA GAA AAT CAA GCA GAA GCA ACA AAG GCT ATA ATA AAC Lys Glu Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala He He Asn 2256 740 745 750
TAT CAG TAT AAT CAA TAT ACT GAG GAA GAG AAA AAT AAT ATT AAT TTT Tyr Gin Tyr Asn Gin Tyr Thr Glu Glu Glu Lys Asn Asn He Asn Phe 2304 755 760 765
AAT ATT GAT GAT TTA AGT TCG AAA CTT AAT GAG TCT ATA AAT AAA GCT Asn He Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser He Asn Lys Ala 2352 770 775 780
ATG ATT AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT TCA TAT TTA Met He Asn He Asn Lys Phe Leu Asn Gin Cys Ser Val Ser Tyr Leu 2400 785 790 795 800
ATG AAT TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA GAT TTT GAT Met Asn Ser Met He Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp 2448 805 810 B15
GCT AGT CTT AAA GAT GCA TTA TTA AAG TAT ATA TAT GAT AAT AGA GGA Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr He Tyr Asp Asn Arg Gly 2496 820 825 830
ACT TTA ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT AAT AAT ACA Thr Leu He Gly Gin Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr 2544 835 840 845
CTT AGT ACA GAT ATA CCT TTT CAG CTT TCC AAA TAC GTA GAT AAT CAA Leu Ser Thr Asp He Pro Phe Gin Leu Ser Lys Tyr Val Asp Asn Gin 2592 850 855 860
AGA TTA TTA TCT ACA TTT ACT GAA TAT ATT AAG TAA Arg Leu Leu Ser Thr Phe Thr Glu Tyr He Lys * 2628 865 870 875 (2) INFORMATION FOR SEQ ID NO: 10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 876 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:
Met Gin Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15
Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30
Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro Glu Arg 35 40 45
Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60
Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80
Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95
Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 100 105 110
Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lys 115 120 125
Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tyr 130 135 140
Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160
He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175
Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro Asp Phe 180 185 190
Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205
Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220
Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240
Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255
Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270
Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285
Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300 Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320
Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335
Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350
Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365
Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tyr 370 375 380
Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400
Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415
Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430
Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445
Ser Ala Asp Gly Ala Leu Asn Asp Leu Cys He Lys Val Asn Asn Trp 450 455 460
Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn 465 470 475 480
Lys Gly Glu Glu He Thr Ser Asp Thr Asn He Glu Ala Ala Glu Glu 485 490 495
Asn He Ser Leu Asp Leu He Gin Gin Tyr Tyr Leu Thr Phe Asn Phe 500 505 510
Asp Asn Glu Pro Glu Asn He Ser He Glu Asn Leu Ser Ser Asp He 515 520 525
He Gly Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe Pro Asn Gly 530 535 540
Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala 545 550 555 560
Gin Glu Phe Glu His Gly Lys Ser Arg He Ala Leu Thr Asn Ser Val 565 570 575
Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe-Phe Ser Ser 580 585 590
Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu 595 600 605
Gly Trp Val Glu Gin Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu 610 615 620
Val Ser Thr Thr Asp Lys He Ala Asp He Thr He He He Pro Tyr 625 630 635 640
He Gly Pro Ala Leu Asn He Gly Asn Met Leu Tyr Lys Asp Asp Phe 645 650 655 Val Gly Ala Leu He Phe Ser Gly Ala Val He Leu Leu Glu Phe He 660 665 670
Pro Glu He Ala He Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr 675 680 685
He Ala Asn Lys Val Leu Thr Val Gin Thr He Asp Asn Ala Leu Ser 690 695 700
Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr He Val Thr Asn 705 710 715 720
Trp Leu Ala Lys Val Asn Thr Gin He Asp Leu He Arg Lys Lys Met 725 730 735
Lys Glu Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala He He Asn 740 745 750
Tyr Gin Tyr Asn Gin Tyr Thr Glu Glu Glu Lys Asn Asn He Asn Phe 755 760 765
Asn He Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser He Asn Lys Ala 770 775 780
Met He Asn He Asn Lys Phe Leu Asn Gin Cys Ser Val Ser Tyr Leu 785 790 795 800
Met Asn Ser Met He Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp 805 810 815
Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr He Tyr Asp Asn Arg Gly 820 825 830
Thr Leu He Gly Gin Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr 835 840 845
Leu Ser Thr Asp He Pro Phe Gin Leu Ser Lys Tyr Val Asp Asn Gin 850 855 860
Arg Leu Leu Ser Thr Phe Thr Glu Tyr He Lys * 865 870 875
(2) INFORMATION FOR SEQ ID NO: 11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2637 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..2637
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:
ATG CAG TTC GTG AAC AAG CAG TTC AAC TAT AAG GAC CCT GTA AAC GGT 48 Met Gin Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15
GTT GAC ATT GCC TAC ATC AAA ATT CCA AAC GCC GGC CAG ATG CAG CCG 96 Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30 GTG AAG GCT TTC AAG ATT CAT AAC AAA ATC TGG GTT ATT CCG GAA err
Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro Glu Arα 144
35 40 45 a
GAT ACA TTT ACG AAC CCG GAA GAA GGA GAC TTG AAC CCG CCG CCC P Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 192 50 55 60
GCA AAG CAG GTG CCA GTT TCA TAC TAC GAT TCA ACC TAT CTG AGC ACA
Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 240
65 70 75 80
GAC AAC GAG AAG GAT AAC TAC CTG AAG GGA GTG ACC AAA TTA TTC GAG Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 288 85 90 95
CGT ATT TAT TCC ACT GAC CTG GGC CGT ATG CTG CTG ACC TCA ATC GTC Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 336 100 105 110
CGC GGA ATC CCA TTT TGG GGT GGC AGT ACC ATT GAC ACG GAG TTG AAG Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lvs 384 115 120 125 y
GTT ATT GAC ACT AAC TGC ATT AAC GTG ATC CAA CCA GAC GGT AGC TAC 432 Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tyr 130 135 140
AGA TCT GAA GAA CTT AAC CTC GTA ATC ATC GGG CCC TCC GCG GAC ATT 480 Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160
ATC CAG TTT GAG TGC AAG AGC TTT GGC CAC GAA GTG TTG AAC CTG ACG 528 He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175
CGT AAC GGT TAC GGC TCT ACT CAG TAC ATT CGT TTC AGC CCA GAC TTC Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro Asp Phe 576 180 185 190
ACG TTC GGT TTC GAG GAG AGC CTG GAG GTT GAT ACC AAC CCG CTG TTC Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 624 195 200 205
GGT GCA GGC AAG TTC GCA ACT GAT CCA GCG GTG ACC CTG GCA CAC GAG K ? Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220
CTG ATC CAC GCC GGT CAT CGT CTG TAT GGC ATT GCG ATT AAC CCG AAC 720 Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240
CGC GTG TTC AAG GTT AAC ACC AAC GCC TAC TAC GAG ATG AGT GGT TTA Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 768 245 250 255
GAA GTA AGC TTC GAG GAA CTG CGC ACG TTC GGT GGC CAT GAT GCG AAG Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lvs 816 260 265 270
TTT ATC GAC AGC TTG CAG GAG AAC GAG TTC CGT CTG TAC TAC TAC AAC Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 864 275 280 285
A ™A™G T-.T.-T-. G sjAnTx AΛTiTi GuCι_AΛ AnGuTi AΛC»_AΛ Cl_TlG-j AΛAACL AAAAGU GGCCTT AAAAGG TTCCCC AATTTT GGTTGG q
Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys A Allaa Lys Ser He Val 290 295 300 GGT ACC ACT GCT TCA TTA CAG TAT ATG AAA AAT GTT TTT AAA GAG AAA 960 Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320
TAT CTC CTA TCT GAA GAT ACA TCT GGA AAA TTT TCG GTA GAT AAA TTA 1008 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335
AAA TTT GAT AAG TTA TAC AAA ATG TTA ACA GAG ATT TAC ACA GAG GAT 1056 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350
AAT TTT GTT AAG TTT TTT AAA GTA CTT AAC AGA AAA ACA TAT TTG AAT 1104 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365
TTT GAT AAA GCC GTA TTT AAG ATA AAT ATA GTA CCT AAG GTA AAT TAC 1152 Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tyr 370 375 380
ACA ATA TAT GAT GGA TTT AAT TTA AGA AAT ACA AAT TTA GCA GCA AAC 1200 Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400
TTT AAT GGT CAA AAT ACA GAA ATT AAT AAT ATG AAT TTT ACT AAA CTA 1248 Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415
AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA 1296 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430
GGG ATA ATA ACT TCT AAA ACT AAA TCA TTA GAT AAA GGA TAC AAT AAG 1344 Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445
ATC GAA GGT CGT TGC GAT GGG GCA TTA AAT GAT TTA TGT ATC AAA GTT 1392 He Glu Gly Arg Cys Asp Gly Ala Leu Asn Asp Leu Cys He Lys Val 450 455 460
AAT AAT TGG GAC TTG TTT TTT AGT CCT TCA GAA GAT AAT TTT ACT AAT 1440 Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn 465 470 475 480
GAT CTA AAT AAA GGA GAA GAA ATT ACA TCT GAT ACT AAT ATA GAA GCA 1488 Asp Leu Asn Lys Gly Glu Glu He Thr Ser Asp Thr Asn He Glu Ala 485 490 495
GCA GAA GAA AAT ATT AGT TTA GAT TTA ATA CAA CAA TAT TAT TTA ACC 1536 Ala Glu Glu Asn He Ser Leu Asp Leu He Gin Gin Tyr Tyr Leu Thr 500 505 510
TTT AAT TTT GAT AAT GAA CCT GAA AAT ATT TCA ATA GAA AAT CTT TCA 1584 Phe Asn Phe Asp Asn Glu Pro Glu Asn He Ser He Glu Asn Leu Ser 515 520 525
AGT GAC ATT ATA GGC CAA TTA GAA CTT ATG CCT AAT ATA GAA AGA TTT 1632 Ser Asp He He Gly Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe 530 535 540
CCT AAT GGA AAA AAG TAT GAG TTA GAT AAA TAT ACT ATG TTC CAT TAT 1680 Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr 545 550 555 560
CTT CGT GCT CAA GAA TTT GAA CAT GGT AAA TCT AGG ATT GCT TTA ACA 1728 Leu Arg Ala Gin Glu Phe Glu His Gly Lys Ser Arg He Ala Leu Thr 565 570 575 AAT TCT GTT AAC GAA GCA TTA TTA AAT CCT AGT CGT GTT TAT ACA TTT 1776 Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe 580 585 590
TTT TCT TCA GAC TAT GTA AAG AAA GTT AAT AAA GCT ACG GAG GCA GCT 1824 Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala 595 600 605
ATG TTT TTA GGC TGG GTA GAA CAA TTA GTA TAT GAT TTT ACC GAT GAA 1872 Met Phe Leu Gly Trp Val Glu Gin Leu Val Tyr Asp Phe Thr Asp Glu 610 615 620
ACT AGC GAA GTA AGT ACT ACG GAT AAA ATT GCG GAT ATA ACT ATA ATT 1920 Thr Ser Glu Val Ser Thr Thr Asp Lys He Ala Asp He Thr He He 625 630 635 640
ATT CCA TAT ATA GGA CCT GCT TTA AAT ATA GGT AAT ATG TTA TAT AAA 1968 He Pro Tyr He Gly Pro Ala Leu Asn He Gly Asn Met Leu Tyr Lys 645 650 655
GAT GAT TTT GTA GGT GCT TTA ATA TTT TCA GGA GCT GTT ATT CTG TTA 2016 Asp Asp Phe Val Gly Ala Leu He Phe Ser Gly Ala Val He Leu Leu 660 665 670
GAA TTT ATA CCA GAG ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT 2064 Glu Phe He Pro Glu He Ala He Pro Val Leu Gly Thr Phe Ala Leu 675 680 685
GTA TCA TAT ATT GCG AAT AAG GTT CTA ACC GTT CAA ACA ATA GAT AAT 2112 Val Ser Tyr He Ala Asn Lys Val Leu Thr Val Gin Thr He Asp Asn 690 695 700
GCT TTA AGT AAA AGA AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA 2160 Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr He 705 710 715 720
GTA ACA AAT TGG TTA GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA 2208 Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gin He Asp Leu He Arg 725 730 735
AAA AAA ATG AAA GAA GCT TTA GAA AAT CAA GCA GAA GCA ACA AAG GCT 2256 Lys Lys Met Lys Glu Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala 740 745 750
ATA ATA AAC TAT CAG TAT AAT CAA TAT ACT GAG GAA GAG AAA AAT AAT 2304 He He Asn Tyr Gin Tyr Asn Gin Tyr Thr Glu Glu Glu Lys Asn Asn 755 760 765
ATT AAT TTT AAT ATT GAT GAT TTA AGT TCG AAA CTT AAT GAG TCT ATA 2352 He Asn Phe Asn He Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser He 770 775 780
AAT AAA GCT ATG ATT AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT 2400 Asn Lys Ala Met He Asn He Asn Lys Phe Leu Asn Gin Cys Ser Val 785 790 795 800
TCA TAT TTA ATG AAT TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA 2448 Ser Tyr Leu Met Asn Ser Met He Pro Tyr Gly Val Lys Arg Leu Glu 805 810 815
GAT TTT GAT GCT AGT CTT AAA GAT GCA TTA TTA AAG TAT ATA TAT GAT 2496 Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr He Tyr Asp 820 825 830
AAT AGA GGA ACT TTA ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT 2544 Asn Arg Gly Thr Leu He Gly Gin Val Asp Arg Leu Lys Asp Lys Val 835 840 845 AAT AAT ACA CTT AGT ACA GAT ATA CCT TTT CAG CTT TCC AAA TAC GTA 2592 Asn Asn Thr Leu Ser Thr Asp He Pro Phe Gin Leu Ser Lys Tyr Val 850 855 860
GAT AAT CAA AGA TTA TTA TCT ACA TTT ACT GAA TAT ATT AAG TAA 2637
Asp Asn Gin Arg Leu Leu Ser Thr Phe Thr Glu Tyr He Lys * 865 870 875
(2) INFORMATION FOR SEQ ID NO: 12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 879 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:
Met Gin Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15
Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30
Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro Glu Arg 35 40 45
Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60
Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80
Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95
Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 100 105 110
Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lys 115 120 125
Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tyr 130 135 140
Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160
He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175
Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro Asp Phe 180 185 190
Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205
Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220
Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240
Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255 Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270
Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285
Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300
Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320
Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335
Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350
Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365
Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tyr 370 375 380
Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400
Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415
Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430
Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445
He Glu Gly Arg Cys Asp Gly Ala Leu Asn Asp Leu Cys He Lys Val 450 455 460
Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn 465 470 475 480
Asp Leu Asn Lys Gly Glu Glu He Thr Ser Asp Thr Asn He Glu Ala 485 490 495
Ala Glu Glu Asn He Ser Leu Asp Leu He Gin Gin Tyr Tyr Leu Thr 500 505 510
Phe Asn Phe Asp Asn Glu Pro Glu Asn He Ser He Glu Asn Leu Ser 515 520 525
Ser Asp He He Gly Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe 530 535 540
Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr 545 550 555 560
Leu Arg Ala Gin Glu Phe Glu His Gly Lys Ser Arg He Ala Leu Thr 565 570 575
Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe 580 585 590
Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala 595 600 605 Met Phe Leu Gly Trp Val Glu Gin Leu Val Tyr Asp Phe Thr Asp Glu 610 615 620
Thr Ser Glu Val Ser Thr Thr Asp Lys He Ala Asp He Thr He He 625 630 635 640
He Pro Tyr He Gly Pro Ala Leu Asn He Gly Asn Met Leu Tyr Lys 645 650 655
Asp Asp Phe Val Gly Ala Leu He Phe Ser Gly Ala Val He Leu Leu 660 665 670
Glu Phe He Pro Glu He Ala He Pro Val Leu Gly Thr Phe Ala Leu 675 680 685
Val Ser Tyr He Ala Asn Lys Val Leu Thr Val Gin Thr He Asp Asn 690 695 700
Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr He 705 710 715 720
Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gin He Asp Leu He Arg 725 730 735
Lys Lys Met Lys Glu Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala 740 745 750
He He Asn Tyr Gin Tyr Asn Gin Tyr Thr Glu Glu Glu Lys Asn Asn 755 760 765
He Asn Phe Asn He Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser He 770 775 780
Asn Lys Ala Met He Asn He Asn Lys Phe Leu Asn Gin Cys Ser Val 785 790 795 800
Ser Tyr Leu Met Asn Ser Met He Pro Tyr Gly Val Lys Arg Leu Glu 805 810 815
Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr He Tyr Asp 820 825 830
Asn Arg Gly Thr Leu He Gly Gin Val Asp Arg Leu Lys Asp Lvs Val 835 840 845
Asn Asn Thr Leu Ser Thr Asp He Pro Phe Gin Leu Ser Lys Tyr Val 850 855 860
Asp Asn Gin Arg Leu Leu Ser Thr Phe Thr Glu Tyr He Lys * 865 870 875
(2) INFORMATION FOR SEQ ID NO: 13:
(l) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2862 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..2862
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: ATG CAG TTC GTG AAC AAG CAG TTC AAC TAT AAG GAC CCT GTA AAC GGT 48 Met Gin Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15
GTT GAC ATT GCC TAC ATC AAA ATT CCA AAC GCC GGC CAG ATG CAG CCG 96 Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30
GTG AAG GCT TTC AAG ATT CAT AAC AAA ATC TGG GTT ATT CCG GAA CGC 144 Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro Glu Arg 35 40 45
GAT ACA TTT ACG AAC CCG GAA GAA GGA GAC TTG AAC CCG CCG CCG GAA 192 Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60
GCA AAG CAG GTG CCA GTT TCA TAC TAC GAT TCA ACC TAT CTG AGC ACA 240 Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80
GAC AAC GAG AAG GAT AAC TAC CTG AAG GGA GTG ACC AAA TTA TTC GAG 288 Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95
CGT ATT TAT TCC ACT GAC CTG GGC CGT ATG CTG CTG ACC TCA ATC GTC 336 Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 100 105 110
CGC GGA ATC CCA TTT TGG GGT GGC AGT ACC ATT GAC ACG GAG TTG AAG 384 Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lys 115 120 125
GTT ATT GAC ACT AAC TGC ATT AAC GTG ATC CAA CCA GAC GGT AGC TAC 432 Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tyr 130 135 140
AGA TCT GAA GAA CTT AAC CTC GTA ATC ATC GGG CCC TCC GCG GAC ATT 480 Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160
ATC CAG TTT GAG TGC AAG AGC TTT GGC CAC GAA GTG TTG AAC CTG ACG 528 He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175
CGT AAC GGT TAC GGC TCT ACT CAG TAC ATT CGT TTC AGC CCA GAC TTC 576 Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro Asp Phe 180 185 190
ACG TTC GGT TTC GAG GAG AGC CTG GAG GTT GAT ACC AAC CCG CTG TTG 624 Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205
GGT GCA GGC AAG TTC GCA ACT GAT CCA GCG GTG ACC CTG GCA CAC GAG 672 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220
CTG ATC CAC GCC GGT CAT CGT CTG TAT GGC ATT GCG ATT AAC CCG AAC 720 Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240
CGC GTG TTC AAG GTT AAC ACC AAC GCC TAC TAC GAG ATG AGT GGT TTA 768 Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255
GAA GTA AGC TTC GAG GAA CTG CGC ACG TTC GGT GGC CAT GAT GCG AAG 816 Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270 TTT ATC GAC AGC TTG CAG GAG AAC GAG TTC CGT CTG TAC TAC TAC AAC 864 Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285
AAG TTT AAA GAT ATT GCA AGT ACA CTG AAC AAG GCT AAG TCC ATT GTG 912 Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300
GGT ACC ACT GCT TCA TTA CAG TAT ATG AAA AAT GTT TTT AAA GAG AAA 960 Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320
TAT CTC CTA TCT GAA GAT ACA TCT GGA AAA TTT TCG GTA GAT AAA TTA 1008 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335
AAA TTT GAT AAG TTA TAC AAA ATG TTA ACA GAG ATT TAC ACA GAG GAT 1056 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350
AAT TTT GTT AAG TTT TTT AAA GTA CTT AAC AGA AAA ACA TAT TTG AAT 1104 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365
TTT GAT AAA GCC GTA TTT AAG ATA AAT ATA GTA CCT AAG GTA AAT TAC 1152 Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tyr 370 375 380
ACA ATA TAT GAT GGA TTT AAT TTA AGA AAT ACA AAT TTA GCA GCA AAC 1200 Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400
TTT AAT GGT CAA AAT ACA GAA ATT AAT AAT ATG AAT TTT ACT AAA CTA 1248 Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415
AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA 1296 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430
GGG ATA ATA ACT TCT AAA ACT AAA TCA TTA GAT AAA GGA TAC AAT AAG 1344 Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445
ATC GAA GGT CGT TGC GAT GGG GCA TTA AAT GAT TTA TGT ATC AAA GTT 1392 He Glu Gly Arg Cys Asp Gly Ala Leu Asn Asp Leu Cys He Lys Val 450 455 460
AAT AAT TGG GAC TTG TTT TTT AGT CCT TCA GAA GAT AAT TTT ACT AAT 1 40 Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn 465 470 475 480
GAT CTA AAT AAA GGA GAA GAA ATT ACA TCT GAT ACT AAT ATA GAA GCA 1488 Asp Leu Asn Lys Gly Glu Glu He Thr Ser Asp Thr Asn He Glu Ala 485 490 495
GCA GAA GAA AAT ATT AGT TTA GAT TTA ATA CAA CAA TAT TAT TTA ACC 1536 Ala Glu Glu Asn He Ser Leu Asp Leu He Gin Gin Tyr Tyr Leu Thr 500 505 510
TTT AAT TTT GAT AAT GAA CCT GAA AAT ATT TCA ATA GAA AAT CTT TCA 1584 Phe Asn Phe Asp Asn Glu Pro Glu Asn He Ser He Glu Asn Leu Ser 515 520 525
AGT GAC ATT ATA GGC CAA TTA GAA CTT ATG CCT AAT ATA GAA AGA TTT 1632 Ser Asp He He Gly Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe 530 535 540 CCT AAT GGA AAA AAG TAT GAG TTA GAT AAA TAT ACT ATG TTC CAT TAT 1680 Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lvs Tyr Thr Met Phe His Tyr 545 550 " 555 560
CTT CGT GCT CAA GAA TTT GAA CAT GGT AAA TCT AGG ATT GCT TTA ACA 1728 Leu Arg Ala Gin Glu Phe Glu His Gly Lys Ser Arg He Ala Leu Thr 565 570 575
AAT TCT GTT AAC GAA GCA TTA TTA AAT CCT AGT CGT GTT TAT ACA TTT 1776 Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe 580 595 590
TTT TCT TCA GAC TAT GTA AAG AAA GTT AAT AAA GCT ACG GAG GCA GCT 1824 Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala 595 600 605
ATG TTT TTA GGC TGG GTA GAA CAA TTA GTA TAT GAT TTT ACC GAT GAA 1872 Met Phe Leu Gly Trp Val Glu Gin Leu Val Tyr Asp Phe Thr Asp Glu 610 615 620
ACT AGC GAA GTA AGT ACT ACG GAT AAA ATT GCG GAT ATA ACT ATA ATT 1920 Thr Ser Glu Val Ser Thr Thr Asp Lys He Ala Asp He Thr He He 625 630 635 640
ATT CCA TAT ATA GGA CCT GCT TTA AAT ATA GGT AAT ATG TTA TAT AAA 1968 He Pro Tyr He Gly Pro Ala Leu Asn He Gly Asn Met Leu Tyr Lys 645 650 655
GAT GAT TTT GTA GGT GCT TTA ATA TTT TCA GGA GCT GTT ATT CTG TTA 2016 Asp Asp Phe Val Gly Ala Leu He Phe Ser Gly Ala Val He Leu Leu 660 665 670
GAA TTT ATA CCA GAG ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT 2064 Glu Phe He Pro Glu He Ala He Pro Val Leu Gly Thr Phe Ala Leu 675 680 685
GTA TCA TAT ATT GCG AAT AAG GTT CTA ACC GTT CAA ACA ATA GAT AAT 2112 Val Ser Tyr He Ala Asn Lys Val Leu Thr Val Gin Thr He Asp Asn 690 695 700
GCT TTA AGT AAA AGA AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA 2160 Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr He 705 710 715 720
GTA ACA AAT TGG TTA GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA 2208 Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gin He Asp Leu He Arg 725 730 735
AAA AAA ATG AAA GAA GCT TTA GAA AAT CAA GCA GAA GCA ACA AAG GCT 2256 Lys Lys Met Lys Glu Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala 740 745 750
ATA ATA AAC TAT CAG TAT AAT CAA TAT ACT GAG GAA GAG AAA AAT AAT 2304 He He Asn Tyr Gin Tyr Asn Gin Tyr Thr Glu Glu Glu Lys Asn Asn 755 760 765
ATT AAT TTT AAT ATT GAT GAT TTA AGT TCG AAA CTT AAT GAG TCT ATA 2352 He Asn Phe Asn He Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser He 770 775 780
AAT AAA GCT ATG ATT AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT 2400 Asn Lys Ala Met He Asn He Asn Lys Phe Leu Asn Gin Cys Ser Val 785 790 795 800
TCA TAT TTA ATG AAT TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA 2448 Ser Tyr Leu Met Asn Ser Met He Pro Tyr Gly Val Lys Arg Leu Glu 805 810 815 GAT TTT GAT GCT AGT CTT AAA GAT GCA TTA TTA AAG TAT ATA TAT GAT 2496 Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr He Tyr Asp 820 825 830
AAT AGA GGA ACT TTA ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT 2544 Asn Arg Gly Thr Leu He Gly Gin Val Asp Arg Leu Lys Asp Lys Val 835 840 845
AAT AAT ACA CTT AGT ACA GAT ATA CCT TTT CAG CTT TCC AAA TAC GTA 2592 Asn Asn Thr Leu Ser Thr Asp He Pro Phe Gin Leu Ser Lys Tyr Val 850 855 860
GAT AAT CAA AGA TTA TTA TCT ACA TTT ACT GAA TAT ATT AAG TCT AGG 2640 Asp Asn Gin Arg Leu Leu Ser Thr Phe Thr Glu Tyr He Lys Ser Arg 865 870 875 880
CCT GGA CCG GAG ACG CTC TGC GGG GCT GAG CTG GTG GAT GCT CTT CAG 2688 Pro Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gin 885 890 895
TTC GTG TGT GGA GAC AGG GGC TTT TAT TTC AAC AAG CCC ACA GGG TAT 2736 Phe Val Cys Gly Asp Arg Gly Phe Tyr Phe Asn Lys Pro Thr Gly Tyr 900 905 910
GGC TCC AGC AGT CGG AGG GCG CCT CAG ACA GGT ATC GTG GAT GAG TGC 2784 Gly Ser Ser Ser Arg Arg Ala Pro Gin Thr Gly He Val Asp Glu Cys 915 920 925
TGC TTC CGG AGC TGT GAT CTA AGG AGG CTG GAG ATG TAT TGC GCA CCC 2832 Cys Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro 930 935 940
CTC AAG CCT GCC AAG TCA GCT GAA GCT TAG 2862
Leu Lys Pro Ala Lys Ser Ala Glu Ala * 945 950
(2) INFORMATION FOR SEQ ID NO: 14:
(l) SEQUENCE CHARACTERISTICS
(A) LENGTH: 954 amino acids
(B) TYPE, ammo acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:
Met Gin Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15
Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30
Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro Glu Arg 35 40 45
Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60
Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80
Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95
Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 100 105 110 Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lys 115 120 125
Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tyr 130 135 140
Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160
He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175
Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro Asp Phe 180 185 190
Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205
Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220
Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240
Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255
Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270
Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285
Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300
Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320
Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335
Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350
Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365
Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tyr 370 375 380
Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400
Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415
Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430
Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445
He Glu Gly Arg Cys Asp Gly Ala Leu Asn Asp Leu Cys He Lys Val 450 455 460 Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn 465 470 475 480
Asp Leu Asn Lys Gly Glu Glu He Thr Ser Asp Thr Asn He Glu Ala 485 490 495
Ala Glu Glu Asn He Ser Leu Asp Leu He Gin Gin Tyr Tyr Leu Thr 500 505 510
Phe Asn Phe Asp Asn Glu Pro Glu Asn He Ser He Glu Asn Leu Ser 515 520 525
Ser Asp He He Gly Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe 530 535 540
Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr 545 550 555 560
Leu Arg Ala Gin Glu Phe Glu His Gly Lys Ser Arg He Ala Leu Thr 565 570 575
Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe 580 585 590
Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala 595 600 605
Met Phe Leu Gly Trp Val Glu Gin Leu Val Tyr Asp Phe Thr Asp Glu 610 615 620
Thr Ser Glu Val Ser Thr Thr Asp Lys He Ala Asp He Thr He He 625 630 635 640
He Pro Tyr He Gly Pro Ala Leu Asn He Gly Asn Met Leu Tyr Lys 645 650 655
Asp Asp Phe Val Gly Ala Leu He Phe Ser Gly Ala Val He Leu Leu 660 665 670
Glu Phe He Pro Glu He Ala He Pro Val Leu Gly Thr Phe Ala Leu 675 680 685
Val Ser Tyr He Ala Asn Lys Val Leu Thr Val Gin Thr He Asp Asn 690 695 700
Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr He 705 710 715 720
Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gin He Asp Leu He Arg 725 730 735
Lys Lys Met Lys Glu Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala 740 745 750
He He Asn Tyr Gin Tyr Asn Gin Tyr Thr Glu Glu Glu Lys Asn Asn 755 760 765
He Asn Phe Asn He Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser He 770 775 780
Asn Lys Ala Met He Asn He Asn Lys Phe Leu Asn Gin Cys Ser Val 785 790 795 800
Ser Tyr Leu Met Asn Ser Met He Pro Tyr Gly Val Lys Arg Leu Glu 805 810 815 Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr He Tyr Asp 820 825 830
Asn Arg Gly Thr Leu He Gly Gin Val Asp Arg Leu Lys Asp Lys Val 835 840 845
Asn Asn Thr Leu Ser Thr Asp He Pro Phe Gin Leu Ser Lys Tyr Val 850 855 860
Asp Asn Gin Arg Leu Leu Ser Thr Phe Thr Glu Tyr He Lys Ser Arg 865 870 875 880
Pro Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gin 885 890 895
Phe Val Cys Gly Asp Arg Gly Phe Tyr Phe Asn Lys Pro Thr Gly Tyr 900 905 910
Gly Ser Ser Ser Arg Arg Ala Pro Gin Thr Gly He Val Asp Glu Cys 915 920 925
Cys Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro 930 935 940
Leu Lys Pro Ala Lys Ser Ala Glu Ala * 945 950
(2) INFORMATION FOR SEQ ID NO . 15-
(l) SEQUENCE CHARACTERISTICS:
(A) LENGTH 2724 base pairs
(B) TYPE, nucleic acid
(C) STRANDEDNESS. double
(D) TOPOLOGY, linear
(n) MOLECULE TYPE: DNA (genomic)
(IX) FEATURE:
(A) NAME/KEY CDS
(B) LOCATION: 1..2724
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15.
ATG CAG TTC GTG AAC AAG CAG TTC AAC TAT AAG GAC CCT GTA AAC GGT 48 Met Gin Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15
GTT GAC ATT GCC TAC ATC AAA ATT CCA AAC GCC GGC CAG ATG CAG CCG 96 Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30
GTG AAG GCT TTC AAG ATT CAT AAC AAA ATC TGG GTT ATT CCG GAA CGC 144
Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro Glu Arg 35 40 45
GAT ACA TTT ACG AAC CCG GAA GAA GGA GAC TTG AAC CCG CCG CCG GAA 192 Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60
GCA AAG CAG GTG CCA GTT TCA TAC TAC GAT TCA ACC TAT CTG AGC ACA 240 Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80
GAC AAC GAG AAG GAT AAC TAC CTG AAG GGA GTG ACC AAA TTA TTC GAG 288 Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95 CGT ATT TAT TCC ACT GAC CTG GGC CGT ATG CTG CTG ACC TCA ATC GTC 336 Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 100 105 110
CGC GGA ATC CCA TTT TGG GGT GGC AGT ACC ATT GAC ACG GAG TTG AAG 384 Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lys 115 120 125
GTT ATT GAC ACT AAC TGC ATT AAC GTG ATC CAA CCA GAC GGT AGC TAC 432 Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tyr 130 135 140
AGA TCT GAA GAA CTT AAC CTC GTA ATC ATC GGG CCC TCC GCG GAC ATT 480 Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160
ATC CAG TTT GAG TGC AAG AGC TTT GGC CAC GAA GTG TTG AAC CTG ACG 528 He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175
CGT AAC GGT TAC GGC TCT ACT CAG TAC ATT CGT TTC AGC CCA GAC TTC 576 Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro ASP Phe 180 185 190
ACG TTC GGT TTC GAG GAG AGC CTG GAG GTT GAT ACC AAC CCG CTG TTG 624 Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205
GGT GCA GGC AAG TTC GCA ACT GAT CCA GCG GTG ACC CTG GCA CAC GAG 672 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220
CTG ATC CAC GCC GGT CAT CGT CTG TAT GGC ATT GCG ATT AAC CCG AAC 720 Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240
CGC GTG TTC AAG GTT AAC ACC AAC GCC TAC TAC GAG ATG AGT GGT TTA 768 Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255
GAA GTA AGC TTC GAG GAA CTG CGC ACG TTC GGT GGC CAT GAT GCG AAG 816 Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270
TTT ATC GAC AGC TTG CAG GAG AAC GAG TTC CGT CTG TAC TAC TAC AAC 864 Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285
AAG TTT AAA GAT ATT GCA AGT ACA CTG AAC AAG GCT AAG TCC ATT GTG 912 Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300
GGT ACC ACT GCT TCA TTA CAG TAT ATG AAA AAT GTT TTT AAA GAG AAA 960 Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320
TAT CTC CTA TCT GAA GAT ACA TCT GGA AAA TTT TCG GTA GAT AAA TTA 1008 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335
AAA TTT GAT AAG TTA TAC AAA ATG TTA ACA GAG ATT TAC ACA GAG GAT 1056 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350
AAT TTT GTT AAG TTT TTT AAA GTA CTT AAC AGA AAA ACA TAT TTG AAT 1104 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365 TTT GAT AAA GCC GTA TTT AAG ATA AAT ATA GTA CCT AAG GTA AAT TAC 1152 Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tyr 370 375 380
ACA ATA TAT GAT GGA TTT AAT TTA AGA AAT ACA AAT TTA GCA GCA AAC 1200 Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400
TTT AAT GGT CAA AAT ACA GAA ATT AAT AAT ATG AAT TTT ACT AAA CTA 1248 Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415
AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA 1296 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430
GGG ATA ATA ACT TCT AAA ACT AAA TCA TTA GAT AAA GGA TAC AAT AAG 13 4 Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445
ATC GAA GGT CGT TGC GAT GGG GCA TTA AAT GAT TTA TGT ATC AAA GTT 1392 He Glu Gly Arg Cys Asp Gly Ala Leu Asn Asp Leu Cys He Lys Val 450 455 460
AAT AAT TGG GAC TTG TTT TTT AGT CCT TCA GAA GAT AAT TTT ACT AAT 1440 Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn 465 470 475 480
GAT CTA AAT AAA GGA GAA GAA ATT ACA TCT GAT ACT AAT ATA GAA GCA 1488 Asp Leu Asn Lys Gly Glu Glu He Thr Ser Asp Thr Asn He Glu Ala 485 490 495
GCA GAA GAA AAT ATT AGT TTA GAT TTA ATA CAA CAA TAT TAT TTA ACC 1536 Ala Glu Glu Asn He Ser Leu Asp Leu He Gin Gin Tyr Tyr Leu Thr 500 505 510
TTT AAT TTT GAT AAT GAA CCT GAA AAT ATT TCA ATA GAA AAT CTT TCA 1584 Phe Asn Phe Asp Asn Glu Pro Glu Asn He Ser He Glu Asn Leu Ser 515 520 525
AGT GAC ATT ATA GGC CAA TTA GAA CTT ATG CCT AAT ATA GAA AGA TTT 1632 Ser Asp He He Gly Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe 530 535 540
CCT AAT GGA AAA AAG TAT GAG TTA GAT AAA TAT ACT ATG TTC CAT TAT 1680 Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr 545 550 555 560
CTT CGT GCT CAA GAA TTT GAA CAT GGT AAA TCT AGG ATT GCT TTA ACA 1728 Leu Arg Ala Gin Glu Phe Glu His Gly Lys Ser Arg He Ala Leu Thr 565 570 575
AAT TCT GTT AAC GAA GCA TTA TTA AAT CCT AGT CGT GTT TAT ACA TTT 1776 Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe 580 585 590
TTT TCT TCA GAC TAT GTA AAG AAA GTT AAT AAA GCT ACG GAG GCA GCT 1824 Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala 595 600 605
ATG TTT TTA GGC TGG GTA GAA CAA TTA GTA TAT GAT TTT ACC GAT GAA 1872 Met Phe Leu Gly Trp Val Glu Gin Leu Val Tyr Asp Phe Thr Asp Glu 610 615 620
ACT AGC GAA GTA AGT ACT ACG GAT AAA ATT GCG GAT ATA ACT ATA ATT 1920 Thr Ser Glu Val Ser Thr Thr Asp Lys He Ala Asp He Thr He He 625 630 635 640 ATT CCA TAT ATA GGA CCT GCT TTA AAT ATA GGT AAT ATG TTA TAT AAA 1968 He Pro Tyr He Gly Pro Ala Leu Asn He Gly Asn Met Leu Tyr Lys 645 650 655
GAT GAT TTT GTA GGT GCT TTA ATA TTT TCA GGA GCT GTT ATT CTG TTA 2016 Asp Asp Phe Val Gly Ala Leu He Phe Ser Gly Ala Val He Leu Leu 660 665 670
GAA TTT ATA CCA GAG ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT 2064 Glu Phe He Pro Glu He Ala He Pro Val Leu Gly Thr Phe Ala Leu 675 680 685
GTA TCA TAT ATT GCG AAT AAG GTT CTA ACC GTT CAA ACA ATA GAT AAT 2112 Val Ser Tyr He Ala Asn Lys Val Leu Thr Val Gin Thr He Asp Asn 690 695 700
GCT TTA AGT AAA AGA AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA 2160 Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr He 705 710 715 720
GTA ACA AAT TGG TTA GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA 2208 Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gin He Asp Leu He Arg 725 730 735
AAA AAA ATG AAA GAA GCT TTA GAA AAT CAA GCA GAA GCA ACA AAG GCT 2256 Lys Lys Met Lys Glu Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala 740 745 750
ATA ATA AAC TAT CAG TAT AAT CAA TAT ACT GAG GAA GAG AAA AAT AAT 2304 He He Asn Tyr Gin Tyr Asn Gin Tyr Thr Glu Glu Glu Lys Asn Asn 755 760 765
ATT AAT TTT AAT ATT GAT GAT TTA AGT TCG AAA CTT AAT GAG TCT ATA 2352 He Asn Phe Asn He Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser He 770 775 780
AAT AAA GCT ATG ATT AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT 2400 Asn Lys Ala Met He Asn He Asn Lys Phe Leu Asn Gin Cys Ser Val 785 790 795 800
TCA TAT TTA ATG AAT TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA 2448 Ser Tyr Leu Met Asn Ser Met He Pro Tyr Gly Val Lys Arg Leu Glu 805 810 815
GAT TTT GAT GCT AGT CTT AAA GAT GCA TTA TTA AAG TAT ATA TAT GAT 2496 Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr He Tyr Asp 820 825 830
AAT AGA GGA ACT TTA ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT 2544 Asn Arg Gly Thr Leu He Gly Gin Val Asp Arg Leu Lys Asp Lys Val 835 840 845
AAT AAT ACA CTT AGT ACA GAT ATA CCT TTT CAG CTT TCC AAA TAC GTA 2592 Asn Asn Thr Leu Ser Thr Asp He Pro Phe Gin Leu Ser Lys Tyr Val 850 855 860
GAT AAT CAA AGA TTA TTA TCT ACA TTT ACT GAA TAT ATT AAG TCT AGG 26 0 Asp Asn Gin Arg Leu Leu Ser Thr Phe Thr Glu Tyr He Lys Ser Arg 865 870 875 880
CCT CAA TCT AAA GTT AAA AGA CAA ATA TTT TCA GGC TAT CAA TCT GAT 2688 Pro Gin Ser Lys Val Lys Arg Gin He Phe Ser Gly Tyr Gin Ser Asp 885 890 895
ATT GAT ACA CAT AAT AGA ATT AAG GAT GAA TTA TGA 2724
He Asp Thr His Asn Arg He Lys Asp Glu Leu * 900 905 (2) INFORMATION FOR SEQ ID NO : 16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 908 ammo acids
(B) TYPE: ammo acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi ) SEQUENCE DESCRIPTION: SEQ ID NO: 16:
Met Gin Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15
Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30
Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro Glu Arg 35 40 45
Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60
Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80
Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95
Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 100 105 110
Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lys 115 120 125
Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tyr 130 135 140
Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160
He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175
Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro Asp Phe 180 185 190
Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205
Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220
Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240
Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255
Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270
Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285
Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300 Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320
Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335
Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350
Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365
Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tyr 370 375 380
Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400
Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415
Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430
Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445
He Glu Gly Arg Cys Asp Gly Ala Leu Asn Asp Leu Cys He Lys Val 450 455 460
Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn 465 470 475 480
Asp Leu Asn Lys Gly Glu Glu He Thr Ser Asp Thr Asn He Glu Ala 485 490 495
Ala Glu Glu Asn He Ser Leu Asp Leu He Gin Gin Tyr Tyr Leu Thr 500 505 510
Phe Asn Phe Asp Asn Glu Pro Glu Asn He Ser He Glu Asn Leu Ser 515 520 525
Ser Asp He He Gly Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe 530 535 540
Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr 545 550 555 560
Leu Arg Ala Gin Glu Phe Glu His Gly Lys Ser Arg He Ala Leu Thr 565 570 575
Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe 580 585 590
Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala 595 600 605
Met Phe Leu Gly Trp Val Glu Gin Leu Val Tyr Asp Phe Thr Asp Glu 610 615 620
Thr Ser Glu Val Ser Thr Thr Asp Lys He Ala Asp He Thr He He 625 630 635 640
He Pro Tyr He Gly Pro Ala Leu Asn He Gly Asn Met Leu Tyr Lys 645 650 655 Asp Asp Phe Val Gly Ala Leu He Phe Ser Gly Ala Val He Leu Leu 660 665 670
Glu Phe He Pro Glu He Ala He Pro Val Leu Gly Thr Phe Ala Leu 675 680 685
Val Ser Tyr He Ala Asn Lys Val Leu Thr Val Gin Thr He Asp Asn 690 695 700
Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr He 705 710 715 720
Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gin He Asp Leu He Arg 725 730 735
Lys Lys Met Lys Glu Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala 740 745 750
He He Asn Tyr Gin Tyr Asn Gin Tyr Thr Glu Glu Glu Lys Asn Asn 755 760 765
He Asn Phe Asn He Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser He 770 775 780
Asn Lys Ala Met He Asn He Asn Lys Phe Leu Asn Gin Cys Ser Val 785 790 795 800
Ser Tyr Leu Met Asn Ser Met He Pro Tyr Gly Val Lys Arg Leu Glu 805 810 815
Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr He Tyr Asp 820 825 830
Asn Arg Gly Thr Leu He Gly Gin Val Asp Arg Leu Lys Asp Lys Val 835 840 845
Asn Asn Thr Leu Ser Thr Asp He Pro Phe Gin Leu Ser Lys Tyr Val 850 855 860
Asp Asn Gin Arg Leu Leu Ser Thr Phe Thr Glu Tyr He Lys Ser Arg 865 870 875 880
Pro Gin Ser Lys Val Lys Arg Gin He Phe Ser Gly Tyr Gin Ser Asp 885 890 895
He Asp Thr His Asn Arg He Lys Asp Glu Leu * 900 905
(2) INFORMATION FOR SEQ ID NO: 17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3042 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:!..3042
( i) SEQUENCE DESCRIPTION: SEQ ID NO: 17:
ATG CAG TTC GTG AAC AAG CAG TTC AAC TAT AAG GAC CCT GTA AAC GGT 48 Met Gin Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15 GTT GAC ATT GCC TAC ATC AAA ATT CCA AAC GCC GGC CAG ATG CAG CCG 96 Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30
GTG AAG GCT TTC AAG ATT CAT AAC AAA ATC TGG GTT ATT CCG GAA CGC 144 Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro Glu Arg 35 40 45
GAT ACA TTT ACG AAC CCG GAA GAA GGA GAC TTG AAC CCG CCG CCG GAA 192 Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60
GCA AAG CAG GTG CCA GTT TCA TAC TAC GAT TCA ACC TAT CTG AGC ACA 240 Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tvr Leu Ser Thr 65 70 75 " 80
GAC AAC GAG AAG GAT AAC TAC CTG AAG GGA GTG ACC AAA TTA TTC GAG 288 Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95
CGT ATT TAT TCC ACT GAC CTG GGC CGT ATG CTG CTG ACC TCA ATC GTC 336 Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 100 105 110
CGC GGA ATC CCA TTT TGG GGT GGC AGT ACC ATT GAC ACG GAG TTG AAG 384 Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lys 115 120 125
GTT ATT GAC ACT AAC TGC ATT AAC GTG ATC CAA CCA GAC GGT AGC TAC 432 Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tyr 130 135 140
AGA TCT GAA GAA CTT AAC CTC GTA ATC ATC GGG CCC TCC GCG GAC ATT 480 Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160
ATC CAG TTT GAG TGC AAG AGC TTT GGC CAC GAA GTG TTG AAC CTG ACG 528 He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175
CGT AAC GGT TAC GGC TCT ACT CAG TAC ATT CGT TTC AGC CCA GAC TTC 576 Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro Asp Phe 180 185 190
ACG TTC GGT TTC GAG GAG AGC CTG GAG GTT GAT ACC AAC CCG CTG TTG 624 Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205
GGT GCA GGC AAG TTC GCA ACT GAT CCA GCG GTG ACC CTG GCA CAC GAG 672 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220
CTG ATC CAC GCC GGT CAT CGT CTG TAT GGC ATT GCG ATT AAC CCG AAC 720 Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240
CGC GTG TTC AAG GTT AAC ACC AAC GCC TAC TAC GAG ATG AGT GGT TTA 768 Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255
GAA GTA AGC TTC GAG GAA CTG CGC ACG TTC GGT GGC CAT GAT GCG AAG 816 Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270
TTT ATC GAC AGC TTG CAG GAG AAC GAG TTC CGT CTG TAC TAC TAC AAC 864 Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285 AAG TTT AAA GAT ATT GCA AGT ACA CTG AAC AAG GCT AAG TCC ATT GTG 912 Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300
GGT ACC ACT GCT TCA TTA CAG TAT ATG AAA AAT GTT TTT AAA GAG AAA 960 Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320
TAT CTC CTA TCT GAA GAT ACA TCT GGA AAA TTT TCG GTA GAT AAA TTA 1008 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335
AAA TTT GAT AAG TTA TAC AAA ATG TTA ACA GAG ATT TAC ACA GAG GAT 1056 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350
AAT TTT GTT AAG TTT TTT AAA GTA CTT AAC AGA AAA ACA TAT TTG AAT 1104 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365
TTT GAT AAA GCC GTA TTT AAG ATA AAT ATA GTA CCT AAG GTA AAT TAC 1152 Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lvs Val Asn Tyr 370 375 380
ACA ATA TAT GAT GGA TTT AAT TTA AGA AAT ACA AAT TTA GCA GCA AAC 1200 Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400
TTT AAT GGT CAA AAT ACA GAA ATT AAT AAT ATG AAT TTT ACT AAA CTA 1248 Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415
AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA 1296 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430
GGG ATA ATA ACT TCT AAA ACT AAA TCA TTA GAT AAA GGA TAC AAT AAG 1344 Gly He He Thr Ser Lys Thr LyS Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445
ATC GAA GGT CGT TGC GAT GGG GCA TTA AAT GAT TTA TGT ATC AAA GTT 1392 He Glu Gly Arg Cys Asp Gly Ala Leu Asn Asp Leu Cys He Lys Val 450 455 460
AAT AAT TGG GAC TTG TTT TTT AGT CCT TCA GAA GAT AAT TTT ACT AAT 1440 Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn 465 470 475 480
GAT CTA AAT AAA GGA GAA GAA ATT ACA TCT GAT ACT AAT ATA GAA GCA 1488 Asp Leu Asn Lys Gly Glu Glu He Thr Ser Asp Thr Asn He Glu Ala 485 490 495
GCA GAA GAA AAT ATT AGT TTA GAT TTA ATA CAA CAA TAT TAT TTA ACC 1536 Ala Glu Glu Asn He Ser Leu Asp Leu He Gin Gin Tyr Tyr Leu Thr 500 505 510
TTT AAT TTT GAT AAT GAA CCT GAA AAT ATT TCA ATA GAA AAT CTT TCA 1584 Phe Asn Phe Asp Asn Glu Pro Glu Asn He Ser He Glu Asn Leu Ser 515 520 525
AGT GAC ATT ATA GGC CAA TTA GAA CTT ATG CCT AAT ATA GAA AGA TTT 1632 Ser Asp He He Gly Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe 530 535 540
CCT AAT GGA AAA AAG TAT GAG TTA GAT AAA TAT ACT ATG TTC CAT TAT 1680 Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr 545 550 555 560 CTT CGT GCT CAA GAA TTT GAA CAT GGT AAA TCT AGG ATT GCT TTA ACA 1728 Leu Arg Ala Gin Glu Phe Glu His Gly Lys Ser Arg He Ala Leu Thr 565 570 575
AAT TCT GTT AAC GAA GCA TTA TTA AAT CCT AGT CGT GTT TAT ACA TTT 1776 Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe 580 585 590
TTT TCT TCA GAC TAT GTA AAG AAA GTT AAT AAA GCT ACG GAG GCA GCT 1824 Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala 595 600 605
ATG TTT TTA GGC TGG GTA GAA CAA TTA GTA TAT GAT TTT ACC GAT GAA 1872 Met Phe Leu Gly Trp Val Glu Gin Leu Val Tyr Asp Phe Thr Asp Glu 610 615 620
ACT AGC GAA GTA AGT ACT ACG GAT AAA ATT GCG GAT ATA ACT ATA ATT 1920 Thr Ser Glu Val Ser Thr Thr Asp Lys He Ala Asp He Thr He He 625 630 635 640
ATT CCA TAT ATA GGA CCT GCT TTA AAT ATA GGT AAT ATG TTA TAT AAA 1968 He Pro Tyr He Gly Pro Ala Leu Asn He Gly Asn Met Leu Tyr Lys 645 650 655
GAT GAT TTT GTA GGT GCT TTA ATA TTT TCA GGA GCT GTT ATT CTG TTA 2016 Asp Asp Phe Val Gly Ala Leu He Phe Ser Gly Ala Val He Leu Leu 660 665 670
GAA TTT ATA CCA GAG ATT GCA ATA CCT GTA TTA GGT ACT TTT GCA CTT 2064 Glu Phe He Pro Glu He Ala He Pro Val Leu Gly Thr Phe Ala Leu 675 680 685
GTA TCA TAT ATT GCG AAT AAG GTT CTA ACC GTT CAA ACA ATA GAT AAT 2112 Val Ser Tyr He Ala Asn Lys Val Leu Thr Val Gin Thr He Asp Asn 690 695 700
GCT TTA AGT AAA AGA AAT GAA AAA TGG GAT GAG GTC TAT AAA TAT ATA 2160 Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr He 705 710 715 720
GTA ACA AAT TGG TTA GCA AAG GTT AAT ACA CAG ATT GAT CTA ATA AGA 2208 Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gin He Asp Leu He Arg 725 730 735
AAA AAA ATG AAA GAA GCT TTA GAA AAT CAA GCA GAA GCA ACA AAG GCT 2256 Lys Lys Met Lys Glu Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala 740 745 750
ATA ATA AAC TAT CAG TAT AAT CAA TAT ACT GAG GAA GAG AAA AAT AAT 2304 He He Asn Tyr Gin Tyr Asn Gin Tyr Thr Glu Glu Glu Lys Asn Asn 755 760 765
ATT AAT TTT AAT ATT GAT GAT TTA AGT TCG AAA CTT AAT GAG TCT ATA 2352 He Asn Phe Asn He Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser He 770 775 780
AAT AAA GCT ATG ATT AAT ATA AAT AAA TTT TTG AAT CAA TGC TCT GTT 2400 Asn Lys Ala Met He Asn He Asn Lys Phe Leu Asn Gin Cys Ser Val 785 790 795 800
TCA TAT TTA ATG AAT TCT ATG ATC CCT TAT GGT GTT AAA CGG TTA GAA 2448 Ser Tyr Leu Met Asn Ser Met He Pro Tyr Gly Val Lys Arg Leu Glu 805 810 815
GAT TTT GAT GCT AGT CTT AAA GAT GCA TTA TTA AAG TAT ATA TAT GAT 2496 Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr He Tyr Asp 820 825 830 AAT AGA GGA ACT TTA ATT GGT CAA GTA GAT AGA TTA AAA GAT AAA GTT 2544 Asn Arg Gly Thr Leu He Gly Gin Val Asp Arg Leu Lys Asp Lys Val 835 840 845
AAT AAT ACA CTT AGT ACA GAT ATA CCT TTT CAG CTT TCC AAA TAC GTA 2592 Asn Asn Thr Leu Ser Thr Asp He Pro Phe Gin Leu Ser Lys Tyr Val 850 855 860
GAT AAT CAA AGA TTA TTA TCT ACA TTT ACT GAA TAT ATT AAG TCA GGC 2640 Asp Asn Gin Arg Leu Leu Ser Thr Phe Thr Glu Tyr He Lys Ser Gly 865 870 875 880
CTG AAT TCC CCG GGT GCA GCT CAT TAT GCG CAA CAC GAT GAA GCC GTA 2688 Leu Asn Ser Pro Gly Ala Ala His Tyr Ala Gin His Asp Glu Ala Val 885 890 895
GAC AAC AAA TTC AAC AAA GAA CAA CAA AAC GCG TTC TAT GAG ATC TTA 2736 Asp Asn Lys Phe Asn Lys Glu Gin Gin Asn Ala Phe Tyr Glu He Leu 900 905 910
CAT TTA CCT AAC TTA AAC GAA GAA CAA CGA AAC GCC TTC ATC CAA AGT 2784 His Leu Pro Asn Leu Asn Glu Glu Gin Arg Asn Ala Phe He Gin Ser 915 920 925
TTA AAA GAT GAC CCA AGC CAA AGC GCT AAC CTT TTA GCA GAA GCT AAA 2832 Leu Lys Asp Asp Pro Ser Gin Ser Ala Asn Leu Leu Ala Glu Ala Lys 930 935 940
AAG CTA AAT GAT GCT CAG GCG CCG AAA GTA GAC AAC AAA TTC AAC AAA 2880 Lvs Leu Asn Asp Ala Gin Ala Pro Lys Val Asp Asn Lys Phe Asn Lys 945 950 955 960
GAA CAA CAA AAC GCG TTC TAT GAG ATC TTA CAT TTA CCT AAC TTA AAC 2928 Glu Gin Gin Asn Ala Phe Tyr Glu He Leu His Leu Pro Asn Leu Asn 965 970 975
GAA GAA CAA CGA AAC GCC TTC ATC CAA AGT TTA AAA GAT GAC CCA AGC 2976 Glu Glu Gin Arg Asn Ala Phe He Gin Ser Leu Lys Asp Asp Pro Ser 980 985 990
CAA AGC GCT AAC CTT TTA GCA GAA GCT AAA AAG CTA AAT GAT GCT CAG 3024 Gin Ser Ala Asn Leu Leu Ala Glu Ala Lys Lys Leu Asn Asp Ala Gin 995 1000 1005
GCG CCG AAA GTA GAC TAG 3042
Ala Pro Lys Val Asp * 1010
(2) INFORMATION FOR SEQ ID NO: 18:
(l) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1014 ammo acids
(B) TYPE: ammo acid (D) TOPOLOGY, linear
(ii) MOLECULE TYPE: protein
(Xl) SEQUENCE DESCRIPTION. SEQ ID NO: 18:
Met Gin Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15
Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30
Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro Glu Arg 35 40 45 Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60
Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80
Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95
Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 100 105 110
Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lys 115 120 125
Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tyr 130 135 140
Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160
He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175
Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro Asp Phe 180 185 190
Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205
Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220
Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240
Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255
Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270
Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285
Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300
Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320
Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335
Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350
Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365
Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tyr 370 375 380
Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400 Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415
Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430
Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445
He Glu Gly Arg Cys Asp Gly Ala Leu Asn Asp Leu Cys He Lys Val 450 455 460
Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn 465 470 475 480
Asp Leu Asn Lys Gly Glu Glu He Thr Ser Asp Thr Asn He Glu Ala 485 490 495
Ala Glu Glu Asn He Ser Leu Asp Leu He Gin Gin Tyr Tyr Leu Thr 500 505 510
Phe Asn Phe Asp Asn Glu Pro Glu Asn He Ser He Glu Asn Leu Ser 515 520 525
Ser Asp He He Gly Gin Leu Glu Leu Met Pro Asn He Glu Arg Phe 530 535 540
Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr 545 550 555 560
Leu Arg Ala Gin Glu Phe Glu His Gly Lys Ser Arg He Ala Leu Thr 565 570 575
Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe 580 585 590
Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala 595 600 605
Met Phe Leu Gly Trp Val Glu Gin Leu Val Tyr Asp Phe Thr Asp Glu 610 615 620
Thr Ser Glu Val Ser Thr Thr Asp Lys He Ala Asp He Thr He He 625 630 635 640
He Pro Tyr He Gly Pro Ala Leu Asn He Gly Asn Met Leu Tyr Lys 645 650 655
Asp Asp Phe Val Gly Ala Leu He Phe Ser Gly Ala Val He Leu Leu 660 665 670
Glu Phe He Pro Glu He Ala He Pro Val Leu Gly Thr Phe Ala ieu 675 680 685
Val Ser Tyr He Ala Asn Lys Val Leu Thr Val Gin Thr He Asp Asn 690 695 700
Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr He 705 710 715 720
Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gin He Asp Leu He Arg 725 730 735
Lys Lys Met Lys Glu Ala Leu Glu Asn Gin Ala Glu Ala Thr Lys Ala 740 745 750 He He Asn Tyr Gin Tyr Asn Gin Tyr Thr Glu Glu Glu Lys Asn Asn 755 760 765
He Asn Phe Asn He Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser He 770 775 780
Asn Lys Ala Met He Asn He Asn Lys Phe Leu Asn Gin Cys Ser Val 785 790 795 800
Ser Tyr Leu Met Asn Ser Met He Pro Tyr Gly Val Lys Arg Leu Glu 805 810 815
Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr He Tvr Asp 820 825 830
Asn Arg Gly Thr Leu He Gly Gin Val Asp Arg Leu Lys Asp Lys Val 835 840 845
Asn Asn Thr Leu Ser Thr Asp He Pro Phe Gin Leu Ser Lys Tyr Val 850 855 860
Asp Asn Gin Arg Leu Leu Ser Thr Phe Thr Glu Tyr He Lys Ser Gly 865 870 875 880
Leu Asn Ser Pro Gly Ala Ala His Tyr Ala Gin His Asp Glu Ala Val 885 890 895
Asp Asn Lys Phe Asn Lys Glu Gin Gin Asn Ala Phe Tyr Glu He Leu 900 905 910
His Leu Pro Asn Leu Asn Glu Glu Gin Arg Asn Ala Phe He Gin Ser 915 920 925
Leu Lys Asp Asp Pro Ser Gin Ser Ala Asn Leu Leu Ala Glu Ala Lys 930 935 940
Lys Leu Asn Asp Ala Gin Ala Pro Lys Val Asp Asn Lys Phe Asn Lys 945 950 955 960
Glu Gin Gin Asn Ala Phe Tyr Glu He Leu His Leu Pro Asn Leu Asn 965 970 975
Glu Glu Gin Arg Asn Ala Phe He Gin Ser Leu Lys Asp Asp Pro Ser 980 985 990
Gin Ser Ala Asn Leu Leu Ala Glu Ala Lys Lys Leu Asn Asp Ala Gin 995 1000 1005
Ala Pro Lys Val Asp * 1010
(2) INFORMATION FOR SEQ~ D NO: 19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3509 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(n) MOLECULE TYPE: DNA (genomic)
(IX) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..3509
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: ATG CCA GTT ACA ATA AAT AAT TTT AAT TAT AAT GAT CCT ATT GAT AAT 48 Met Pro Val Thr He Asn Asn Phe Asn Tyr Asn Asp Pro He Asp Asn 1 5 10 15
AAT AAT ATT ATT ATG ATG GAG CCT CCA TTT GCG AGA GGT ACG GGG AGA 96 Asn Asn He He Met Met Glu Pro Pro Phe Ala Arg Gly Thr Gly Arg 20 25 30
TAT TAT AAA GCT TTT AAA ATC ACA GAT CGT ATT TGG ATA ATA CCG GAA 144 Tyr Tyr Lys Ala Phe Lys He Thr Asp Arg He Trp He He Pro Glu 35 40 45
AGA TAT ACT TTT GGA TAT AAA CCT GAG GAT TTT AAT AAA AGT TCC GGT 192 Arg Tyr Thr Phe Gly Tyr Lys Pro Glu Asp Phe Asn Lys Ser Ser Gly 50 55 60
ATT TTT AAT AGA GAT GTT TGT GAA TAT TAT GAT CCA GAT TAC TTA AAT 240 He Phe Asn Arg Asp Val Cys Glu Tyr Tyr Asp Pro Asp Tyr Leu Asn 65 70 75 80
ACT AAT GAT AAA AAG AAT ATA TTT TTA CAA ACA ATG ATC AAG TTA TTT 288 Thr Asn Asp Lys Lys Asn He Phe Leu Gin Thr Met He Lys Leu Phe 85 90 95
AAT AGA ATC AAA TCA AAA CCA TTG GGT GAA AAG TTA TTA GAG ATG ATT 336 Asn Arg He Lys Ser Lys Pro Leu Gly Glu Lys Leu Leu Glu Met He 100 105 110
ATA AAT GGT ATA CCT TAT CTT GGA GAT AGA CGT GTT CCA CTC GAA GAG 384 He Asn Gly He Pro Tyr Leu Gly Asp Arg Arg Val Pro Leu Glu Glu 115 120 125
TTT AAC ACA AAC ATT GCT AGT GTA ACT GTT AAT AAA TTA ATC AGT AAT 432 Phe Asn Thr Asn He Ala Ser Val Thr Val Asn Lys Leu He Ser Asn 130 135 140
CCA GGA GAA GTG GAG CGA AAA AAA GGT ATT TTC GCA AAT TTA ATA ATA 480 Pro Gly Glu Val Glu Arg Lys Lys Gly He Phe Ala Asn Leu He He 145 150 155 160
TTT GGA CCT GGG CCA GTT TTA AAT GAA AAT GAG ACT ATA GAT ATA GGT 528 Phe Gly Pro Gly Pro Val Leu Asn Glu Asn Glu Thr He Asp He Gly 165 170 175
ATA CAA AAT CAT TTT GCA TCA AGG GAA GGC TTC GGG GGT ATA ATG CAA 576 He Gin Asn His Phe Ala Ser Arg Glu Gly Phe Gly Gly He Met Gin 180 185 190
ATG AAG TTT TGC CCA GAA TAT GTA AGC GTA TTT AAT AAT GTT CAA GAA 624 Met Lys Phe Cys Pro Glu Tyr Val Ser Val Phe Asn Asn Val Gin Glu 195 200 205
AAC AAA GGC GCA AGT ATA TTT AAT AGA CGT GGA TAT TTT TCA GAT CCA 672 Asn Lys Gly Ala Ser He Phe Asn Arg Arg Gly Tyr Phe Ser Asp Pro 210 215 220
GCC TTG ATA TTA ATG CAT GAA CTT ATA CAT GTT TTA CAT GGA TTA TAT 720 Ala Leu He Leu Met His Glu Leu He His Val Leu His Gly Leu Tyr 225 230 235 240
GGC ATT AAA GTA GAT GAT TTA CCA ATT GTA CCA AAT GAA AAA AAA TTT 768 Gly He Lys Val Asp Asp Leu Pro He Val Pro Asn Glu Lys Lys Phe 245 250 255
TTT ATG CAA TCT ACA GAT GCT ATA CAG GCA GAA GAA CTA TAT ACA TTT 816 Phe Met Gin Ser Thr Asp Ala He Gin Ala Glu Glu Leu Tyr Thr Phe 260 265 270 GGA GGA CAA GAT CCC AGC ATC ATA ACT CCT TCT ACG GAT AAA AGT ATC 864 Gly Gly Gin Asp Pro Ser He He Thr Pro Ser Thr Asp Lys Ser He 275 280 285
TAT GAT AAA GTT TTG CAA AAT TTT AGA GGG ATA GTT GAT AGA CTT AAC 912 Tyr Asp Lys Val Leu Gin Asn Phe Arg Gly He Val Asp Arg Leu Asn 290 295 300
AAG GTT TTA GTT TGC ATA TCA GAT CCT AAC ATT AAT ATT AAT ATA TAT 960 Lys Val Leu Val Cys He Ser Asp Pro Asn He Asn He Asn He Tyr 305 310 315 320
AAA AAT AAA TTT AAA GAT AAA TAT AAA TTC GTT GAA GAT TCT GAG GGA 1008 Lys Asn Lys Phe Lys Asp Lys Tyr Lys Phe Val Glu Asp Ser Glu Gly 325 330 335
AAA TAT AGT ATA GAT GTA GAA AGT TTT GAT AAA TTA TAT AAA AGC TTA 1056 Lys Tyr Ser He Asp Val Glu Ser Phe Asp Lys Leu Tyr Lys Ser Leu 340 345 350
ATG TTT GGT TTT ACA GAA ACT AAT ATA GCA GAA AAT TAT AAA ATA AAA 1104 Met Phe Gly Phe Thr Glu Thr Asn He Ala Glu Asn Tyr Lys He Lys 355 360 365
ACT AGA GCT TCT TAT TTT AGT GAT TCC TTA CCA CCA GTA AAA ATA AAA 1152 Thr Arg Ala Ser Tyr Phe Ser Asp Ser Leu Pro Pro Val Lys He Lys 370 375 380
AAT TTA TTA GAT AAT GAA ATC TAT ACT ATA GAG GAA GGG TTT AAT ATA 1200 Asn Leu Leu Asp Asn Glu He Tyr Thr He Glu Glu Gly Phe Asn He 385 390 395 400
TCT GAT AAA GAT ATG GAA AAA GAA TAT AGA GGT CAG AAT AAA GCT ATA 1248 Ser Asp Lys Asp Met Glu Lys Glu Tyr Arg Gly Gin Asn Lys Ala He 405 410 415
AAT AAA CAA GCT TAT GAA GAA ATT AGC AAG GAG CAT TTG GCT GTA TAT 1296 Asn Lys Gin Ala Tyr Glu Glu He Ser Lys Glu His Leu Ala Val Tyr 420 425 430
AAG ATA CAA ATG TGT AAA AGT GTT AAA GCT CCA GGA ATA TGT ATT GAT 1344 Lys He Gin Met Cys Lys Ser Val Lys Ala Pro Gly He Cys He Asp 435 440 445
GTT GAT AAT GAA GAT TTG TTC TTT ATA GCT GAT AAA AAT AGT TTT TCA 1392 Val Asp Asn Glu Asp Leu Phe Phe He Ala Asp Lys Asn Ser Phe Ser 450 455 460
GAT GAT TTA TCT AAA AAC GAA AGA ATA GAA TAT AAT ACA CAG AGT AAT 1440 Asp Asp Leu Ser Lys Asn Glu Arg He Glu Tyr Asn Thr Gin Ser Asn 465 470 475 480
TAT ATA GAA AAT GAC TTC CCT ATA AAT GAA TTA ATT TTA GAT ACT GAT 1488 Tyr He Glu Asn Asp Phe Pro He Asn Glu Leu He Leu Asp Thr Asp 485 490 495
TTA ATA AGT AAA ATA GAA TTA CCA AGT GAA AAT ACA GAA TCA CTT ACT 1536 Leu He Ser Lys He Glu Leu Pro Ser Glu Asn Thr Glu Ser Leu Thr 500 505 510
GAT TTT AAT GTA GAT GTT CCA GTA TAT GAA AAA CAA CCC GCT ATA AAA 1584 Asp Phe Asn Val Asp Val Pro Val Tyr Glu Lys Gin Pro Ala He Lys 515 520 525
AAA ATT TTT ACA GAT GAA AAT ACC ATC TTT CAA TAT TTA TAC TCT CAG 1632 Lys He Phe Thr Asp Glu Asn Thr He Phe Gin Tyr Leu Tyr Ser Gin 530 535 540 ACA TTT CCT CTA GAT ATA AGA GAT ATA AGT TTA ACA TCT TCA TTT GAT 1680 Thr Phe Pro Leu Asp He Arg Asp He Ser Leu Thr Ser Ser Phe Asp 545 550 555 560
GAT GCA TTA TTA TTT TCT AAC AAA GTT TAT TCA TTT TTT TCT ATG GAT 1728 Asp Ala Leu Leu Phe Ser Asn Lys Val Tyr Ser Phe Phe Ser Met Asp 565 570 575
TAT ATT AAA ACT GCT AAT AAA GTG GTA GAA GCA GGA TTA TTT GCA GGT 1776 Tyr He Lys Thr Ala Asn Lys Val Val Glu Ala Gly Leu Phe Ala Gly 580 585 590
TGG GTG AAA CAG ATA GTA AAT GAT TTT GTA ATC GAA GCT AAT AAA AGC 1824 Trp Val Lys Gin He Val Asn Asp Phe Val He Glu Ala Asn Lys Ser 595 600 605
AAT ACT ATG GAT AAA ATT GCA GAT ATA TCT CTA ATT GTT CCT TAT ATA 1872 Asn Thr Met Asp Lys He Ala Asp He Ser Leu He Val Pro Tyr He 610 615 620
GGA TTA GCT TTA AAT GTA GGA AAT GAA ACA GCT AAA GGA AAT TTT GAA 1920 Gly Leu Ala Leu Asn Val Gly Asn Glu Thr Ala Lys Gly Asn Phe Glu 625 630 635 640
AAT GCT TTT GAG ATT GCA GGA GCC AGT ATT CTA CTA GAA TTT ATA CCA 1968 Asn Ala Phe Glu He Ala Gly Ala Ser He Leu Leu Glu Phe He Pro 645 650 655
GAA CTT TTA ATA CCT GTA GTT GGA GCC TTT TTA TTA GAA TCA TAT ATT 2016 Glu Leu Leu He Pro Val Val Gly Ala Phe Leu Leu Glu Ser Tyr He 660 665 670
GAC AAT AAA AAT AAA ATT ATT AAA ACA ATA GAT AAT GCT TTA ACT AAA 2064 Asp Asn Lys Asn Lys He He Lys Thr He Asp Asn Ala Leu Thr Lys 675 680 685
AGA AAT GAA AAA TGG AGT GAT ATG TAC GGA TTA ATA GTA GCG CAA TGG 2112 Arg Asn Glu Lys Trp Ser Asp Met Tyr Gly Leu He Val Ala Gin Trp 690 695 700
CTC TCA ACA GTT AAT ACT CAA TTT TAT ACA ATA AAA GAG GGA ATG TAT 2160 Leu Ser Thr Val Asn Thr Gin Phe Tyr Thr He Lys Glu Gly Met Tyr 705 710 715 720
AAG GCT TTA AAT TAT CAA GCA CAA GCA TTG GAA GAA ATA ATA AAA TAC 2208 Lys Ala Leu Asn Tyr Gin Ala Gin Ala Leu Glu Glu He He Lys Tyr 725 730 735
AGA TAT AAT ATA TAT TCT GAA AAA GAA AAG TCA AAT ATT AAC ATC GAT 2256 Arg Tyr Asn He Tyr Ser Glu Lys Glu Lys Ser Asn He Asn He Asp 740 745 750
TTT AAT GAT ATA AAT TCT AAA CTT AAT GAG GGT ATT AAC CAA GCT ATA 2304 Phe Asn Asp He Asn Ser Lys Leu Asn Glu Gly He Asn Gin Ala He 755 760 765
GAT AAT ATA AAT AAT TTT ATA AAT GGA TGT TCT GTA TCA TAT TTA ATG 2352 Asp Asn He Asn Asn Phe He Asn Gly Cys Ser Val Ser Tyr Leu Met 770 775 780
AAA AAA ATG ATT CCA TTA GCT GTA GAA AAA TTA CTA GAC TTT GAT AAT 2400 Lys Lys Met He Pro Leu Ala Val Glu Lys Leu Leu Asp Phe Asp Asn 785 790 795 800
ACT CTC AAA AAA AAT TTG TTA AAT TAT ATA GAT GAA AAT AAA TTA TAT 2448 Thr Leu Lys Lys Asn Leu Leu Asn Tyr He Asp Glu Asn Lys Leu Tyr 805 810 815 TTG ATT GGA AGT GCA GAA TAT GAA AAA TCA AAA GTA AAT AAA TAC TTG 2496 Leu He Gly Ser Ala Glu Tyr Glu Lys Ser Lys Val Asn Lys Tyr Leu 820 825 830
AAA ACC ATT ATG CCG TTT GAT CTT TCA ATA TAT ACC AAT GAT ACA ATA 2544 Lys Thr He Met Pro Phe Asp Leu Ser He Tyr Thr Asn Asp Thr He 835 840 845
CTA ATA GAA ATG TTT AAT AAA TAT AAT AGC GAA ATT TTA AAT AAT ATT 2592 Leu He Glu Met Phe Asn Lys Tyr Asn Ser Glu He Leu Asn Asn He 850 855 860
ATC TTA AAT TTA AGA TAT AAG GAT AAT AAT TTA ATA GAT TTA TCA GGA 2640 He Leu Asn Leu Arg Tyr Lys Asp Asn Asn Leu He Asp Leu Ser Gly 865 870 875 880
TAT GGG GCA AAG GTA GAG GTA TAT GAT GGA GTC GAG CTT AAT GAT AAA 2688 Tyr Gly Ala Lys Val Glu Val Tyr Asp Gly Val Glu Leu Asn Asp Lys 885 890 895
AAT CAA TTT AAA TTA ACT AGT TCA GCA AAT AGT AAG ATT AGA GTG ACT 2736 Asn Gin Phe Lys Leu Thr Ser Ser Ala Asn Ser Lys He Arg Val Thr 900 905 910
CAA AAT CAG AAT ATC ATA TTT AAT AGT GTG TTC CTT GAT TTT AGC GTT 2784 Gin Asn Gin Asn He He Phe Asn Ser Val Phe Leu Asp Phe Ser Val 915 920 925
AGC TTT TGG ATA AGA ATA CCT AAA TAT AAG AAT GAT GGT ATA CAA AAT 2832 Ser Phe Trp He Arg He Pro Lys Tyr Lys Asn Asp Gly He Gin Asn 930 935 940
TAT ATT CAT AAT GAA TAT ACA ATA ATT AAT TGT ATG AAA AAT AAT TCG 2880 Tyr He His Asn Glu Tyr Thr He He Asn Cys Met Lys Asn Asn Ser 945 950 955 960
GGC TGG AAA ATA TCT ATT AGG GGT AAT AGG ATA ATA TGG ACT TTA ATT 2928 Gly Trp Lys He Ser He Arg Gly Asn Arg He He Trp Thr Leu He 965 970 975
GAT ATA AAT GGA AAA ACC AAA TCG GTA TTT TTT GAA TAT AAC ATA AGA 2976 Asp He Asn Gly Lys Thr Lys Ser Val Phe Phe Glu Tyr Asn He Arg 980 985 990
GAA GAT ATA TCA GAG TAT ATA AAT AGA TGG TTT TTT GTA ACT ATT ACT 3024 Glu Asp He Ser Glu Tyr He Asn Arg Trp Phe Phe Val Thr He Thr 995 1000 1005
AAT AAT TTG AAT AAC GCT AAA ATT TAT ATT AAT GGT AAG CTA GAA TCA 3072 Asn Asn Leu Asn Asn Ala Lys He Tyr He Asn Gly Lys Leu Glu Ser 1010 1015 1020
AAT ACA GAT ATT AAA GAT ATA AGA GAA GTT ATT GCT AAT GGT GAA ATA 3120 Asn Thr Asp He Lys Asp He Arg Glu Val He Ala Asn Gly Glu He 1025 1030 1035 1040
ATA TTT AAA TTA GAT GGT GAT ATA GAT AGA ACA CAA TTT ATT TGG ATG 3168 He Phe Lys Leu Asp Gly Asp He Asp Arg Thr Gin Phe He Trp Met 1045 1050 1055
AAA TAT TTC AGT ATT TTT AAT ACG GAA TTA AGT CAA TCA AAT ATT GAA 3216 Lys Tyr Phe Ser He Phe Asn Thr Glu Leu Ser Gin Ser Asn He Glu 1060 1065 1070
GAA AGA TAT AAA ATT CAA TCA TAT AGC GAA TAT TTA AAA GAT TTT TGG 3264 Glu Arg Tyr Lys He Gin Ser Tyr Ser Glu Tyr Leu Lys Asp Phe Trp 1075 1080 1085 GGA AAT CCT TTA ATG TAC AAT AAA GAA TAT TAT ATG TTT AAT GCG GGG 3312 Gly Asn Pro Leu Met Tyr Asn Lys Glu Tyr Tyr Met Phe Asn Ala Gly 1090 1095 1100
AAT AAA AAT TCA TAT ATT AAA CTA AAG AAA GAT TCA CCT GTA GGT GAA 3360 Asn Lys Asn Ser Tyr He Lys Leu Lys Lys Asp Ser Pro Val Gly Glu 1105 1110 1115 1120
ATT TTA ACA CGT AGC AAA TAT AAT CAA AAT TCT AAA TAT ATA AAT TAT 3408 He Leu Thr Arg Ser Lys Tyr Asn Gin Asn Ser Lys Tyr He Asn Tyr 1125 1130 1135
AGA GAT TTA TAT ATT GGA GAA AAA TTT ATT ATA AGA AGA AAG TCA AAT 3456 Arg Asp Leu Tyr He Gly Glu Lys Phe He He Arg Arg Lys Ser Asn 1140 1145 1150
TCT CAA TCT ATA AAT GAT GAT ATA GTT AGA AAA GAA GAT TAT ATA TAT 3504 Ser Gin Ser He Asn Asp Asp He Val Arg Lys Glu Asp Tyr He Tyr 1155 1160 1165
CTA GA 3509
Leu
(2) INFORMATION FOR SEQ ID NO: 20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1169 ammo acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:
Met Pro Val Thr He Asn Asn Phe Asn Tyr Asn Asp Pro He Asp Asn 1 5 10 15
Asn Asn He He Met Met Glu Pro Pro Phe Ala Arg Gly Thr Gly Arg 20 25 30
Tyr Tyr Lys Ala Phe Lys He Thr Asp Arg He Trp He He Pro Glu 35 40 45
Arg Tyr Thr Phe Gly Tyr Lys Pro Glu Asp Phe Asn Lys Ser Ser Gly 50 55 60
He Phe Asn Arg Asp Val Cys Glu Tyr Tyr Asp Pro Asp Tyr Leu Asn 65 70 75 80
Thr Asn Asp Lys Lys Asn He Phe Leu Gin Thr Met He Lys Leu Phe 85 90 95
Asn Arg He Lys Ser Lys Pro Leu Gly Glu Lys Leu Leu Glu Met He 100 105 110
He Asn Gly He Pro Tyr Leu Gly Asp Arg Arg Val Pro Leu Glu Glu 115 120 125
Phe Asn Thr Asn He Ala Ser Val Thr Val Asn Lys Leu He Ser Asn 130 135 140
Pro Gly Glu Val Glu Arg Lys Lys Gly He Phe Ala Asn Leu He He 145 150 155 160
Phe Gly Pro Gly Pro Val Leu Asn Glu Asn Glu Thr He Asp He Gly 165 170 175 He Gin Asn His Phe Ala Ser Arg Glu Gly Phe Gly Gly He Met Gin 180 185 190
Met Lys Phe Cys Pro Glu Tyr Val Ser Val Phe Asn Asn Val Gin Glu 195 200 205
Asn Lys Gly Ala Ser He Phe Asn Arg Arg Gly Tyr Phe Ser Asp Pro 210 215 220
Ala Leu He Leu Met His Glu Leu He His Val Leu His Gly Leu Tyr 225 230 235 240
Gly He Lys Val Asp Asp Leu Pro He Val Pro Asn Glu Lys Lys Phe 245 250 255
Phe Met Gin Ser Thr Asp Ala He Gin Ala Glu Glu Leu Tyr Thr Phe 260 265 270
Gly Gly Gin Asp Pro Ser He He Thr Pro Ser Thr Asp Lys Ser He 275 280 285
Tyr Asp Lys Val Leu Gin Asn Phe Arg Gly He Val Asp Arg Leu Asn 290 295 300
Lys Val Leu Val Cys He Ser Asp Pro Asn He Asn He Asn He Tyr 305 310 315 320
Lys Asn Lys Phe Lys Asp Lys Tyr Lys Phe Val Glu Asp Ser Glu Gly 325 330 335
Lys Tyr Ser He Asp Val Glu Ser Phe Asp Lys Leu Tyr Lys Ser Leu 340 345 350
Met Phe Gly Phe Thr Glu Thr Asn He Ala Glu Asn Tyr Lys He Lys 355 360 365
Thr Arg Ala Ser Tyr Phe Ser Asp Ser Leu Pro Pro Val Lys He Lys 370 375 380
Asn Leu Leu Asp Asn Glu He Tyr Thr He Glu Glu Gly Phe Asn He 385 390 395 400
Ser Asp Lys Asp Met Glu Lys Glu Tyr Arg Gly Gin Asn Lys Ala He 405 410 415
Asn Lys Gin Ala Tyr Glu Glu He Ser Lys Glu His Leu Ala Val Tyr 420 425 430
Lys He Gin Met Cys Lys Ser Val Lys Ala Pro Gly He Cys He Asp 435 440 445
Val Asp Asn Glu Asp Leu Phe Phe He Ala Asp Lys Asn Ser Phe Ser
Asp Asp Leu Ser Lys Asn Glu Arg He Glu Tyr Asn Thr Gin Ser Asn 465 470 475 480
Tyr He Glu Asn Asp Phe Pro He Asn Glu Leu He Leu Asp Thr Asp 485 490 495
Leu He Ser Lys He Glu Leu Pro Ser Glu Asn Thr Glu Ser Leu Thr 500 505 510
Asp Phe Asn Val Asp Val Pro Val Tyr Glu Lys Gin Pro Ala He Lys 515 520 525 Lys He Phe Thr Asp Glu Asn Thr He Phe Gin Tyr Leu Tyr Ser Gin 530 535 540
Thr Phe Pro Leu Asp He Arg Asp He Ser Leu Thr Ser Ser Phe Asp 545 550 555 560
Asp Ala Leu Leu Phe Ser Asn Lys Val Tyr Ser Phe Phe Ser Met Asp 565 570 575
Tyr He Lys Thr Ala Asn Lys Val Val Glu Ala Gly Leu Phe Ala Gly 580 585 590
Trp Val Lys Gin He Val Asn Asp Phe Val He Glu Ala Asn Lys Ser 595 600 605
Asn Thr Met Asp Lys He Ala Asp He Ser Leu He Val Pro Tyr He 610 615 620
Gly Leu Ala Leu Asn Val Gly Asn Glu Thr Ala Lys Gly Asn Phe Glu 625 630 635 640
Asn Ala Phe Glu He Ala Gly Ala Ser He Leu Leu Glu Phe He Pro 645 650 655
Glu Leu Leu He Pro Val Val Gly Ala Phe Leu Leu Glu Ser Tyr He 660 665 670
Asp Asn Lys Asn Lys He He Lys Thr He Asp Asn Ala Leu Thr Lys 675 680 685
Arg Asn Glu Lys Trp Ser Asp Met Tyr Gly Leu He Val Ala Gin Trp 690 695 700
Leu Ser Thr Val Asn Thr Gin Phe Tyr Thr He Lys Glu Gly Met Tyr 705 710 715 720
Lys Ala Leu Asn Tyr Gin Ala Gin Ala Leu Glu Glu He He Lys Tyr 725 730 735
Arg Tyr Asn He Tyr Ser Glu Lys Glu Lys Ser Asn He Asn He Asp 740 745 750
Phe Asn Asp He Asn Ser Lys Leu Asn Glu Gly He Asn Gin Ala He 755 760 765
Asp Asn He Asn Asn Phe He Asn Gly Cys Ser Val Ser Tyr Leu Met 770 775 780
Lys Lys Met He Pro Leu Ala Val Glu Lys Leu Leu Asp Phe Asp Asn 785 790 795 800
Thr Leu Lys Lys Asn Leu Leu Asn Tyr He Asp Glu Asn Lys Leu Tyr 805 810 815
Leu He Gly Ser Ala Glu Tyr Glu Lys Ser Lys Val Asn Lys Tyr Leu 820 825 830
Lys Thr He Met Pro Phe Asp Leu Ser He Tyr Thr Asn Asp Thr He 835 840 845
Leu He Glu Met Phe Asn Lys Tyr Asn Ser Glu He Leu Asn Asn He 850 855 860
He Leu Asn Leu Arg Tyr Lys Asp Asn Asn Leu He Asp Leu Ser Gly 865 870 875 880 Tyr Gly Ala Lys Val Glu Val Tyr Asp Gly Val Glu Leu Asn Asp Lys 885 890 895
Asn Gin Phe Lys Leu Thr Ser Ser Ala Asn Ser Lys He Arg Val Thr 900 905 910
Gin Asn Gin Asn He He Phe Asn Ser Val Phe Leu Asp Phe Ser Val 915 920 925
Ser Phe Trp He Arg He Pro Lys Tyr Lys Asn Asp Gly He Gin Asn 930 935 940
Tyr He His Asn Glu Tyr Thr He He Asn Cys Met Lys Asn Asn Ser 945 950 955 960
Gly Trp Lys He Ser He Arg Gly Asn Arg He He Trp Thr Leu He 965 970 975
Asp He Asn Gly Lys Thr Lys Ser Val Phe Phe Glu Tyr Asn He Arg 980 985 990
Glu Asp He Ser Glu Tyr He Asn Arg Trp Phe Phe Val Thr He Thr 995 1000 1005
Asn Asn Leu Asn Asn Ala Lys He Tyr He Asn Gly Lys Leu Glu Ser 1010 1015 1020
Asn Thr Asp He Lys Asp He Arg Glu Val He Ala Asn Gly Glu He 1025 1030 1035 1040
He Phe Lys Leu Asp Gly Asp He Asp Arg Thr Gin Phe He Trp Met 1045 1050 1055
Lys Tyr Phe Ser He Phe Asn Thr Glu Leu Ser Gin Ser Asn He Glu 1060 1065 1070
Glu Arg Tyr Lys He Gin Ser Tyr Ser Glu Tyr Leu Lys Asp Phe Trp 1075 1080 1085
Gly Asn Pro Leu Met Tyr Asn Lys Glu Tyr Tyr Met Phe Asn Ala Gly 1090 1095 1100
Asn Lys Asn Ser Tyr He Lys Leu Lys Lys Asp Ser Pro Val Gly Glu 1105 1110 1115 1120
He Leu Thr Arg Ser Lys Tyr Asn Gin Asn Ser Lys Tyr He Asn Tyr 1125 1130 1135
Arg Asp Leu Tyr He Gly Glu Lys Phe He He Arg Arg Lys Ser Asn 1140 1145 1150
Ser Gin Ser He Asn Asp Asp He Val Arg Lys Glu Asp Tyr He Tyr 1155 1160 1165
Leu
(2) INFORMATION FOR SEQ ID NO: 21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2574 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic) ( ix) FEATURE :
(A) NAME/KEY: CDS
(B) LOCATION: 1..2574
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:
ATG CCA GTT ACA ATA AAT AAT TTT AAT TAT AAT GAT CCT ATT GAT AAT 48 Met Pro Val Thr He Asn Asn Phe Asn Tyr Asn Asp Pro He Asp Asn 1 5 10 15
AAT AAT ATT ATT ATG ATG GAG CCT CCA TTT GCG AGA GGT ACG GGG AGA 96 Asn Asn He He Met Met Glu Pro Pro Phe Ala Arg Gly Thr Gly Arg 20 25 30
TAT TAT AAA GCT TTT AAA ATC ACA GAT CGT ATT TGG ATA ATA CCG GAA 144 Tyr Tyr Lys Ala Phe Lys He Thr Asp Arg He Trp He He Pro Glu 35 40 45
AGA TAT ACT TTT GGA TAT AAA CCT GAG GAT TTT AAT AAA AGT TCC GGT 192 Arg Tyr Thr Phe Gly Tyr Lys Pro Glu Asp Phe Asn Lys Ser Ser Gly 50 55 60
ATT TTT AAT AGA GAT GTT TGT GAA TAT TAT GAT CCA GAT TAC TTA AAT 240 He Phe Asn Arg Asp Val Cys Glu Tyr Tyr Asp Pro Asp Tyr Leu Asn 65 70 75 80
ACT AAT GAT AAA AAG AAT ATA TTT TTA CAA ACA ATG ATC AAG TTA TTT 288 Thr Asn Asp Lys Lys Asn He Phe Leu Gin Thr Met He Lys Leu Phe 85 90 95
AAT AGA ATC AAA TCA AAA CCA TTG GGT GAA AAG TTA TTA GAG ATG ATT 336 Asn Arg He Lys Ser Lys Pro Leu Gly Glu Lys Leu Leu Glu Met He 100 105 110
ATA AAT GGT ATA CCT TAT CTT GGA GAT AGA CGT GTT CCA CTC GAA GAG 384 He Asn Gly He Pro Tyr Leu Gly Asp Arg Arg Val Pro Leu Glu Glu 115 120 125
TTT AAC ACA AAC ATT GCT AGT GTA ACT GTT AAT AAA TTA ATC AGT AAT 432 Phe Asn Thr Asn He Ala Ser Val Thr Val Asn Lys Leu He Ser Asn 130 135 140
CCA GGA GAA GTG GAG CGA AAA AAA GGT ATT TTC GCA AAT TTA ATA ATA 480 Pro Gly Glu Val Glu Arg Lys Lys Gly He Phe Ala Asn Leu He He 145 150 155 160
TTT GGA CCT GGG CCA GTT TTA AAT GAA AAT GAG ACT ATA GAT ATA GGT 528 Phe Gly Pro Gly Pro Val Leu Asn Glu Asn Glu Thr He Asp He Gly 165 170 175
ATA CAA AAT CAT"TTT GCA TCA AGG GAA GGC TTC GGG GGT ATA ATG CAA 576 He Gin Asn His Phe Ala Ser Arg Glu Gly Phe Gly Gly He Met Gin 180 185 190
ATG AAG TTT TGC CCA GAA TAT GTA AGC GTA TTT AAT AAT GTT CAA GAA 624 Met Lys Phe Cys Pro Glu Tyr Val Ser Val Phe Asn Asn Val Gin Glu 195 200 205
AAC AAA GGC GCA AGT ATA TTT AAT AGA CGT GGA TAT TTT TCA GAT CCA 672 Asn Lys Gly Ala Ser He Phe Asn Arg Arg Gly Tyr Phe Ser Asp Pro 210 215 220
GCC TTG ATA TTA ATG CAT GAA CTT ATA CAT GTT TTA CAT GGA TTA TAT 720 Ala Leu He Leu Met His Glu Leu He His Val Leu His Gly Leu Tyr 225 230 235 240 GGC ATT AAA GTA GAT GAT TTA CCA ATT GTA CCA AAT GAA AAA AAA TTT 768 Gly He Lys Val Asp Asp Leu Pro He Val Pro Asn Glu Lys Lys Phe 245 250 255
TTT ATG CAA TCT ACA GAT GCT ATA CAG GCA GAA GAA CTA TAT ACA TTT 816 Phe Met Gin Ser Thr Asp Ala He Gin Ala Glu Glu Leu Tyr Thr Phe 260 265 270
GGA GGA CAA GAT CCC AGC ATC ATA ACT CCT TCT ACG GAT AAA AGT ATC 864 Gly Gly Gin Asp Pro Ser He He Thr Pro Ser Thr Asp Lys Ser He 275 280 285
TAT GAT AAA GTT TTG CAA AAT TTT AGA GGG ATA GTT GAT AGA CTT AAC 912 Tyr Asp Lys Val Leu Gin Asn Phe Arg Gly He Val Asp Arg Leu Asn 290 295 300
AAG GTT TTA GTT TGC ATA TCA GAT CCT AAC ATT AAT ATT AAT ATA TAT 960 Lys Val Leu Val Cys He Ser Asp Pro Asn He Asn He Asn He Tyr 305 310 315 320
AAA AAT AAA TTT AAA GAT AAA TAT AAA TTC GTT GAA GAT TCT GAG GGA 1008 Lys Asn Lys Phe Lys Asp Lys Tyr Lys Phe Val Glu Asp Ser Glu Gly 325 330 335
AAA TAT AGT ATA GAT GTA GAA AGT TTT GAT AAA TTA TAT AAA AGC TTA 1056 Lys Tyr Ser He Asp Val Glu Ser Phe Asp Lys Leu Tyr Lys Ser Leu 340 345 350
ATG TTT GGT TTT ACA GAA ACT AAT ATA GCA GAA AAT TAT AAA ATA AAA 1104 Met Phe Gly Phe Thr Glu Thr Asn He Ala Glu Asn Tyr Lys He Lys 355 360 365
ACT AGA GCT TCT TAT TTT AGT GAT TCC TTA CCA CCA GTA AAA ATA AAA 1152 Thr Arg Ala Ser Tyr Phe Ser Asp Ser Leu Pro Pro Val Lys He Lys 370 375 380
AAT TTA TTA GAT AAT GAA ATC TAT ACT ATA GAG GAA GGG TTT AAT ATA 1200 Asn Leu Leu Asp Asn Glu He Tyr Thr He Glu Glu Gly Phe Asn He 385 390 395 400
TCT GAT AAA GAT ATG GAA AAA GAA TAT AGA GGT CAG AAT AAA GCT ATA 1248 Ser Asp Lys Asp Met Glu Lys Glu Tyr Arg Gly Gin Asn Lys Ala He 405 410 415
AAT AAA CAA GCT TAT GAA GAA ATT AGC AAG GAG CAT TTG GCT GTA TAT 1296 Asn Lys Gin Ala Tyr Glu Glu He Ser Lys Glu His Leu Ala Val Tyr 420 425 430
AAG ATA CAA ATG TGT AAA AGT GTT AAA GCT CCA GGA ATA TGT ATT GAT 1344 Lys He Gin Met Cys Lys Ser Val Lys Ala Pro Gly He Cys He Asp 435 440 445
GTT GAT AAT GAA GAT TTG TTC TTT ATA GCT GAT AAA AAT AGT TTT TCA 1392 Val Asp Asn Glu Asp Leu Phe Phe He Ala Asp Lys Asn Ser Phe Ser 450 455 460
GAT GAT TTA TCT AAA AAC GAA AGA ATA GAA TAT AAT ACA CAG AGT AAT 1440 Asp Asp Leu Ser Lys Asn Glu Arg He Glu Tyr Asn Thr Gin Ser Asn 465 470 475 480
TAT ATA GAA AAT GAC TTC CCT ATA AAT GAA TTA ATT TTA GAT ACT GAT 1488 Tyr He Glu Asn Asp Phe Pro He Asn Glu Leu He Leu Asp Thr Asp 485 490 495
TTA ATA AGT AAA ATA GAA TTA CCA AGT GAA AAT ACA GAA TCA CTT ACT 1536 Leu He Ser Lys He Glu Leu Pro Ser Glu Asn Thr Glu Ser Leu Thr 500 505 510 GAT TTT AAT GTA GAT GTT CCA GTA TAT GAA AAA CAA CCC GCT ATA AAA 1584 Asp Phe Asn Val Asp Val Pro Val Tyr Glu Lys Gin Pro Ala He Lys 515 520 525
AAA ATT TTT ACA GAT GAA AAT ACC ATC TTT CAA TAT TTA TAC TCT CAG 1632 Lys He Phe Thr Asp Glu Asn Thr He Phe Gin Tyr Leu Tyr Ser Gin 530 535 540
ACA TTT CCT CTA GAT ATA AGA GAT ATA AGT TTA ACA TCT TCA TTT GAT 1680 Thr Phe Pro Leu Asp He Arg Asp He Ser Leu Thr Ser Ser Phe Asp 545 550 555 560
GAT GCA TTA TTA TTT TCT AAC AAA GTT TAT TCA TTT TTT TCT ATG GAT 1728 Asp Ala Leu Leu Phe Ser Asn Lys Val Tyr Ser Phe Phe Ser Met Asp 565 570 575
TAT ATT AAA ACT GCT AAT AAA GTG GTA GAA GCA GGA TTA TTT GCA GGT 1776 Tyr He Lys Thr Ala Asn Lys Val Val Glu Ala Gly Leu Phe Ala Gly 580 585 590
TGG GTG AAA CAG ATA GTA AAT GAT TTT GTA ATC GAA GCT AAT AAA AGC 1824 Trp Val Lys Gin He Val Asn Asp Phe Val He Glu Ala Asn Lys Ser 595 600 605
AAT ACT ATG GAT AAA ATT GCA GAT ATA TCT CTA ATT GTT CCT TAT ATA 1872 Asn Thr Met Asp Lys He Ala Asp He Ser Leu He Val Pro Tyr He 610 615 620
GGA TTA GCT TTA AAT GTA GGA AAT GAA ACA GCT AAA GGA AAT TTT GAA 1920 Gly Leu Ala Leu Asn Val Gly Asn Glu Thr Ala Lys Gly Asn Phe Glu 625 630 635 640
AAT GCT TTT GAG ATT GCA GGA GCC AGT ATT CTA CTA GAA TTT ATA CCA 1968 Asn Ala Phe Glu He Ala Gly Ala Ser He Leu Leu Glu Phe He Pro 645 650 655
GAA CTT TTA ATA CCT GTA GTT GGA GCC TTT TTA TTA GAA TCA TAT ATT 2016 Glu Leu Leu He Pro Val Val Gly Ala Phe Leu Leu Glu Ser Tyr He 660 665 670
GAC AAT AAA AAT AAA ATT ATT AAA ACA ATA GAT AAT GCT TTA ACT AAA 2064 Asp Asn Lys Asn Lys He He Lys Thr He Asp Asn Ala Leu Thr Lys 675 680 685
AGA AAT GAA AAA TGG AGT GAT ATG TAC GGA TTA ATA GTA GCG CAA TGG 2112 Arg Asn Glu Lys Trp Ser Asp Met Tyr Gly Leu He Val Ala Gin Trp 690 695 700
CTC TCA ACA GTT AAT ACT CAA TTT TAT ACA ATA AAA GAG GGA ATG TAT 2160 Leu Ser Thr Val Asn Thr Gin Phe Tyr Thr He Lys Glu Gly Met Tyr 705 710 715 720
AAG GCT TTA AAT TAT CAA GCA CAA GCA TTG GAA GAA ATA ATA AAA TAC 2208 Lys Ala Leu Asn Tyr Gin Ala Gin Ala Leu Glu Glu He He Lys Tyr 725 730 735
AGA TAT AAT ATA TAT TCT GAA AAA GAA AAG TCA AAT ATT AAC ATC GAT 2256 Arg Tyr Asn He Tyr Ser Glu Lys Glu Lys Ser Asn He Asn He Asp 740 745 750
TTT AAT GAT ATA AAT TCT AAA CTT AAT GAG GGT ATT AAC CAA GCT ATA 2304 Phe Asn Asp He Asn Ser Lys Leu Asn Glu Gly He Asn Gin Ala He 755 760 765
GAT AAT ATA AAT AAT TTT ATA AAT GGA TGT TCT GTA TCA TAT TTA ATG 2352 Asp Asn He Asn Asn Phe He Asn Gly Cys Ser Val Ser Tyr Leu Met 770 775 780 AAA AAA ATG ATT CCA TTA GCT GTA GAA AAA TTA CTA GAC TTT GAT AAT 2400 Lys Lys Met He Pro Leu Ala Val Glu Lys Leu Leu Asp Phe Asp Asn 785 790 795 800
ACT CTC AAA AAA AAT TTG TTA AAT TAT ATA GAT GAA AAT AAA TTA TAT 2448 Thr Leu Lys Lys Asn Leu Leu Asn Tyr He Asp Glu Asn Lys Leu Tyr 805 810 815
TTG ATT GGA AGT GCA GAA TAT GAA AAA TCA AAA GTA AAT AAA TAC TTG 2496 Leu He Gly Ser Ala Glu Tyr Glu Lys Ser Lys Val Asn Lys Tyr Leu 820 825 830
AAA ACC ATT ATG CCG TTT GAT CTT TCA ATA TAT ACC AAT GAT ACA ATA 2544 Lys Thr He Met Pro Phe Asp Leu Ser He Tyr Thr Asn Asp Thr He 835 840 845
CTA ATA GAA ATG TTT AAT AAA TAT AAT AGC 2574
Leu He Glu Met Phe Asn Lys Tyr Asn Ser 850 855
(2) INFORMATION FOR SEQ ID NO: 22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 858 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:
Met Pro Val Thr He Asn Asn Phe Asn Tyr Asn Asp Pro He Asp Asn 1 5 10 15
Asn Asn He He Met Met Glu Pro Pro Phe Ala Arg Gly Thr Gly Arg 20 25 30
Tyr Tyr Lys Ala Phe Lys He Thr Asp Arg He Trp He He Pro Glu 35 40 45
Arg Tyr Thr Phe Gly Tyr Lys Pro Glu Asp Phe Asn Lys Ser Ser Gly 50 55 60
He Phe Asn Arg Asp Val Cys Glu Tyr Tyr Asp Pro Asp Tyr Leu Asn 65 70 75 80
Thr Asn Asp Lys Lys Asn He Phe Leu Gin Thr Met He Lys Leu Phe 85 90 95
Asn Arg He Lys Ser Lys Pro Leu Gly Glu Lys Leu Leu Glu Met He 100 105 110
He Asn Gly He Pro Tyr Leu Gly Asp Arg Arg Val Pro Leu Glu Glu 115 120 125
Phe Asn Thr Asn He Ala Ser Val Thr Val Asn Lys Leu He Ser Asn 130 135 140
Pro Gly Glu Val Glu Arg Lys Lys Gly He Phe Ala Asn Leu He He 145 150 155 160
Phe Gly Pro Gly Pro Val Leu Asn Glu Asn Glu Thr He Asp He Gly 165 170 175
He Gin Asn His Phe Ala Ser Arg Glu Gly Phe Gly Gly He Met Gin 180 185 190 Met Lys Phe Cys Pro Glu Tyr Val Ser Val Phe Asn Asn Val Gin Glu 195 200 205
Asn Lys Gly Ala Ser He Phe Asn Arg Arg Gly Tyr Phe Ser Asp Pro 210 215 220
Ala Leu He Leu Met His Glu Leu He His Val Leu His Gly Leu Tyr 225 230 235 240
Gly He Lys Val Asp Asp Leu Pro He Val Pro Asn Glu Lys Lys Phe 245 250 255
Phe Met Gin Ser Thr Asp Ala He Gin Ala Glu Glu Leu Tyr Thr Phe 260 265 270
Gly Gly Gin Asp Pro Ser He He Thr Pro Ser Thr Asp Lys Ser He 275 280 285
Tyr Asp Lys Val Leu Gin Asn Phe Arg Gly He Val Asp Arg Leu Asn 290 295 300
Lys Val Leu Val Cys He Ser Asp Pro Asn He Asn He Asn He Tyr 305 310 315 320
Lys Asn Lys Phe Lys Asp Lys Tyr Lys Phe Val Glu Asp Ser Glu Gly 325 330 335
Lys Tyr Ser He Asp Val Glu Ser Phe Asp Lys Leu Tyr Lys Ser Leu 340 345 350
Met Phe Gly Phe Thr Glu Thr Asn He Ala Glu Asn Tyr Lys He Lys 355 360 365
Thr Arg Ala Ser Tyr Phe Ser Asp Ser Leu Pro Pro Val Lys He Lys 370 375 380
Asn Leu Leu Asp Asn Glu He Tyr Thr He Glu Glu Gly Phe Asn He 385 390 395 400
Ser Asp Lys Asp Met Glu Lys Glu Tyr Arg Gly Gin Asn Lys Ala He 405 410 415
Asn Lys Gin Ala Tyr Glu Glu He Ser Lys Glu His Leu Ala Val Tyr 420 425 430
Lys He Gin Met Cys Lys Ser Val Lys Ala Pro Gly He Cys He Asp 435 440 445
Val Asp Asn Glu Asp Leu Phe Phe He Ala Asp Lys Asn Ser Phe Ser 450 455 460
Asp Asp Leu Ser Lys Asn Glu" Arg He Glu Tyr Asn Thr Gin Ser Asn 465 470 475 480
Tyr He Glu Asn Asp Phe Pro He Asn Glu Leu He Leu Asp Thr Asp 485 490 495
Leu He Ser Lys He Glu Leu Pro Ser Glu Asn Thr Glu Ser Leu Thr 500 505 510
Asp Phe Asn Val Asp Val Pro Val Tyr Glu Lys Gin Pro Ala He Lys 515 520 525
Lys lie Phe Thr Asp Glu Asn Thr He Phe Gin Tyr Leu Tyr Ser Gin 530 535 540 Thr Phe Pro Leu Asp He Arg Asp He Ser Leu Thr Ser Ser Phe Asp 545 550 555 560
Asp Ala Leu Leu Phe Ser Asn Lys Val Tyr Ser Phe Phe Ser Met Asp 565 570 575
Tyr He Lys Thr Ala Asn Lys Val Val Glu Ala Gly Leu Phe Ala Gly 580 585 590
Trp Val Lys Gin He Val Asn Asp Phe Val He Glu Ala Asn Lys Ser 595 600 605
Asn Thr Met Asp Lys He Ala Asp He Ser Leu He Val Pro Tyr He 610 615 620
Gly Leu Ala Leu Asn Val Gly Asn Glu Thr Ala Lys Gly Asn Phe Glu 625 630 635 640
Asn Ala Phe Glu He Ala Gly Ala Ser He Leu Leu Glu Phe He Pro 645 650 655
Glu Leu Leu He Pro Val Val Gly Ala Phe Leu Leu Glu Ser Tyr He 660 665 670
Asp Asn Lys Asn Lys He He Lys Thr He Asp Asn Ala Leu Thr Lys 675 680 685
Arg Asn Glu Lys Trp Ser Asp Met Tyr Gly Leu He Val Ala Gin Trp 690 695 700
Leu Ser Thr Val Asn Thr Gin Phe Tyr Thr He Lys Glu Gly Met Tyr 705 710 715 720
Lys Ala Leu Asn Tyr Gin Ala Gin Ala Leu Glu Glu He He Lys Tyr 725 730 735
Arg Tyr Asn He Tyr Ser Glu Lys Glu Lys Ser Asn He Asn He Asp 740 745 750
Phe Asn Asp He Asn Ser Lys Leu Asn Glu Gly He Asn Gin Ala He 755 760 765
Asp Asn He Asn Asn Phe He Asn Gly Cys Ser Val Ser Tyr Leu Met 770 775 780
Lys Lys Met He Pro Leu Ala Val Glu Lys Leu Leu Asp Phe Asp Asn 785 790 795 800
Thr Leu Lys Lys Asn Leu Leu Asn Tyr He Asp Glu Asn Lys Leu Tyr 805 810 815
Leu He Gly Ser Ala Glu Tyr Glu Lys Ser Lys Val Asn Lys Tyr Leu 820 825 830
Lys Thr He Met Pro Phe Asp Leu Ser He Tyr Thr Asn Asp Thr He 835 840 845
Leu He Glu Met Phe Asn Lys Tyr Asn Ser 850 855
(2) INFORMATION FOR SEQ ID NO : 23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1644 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear (11 ) MOLECULE TYPE DNA (genomic)
(ix) FEATURE
(A) NAME/KEY CDS
(B) LOCATION 1 1644
(xi ) SEQUENCE DESCRIPTION SEQ ID NO 23
ATG CCA GTT ACA ATA AAT AAT TTT AAT TAT AAT GAT CCT ATT GAT AAT 48 Met Pro Val Thr He Asn Asn Phe Asn Tyr Asn Asp Pro He Asp Asn 1 5 10 15
AAT AAT ATT ATT ATG ATG GAG CCT CCA TTT GCG AGA GGT ACG GGG AGA 96 Asn Asn He He Met Met Glu Pro Pro Phe Ala Arg Gly Thr Gly Arg 20 25 30
TAT TAT AAA GCT TTT AAA ATC ACA GAT CGT ATT TGG ATA ATA CCG GAA 144 Tyr Tyr Lys Ala Phe Lys He Thr Asp Arg He Trp He He Pro Glu 35 40 45
AGA TAT ACT TTT GGA TAT AAA CCT GAG GAT TTT AAT AAA AGT TCC GGT 192 Arg Tyr Thr Phe Gly Tyr Lys Pro Glu Asp Phe Asn Lys Ser Ser Gly 50 55 60
ATT TTT AAT AGA GAT GTT TGT GAA TAT TAT GAT CCA GAT TAC TTA AAT 240 He Phe Asn Arg Asp Val Cys Glu Tyr Tyr Asp Pro Asp Tyr Leu Asn 65 70 75 80
ACT AAT GAT AAA AAG AAT ATA TTT TTA CAA ACA ATG ATC AAG TTA TTT 288 Thr Asn Asp Lys Lys Asn He Phe Leu Gin Thr Met He Lys Leu Phe 85 90 95
AAT AGA ATC AAA TCA AAA CCA TTG GGT GAA AAG TTA TTA GAG ATG ATT 336 Asn Arg He Lys Ser Lys Pro Leu Gly Glu Lys Leu Leu Glu Met He 100 105 110
ATA AAT GGT ATA CCT TAT CTT GGA GAT AGA CGT GTT CCA CTC GAA GAG 384 He Asn Gly He Pro Tyr Leu Gly Asp Arg Arg Val Pro Leu Glu Glu 115 120 125
TTT AAC ACA AAC ATT GCT AGT GTA ACT GTT AAT AAA TTA ATC AGT AAT 432 Phe Asn Thr Asn He Ala Ser Val Thr Val Asn Lys Leu He Ser Asn 130 135 140
CCA GGA GAA GTG GAG CGA AAA AAA GGT ATT TTC GCA AAT TTA ATA ATA 480 Pro Gly Glu Val Glu Arg Lys Lys Gly He Phe Ala Asn Leu He He 145 150 155 160
TTT GGA CCT GGG CCA GTT TTA AAT GAA AAT GAG ACT ATA GAT ATA GGT 528 Phe Gly Pro Gly Pro Val Leu Asn Glu Asn Glu Thr He Asp He Gly 165 170 175
ATA CAA AAT CAT TTT GCA TCA AGG GAA GGC TTC GGG GGT ATA ATG CAA 576 He Gin Asn His Phe Ala Ser Arg Glu Gly Phe Gly Gly He Met Gin 180 185 190
ATG AAG TTT TGC CCA GAA TAT GTA AGC GTA TTT AAT AAT GTT CAA GAA 624 Met Lys Phe Cys Pro Glu Tyr Val Ser Val Phe Asn Asn Val Gin Glu 195 200 205
AAC AAA GGC GCA AGT ATA TTT AAT AGA CGT GGA TAT TTT TCA GAT CCA 672 Asn Lys Gly Ala Ser He Phe Asn Arg Arg Gly Tyr Phe Ser Asp Pro 210 215 220 GCC TTG ATA TTA ATG CAT GAA CTT ATA CAT GTT TTA CAT GGA TTA TAT 720
Ala Leu He Leu Met His Glu Leu He His Val Leu His Gly Leu Tyr 225 230 235 ' 240
GGC ATT AAA GTA GAT GAT TTA CCA ATT GTA CCA AAT GAA AAA AAA TTT 768
Gly He Lys Val Asp Asp Leu Pro He Val Pro Asn Glu Lys Lys Phe
245 250 255
TTT ATG CAA TCT ACA GAT GCT ATA CAG GCA GAA GAA CTA TAT ACA TTT 816
Phe Met Gin Ser Thr Asp Ala He Gin Ala Glu Glu Leu Tyr Thr Phe 260 265 270
GGA GGA CAA GAT CCC AGC ATC ATA ACT CCT TCT ACG GAT AAA AGT ATC 864
Gly Gly Gin Asp Pro Ser He He Thr Pro Ser Thr Asp Lys Ser He 275 280 285
TAT GAT AAA GTT TTG CAA AAT TTT AGA GGG ATA GTT GAT AGA CTT AAC 912
Tyr Asp Lys Val Leu Gin Asn Phe Arg Gly He Val Asp Arg Leu Asn 290 295 300
AAG GTT TTA GTT TGC ATA TCA GAT CCT AAC ATT AAT ATT AAT ATA TAT 960
Lys Val Leu Val Cys He Ser Asp Pro Asn He Asn He Asn He Tyr 305 310 315 320
AAA AAT AAA TTT AAA GAT AAA TAT AAA TTC GTT GAA GAT TCT GAG GGA 1008
Lys Asn Lys Phe Lys Asp Lys Tyr Lys Phe Val Glu Asp Ser Glu Gly
325 330 335
AAA TAT AGT ATA GAT GTA GAA AGT TTT GAT AAA TTA TAT AAA AGC TTA 1056
Lys Tyr Ser He Asp Val Glu Ser Phe Asp Lys Leu Tyr Lys Ser Leu 340 345 350
ATG TTT GGT TTT ACA GAA ACT AAT ATA GCA GAA AAT TAT AAA ATA AAA 1104
Met Phe Gly Phe Thr Glu Thr Asn He Ala Glu Asn Tyr Lys He Lys 355 360 365
ACT AGA GCT TCT TAT TTT AGT GAT TCC TTA CCA CCA GTA AAA ATA AAA 1152
Thr Arg Ala Ser Tyr Phe Ser Asp Ser Leu Pro Pro Val Lys He Lys 370 375 380
AAT TTA TTA GAT AAT GAA ATC TAT ACT ATA GAG GAA GGG TTT AAT ATA 1200
Asn Leu Leu Asp Asn Glu He Tyr Thr He Glu Glu Gly Phe Asn He 385 390 395 400
TCT GAT AAA GAT ATG GAA AAA GAA TAT AGA GGT CAG AAT AAA GCT ATA 1248
Ser Asp Lys Asp Met Glu Lys Glu Tyr Arg Gly Gin Asn Lys Ala He
405 410 415
AAT AAA CAA GCT TAT GAA GAA ATT AGC AAG GAG CAT TTG GCT GTA TAT 1296
Asn Lys Gin Ala Tyr Glu Glu He Ser Lys Glu His Leu Ala Val Tyr 420 425 430
AAG ATA CAA ATG TGT AAA AGT GTT AAA GCT CCA GGA ATA TGT ATT GAT 1344
Lys He Gin Met Cys Lys Ser Val Lys Ala Pro Gly He Cys He Asp 435 440 445
GTT GAT AAT GAA GAT TTG TTC TTT ATA GCT GAT AAA AAT AGT TTT TCA 1392
Val Asp Asn Glu Asp Leu Phe Phe He Ala Asp Lys Asn Ser Phe Ser 450 455 460
GAT GAT TTA TCT AAA AAC GAA AGA ATA GAA TAT AAT ACA CAG AGT AAT 1440
Asp Asp Leu Ser Lys Asn Glu Arg He Glu Tyr Asn Thr Gin Ser Asn 465 470 475 480
TAT ATA GAA AAT GAC TTC CCT ATA AAT GAA TTA ATT TTA GAT ACT GAT 1488
Tyr He Glu Asn Asp Phe Pro He Asn Glu Leu He Leu Asp Thr Asp
485 490 495 TTA ATA AGT AAA ATA GAA TTA CCA AGT GAA AAT ACA GAA TCA CTT ACT 1536 Leu He Ser Lys He Glu Leu Pro Ser Glu Asn Thr Glu Ser Leu Thr 500 505 510
GAT TTT AAT GTA GAT GTT CCA GTA TAT GAA AAA CAA CCC GCT ATA AAA 1584 Asp Phe Asn Val Asp Val Pro Val Tyr Glu Lys Gin Pro Ala He Lys 515 520 525
AAA ATT TTT ACA GAT GAA AAT ACC ATC TTT CAA TAT TTA TAC TCT CAG 1632 Lys He Phe Thr Asp Glu Asn Thr He Phe Gin Tyr Leu Tyr Ser Gin 530 535 540
ACA TTT CCT CTA 1644
Thr Phe Pro Leu
545
(2) INFORMATION FOR SEQ ID NO: 24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 548 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 24:
Met Pro Val Thr He Asn Asn Phe Asn Tyr Asn Asp Pro He Asp Asn 1 5 10 15
Asn Asn He He Met Met Glu Pro Pro Phe Ala Arg Gly Thr Gly Arg 20 25 30
Tyr Tyr Lys Ala Phe Lys He Thr Asp Arg He Trp He He Pro Glu 35 40 45
Arg Tyr Thr Phe Gly Tyr Lys Pro Glu Asp Phe Asn Lys Ser Ser Gly 50 55 60
He Phe Asn Arg Asp Val Cys Glu Tyr Tyr Asp Pro Asp Tyr Leu Asn 65 70 75 80
Thr Asn Asp Lys Lys Asn He Phe Leu Gin Thr Met He Lys Leu Phe 85 90 95
Asn Arg He Lys Ser Lys Pro Leu Gly Glu Lys Leu Leu Glu Met He 100 105 110
He Asn Gly He Pro Tyr Leu Gly Asp Arg Arg Val Pro Leu Glu Glu 115 120 125
Phe Asn Thr Asn He Ala Ser Val Thr Val Asπ Lys Leu He Ser Asn 130 135 140
Pro Gly Glu Val Glu Arg Lys Lys Gly He Phe Ala Asn Leu He He 145 150 155 160
Phe Gly Pro Gly Pro Val Leu Asn Glu Asn Glu Thr He Asp He Gly 165 170 175
He Gin Asn His Phe Ala Ser Arg Glu Gly Phe Gly Gly He Met Gin 180 185 190
Met Lys Phe Cys Pro Glu Tyr Val Ser Val Phe Asn Asn Val Gin Glu 195 200 205 Asn Lys Gly Ala Ser He Phe Asn Arg Arg Gly Tyr Phe Ser Asp Pro 210 215 220
Ala Leu He Leu Met His Glu Leu He His Val Leu His Gly Leu Tyr 225 230 235 240
Gly He Lys Val Asp Asp Leu Pro He Val Pro Asn Glu Lys Lys Phe 245 250 255
Phe Met Gin Ser Thr Asp Ala He Gin Ala Glu Glu Leu Tyr Thr Phe 260 265 270
Gly Gly Gin Asp Pro Ser He He Thr Pro Ser Thr Asp Lys Ser He 275 280 285
Tyr Asp Lys Val Leu Gin Asn Phe Arg Gly He Val Asp Arg Leu Asn 290 295 300
Lys Val Leu Val Cys He Ser Asp Pro Asn He Asn He Asn He Tyr 305 310 315 320
Lys Asn Lys Phe Lys Asp Lys Tyr Lys Phe Val Glu Asp Ser Glu Gly 325 330 335
Lys Tyr Ser He Asp Val Glu Ser Phe Asp Lys Leu Tyr Lys Ser Leu 340 345 350
Met Phe Gly Phe Thr Glu Thr Asn He Ala Glu Asn Tyr Lys He Lys 355 360 365
Thr Arg Ala Ser Tyr Phe Ser Asp Ser Leu Pro Pro Val Lys He Lys 370 375 380
Asn Leu Leu Asp Asn Glu He Tyr Thr He Glu Glu Gly Phe Asn He 385 390 395 400
Ser Asp Lys Asp Met Glu Lys Glu Tyr Arg Gly Gin Asn Lys Ala He 405 410 415
Asn Lys Gin Ala Tyr Glu Glu He Ser Lys Glu His Leu Ala Val Tyr 420 425 430
Lys He Gin Met Cys Lys Ser Val Lys Ala Pro Gly He Cys He Asp 435 440 445
Val Asp Asn Glu Asp Leu Phe Phe He Ala Asp Lys Asn Ser Phe Ser 450 455 460
Asp Asp Leu Ser Lys Asn Glu Arg He Glu Tyr Asn Thr Gin Ser Asn 465 470 475 480
Tyr He Glu Asn Asp Phe Pro He Asn Glu Leu He Leu Asp Thr Asp 485 490 495
Leu He Ser Lys He Glu Leu Pro Ser Glu Asn Thr Glu Ser Leu Thr 500 505 510
Asp Phe Asn Val Asp Val Pro Val Tyr Glu Lys Gin Pro Ala He Lys 515 520 525
Lys He Phe Thr Asp Glu Asn Thr He Phe Gin Tyr Leu Tyr Ser Gin 530 535 540
Thr Phe Pro Leu 545 (2) INFORMATION FOR SEQ ID NO : 25:
(l) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2616 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(n) MOLECULE TYPE. DNA (genomic)
(ix) FEATURE.
(A) NAME/KEY: CDS
(B) LOCATION: 1..2616
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25.
ATG CAG TTC GTG AAC AAG CAG TTC AAC TAT AAG GAC CCT GTA AAC GGT 48 Met Gin Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly
1 5 10 15
GTT GAC ATT GCC TAC ATC AAA ATT CCA AAC GCC GGC CAG ATG CAG CCG 96 Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30
GTG AAG GCT TTC AAG ATT CAT AAC AAA ATC TGG GTT ATT CCG GAA CGC 144 Val Lys Ala Phe Lys He His Asn Lys He Trp Val He Pro Glu Arg 35 40 45
GAT ACA TTT ACG AAC CCG GAA GAA GGA GAC TTG AAC CCG CCG CCG GAA 192 Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60
GCA AAG CAG GTG CCA GTT TCA TAC TAC GAT TCA ACC TAT CTG AGC ACA 240 Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80
GAC AAC GAG AAG GAT AAC TAC CTG AAG GGA GTG ACC AAA TTA TTC GAG 288 Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95
CGT ATT TAT TCC ACT GAC CTG GGC CGT ATG CTG CTG ACC TCA ATC GTC 336 Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 100 105 110
CGC GGA ATC CCA TTT TGG GGT GGC AGT ACC ATT GAC ACG GAG TTG AAG 384 Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lys 115 120 125
GTT ATT GAC ACT AAC TGC ATT AAC GTG ATC CAA CCA GAC GGT AGC TAC 432 Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tyr 130 135 140
AGA TCT GAA GAA CTT AAC CTC GTA ATC ATC GGG CCC TCC GCG GAC ATT 480 Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160
ATC CAG TTT GAG TGC AAG AGC TTT GGC CAC GAA GTG TTG AAC CTG ACG 528 He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175
CGT AAC GGT TAC GGC TCT ACT CAG TAC ATT CGT TTC AGC CCA GAC TTC 576 Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro Asp Phe 180 185 190 ACG TTC GGT TTC GAG GAG AGC CTG GAG GTT GAT ACC AAC CCG CTG TTG 624 Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205
GGT GCA GGC AAG TTC GCA ACT GAT CCA GCG GTG ACC CTG GCA CAC GAG 672 Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220
CTG ATC CAC GCC GGT CAT CGT CTG TAT GGC ATT GCG ATT AAC CCG AAC 720 Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240
CGC GTG TTC AAG GTT AAC ACC AAC GCC TAC TAC GAG ATG AGT GGT TTA 768 Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255
GAA GTA AGC TTC GAG GAA CTG CGC ACG TTC GGT GGC CAT GAT GCG AAG 816 Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270
TTT ATC GAC AGC TTG CAG GAG AAC GAG TTC CGT CTG TAC TAC TAC AAC 864 Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285
AAG TTT AAA GAT ATT GCA AGT ACA CTG AAC AAG GCT AAG TCC ATT GTG 912 Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300
GGT ACC ACT GCT TCA TTA CAG TAT ATG AAA AAT GTT TTT AAA GAG AAA 960 Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320
TAT CTC CTA TCT GAA GAT ACA TCT GGA AAA TTT TCG GTA GAT AAA TTA 1008 Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335
AAA TTT GAT AAG TTA TAC AAA ATG TTA ACA GAG ATT TAC ACA GAG GAT 1056 Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350
AAT TTT GTT AAG TTT TTT AAA GTA CTT AAC AGA AAA ACA TAT TTG AAT 1104 Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365
TTT GAT AAA GCC GTA TTT AAG ATA AAT ATA GTA CCT AAG GTA AAT TAC 1152 Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tyr 370 375 380
ACA ATA TAT GAT GGA TTT AAT TTA AGA AAT ACA AAT TTA GCA GCA AAC 1200 Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400
TTT AAT GGT CAA AAT ACA GAA ATT AAT AAT ATG AAT TTT ACT AAA CTA 1248 Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415
AAA AAT TTT ACT GGA TTG TTT GAA TTT TAT AAG TTG CTA TGT GTA AGA 1296 Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430
GGG ATA ATA ACT TCT AAA ACT AAA TCA TTA GAT AAA GGA TAC AAT AAG 1344 Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445
GCA TTA AAT GAT TTA TGT ATC AAA GTT AAT AAT TGG GAC TTG TTT TTT 1392 Ala Leu Asn Asp Leu Cys He Lys Val Asn Asn Trp Asp Leu Phe Phe 450 455 460 AGT CCT TCA GAA GAT AAT TTT ACT AAT GAT CTA AAT AAA GGA GAA GAA 1440 Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu 465 470 475 480
ATT ACA TCT GAT ACT AAT ATA GAA GCA GCA GAA GAA AAT ATT AGT TTA 1488 He Thr Ser Asp Thr Asn He Glu Ala Ala Glu Glu Asn He Ser Leu 485 490 495
GAT TTA ATA CAA CAA TAT TAT TTA ACC TTT AAT TTT GAT AAT GAA CCT 1536 Asp Leu He Gin Gin Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro 500 505 510
GAA AAT ATT TCA ATA GAA AAT CTT TCA AGT GAC ATT ATA GGC CAA TTA 1584 Glu Asn He Ser He Glu Asn Leu Ser Ser Asp He He Gly Gin Leu 515 520 525
GAA CTT ATG CCT AAT ATA GAA AGA TTT CCT AAT GGA AAA AAG TAT GAG 1632 Glu Leu Met Pro Asn He Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu 530 535 540
TTA GAT AAA TAT ACT ATG TTC CAT TAT CTT CGT GCT CAA GAA TTT GAA 1680 Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gin Glu Phe Glu 545 550 555 560
CAT GGT AAA TCT AGG ATT GCT TTA ACA AAT TCT GTT AAC GAA GCA TTA 1728 His Gly Lys Ser Arg He Ala Leu Thr Asn Ser Val Asn Glu Ala Leu 565 570 575
TTA AAT CCT AGT CGT GTT TAT ACA TTT TTT TCT TCA GAC TAT GTA AAG 1776 Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys 580 585 590
AAA GTT AAT AAA GCT ACG GAG GCA GCT ATG TTT TTA GGC TGG GTA GAA 1824 Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu 595 600 605
CAA TTA GTA TAT GAT TTT ACC GAT GAA ACT AGC GAA GTA AGT ACT ACG 1872 Gin Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr 610 615 620
GAT AAA ATT GCG GAT ATA ACT ATA ATT ATT CCA TAT ATA GGA CCT GCT 1920 Asp Lys He Ala Asp He Thr He He He Pro Tyr He Glv Pro Ala 625 630 635 ' 640
TTA AAT ATA GGT AAT ATG TTA TAT AAA GAT GAT TTT GTA GGT GCT TTA 1968 Leu Asn He Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu 645 650 655
ATA TTT TCA GGA GCT GTT ATT CTG TTA GAA TTT ATA CCA GAG ATT GCA 2016 He Phe Ser Gly Ala Val He Leu Leu Glu Phe He Pro Glu He Ala 660 665 670
ATA CCT GTA TTA GGT ACT TTT GCA CTT GTA TCA TAT ATT GCG AAT AAG 2064 He Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr He Ala Asn Lys 675 680 685
GTT CTA ACC GTT CAA ACA ATA GAT AAT GCT TTA AGT AAA AGA AAT GAA 2112 Val Leu Thr Val Gin Thr He Asp Asn Ala Leu Ser Lys Arg Asn Glu 690 695 700
AAA TGG GAT GAG GTC TAT AAA TAT ATA GTA ACA AAT TGG TTA GCA AAG 2160 Lys Trp Asp Glu Val Tyr Lys Tyr He Val Thr Asn Trp Leu Ala Lys 705 710 715 720
GTT AAT ACA CAG ATT GAT CTA ATA AGA AAA AAA ATG AAA GAA GCT TTA 2208 Val Asn Thr Gin He Asp Leu He Arg Lys Lys Met Lys Glu Ala Leu 725 730 735 GAA AAT CAA GCA GAA GCA ACA AAG GCT ATA ATA AAC TAT CAG TAT AAT 2256 Glu Asn Gin Ala Glu Ala Thr Lys Ala He He Asn Tyr Gin Tyr Asn 740 745 750
CAA TAT ACT GAG GAA GAG AAA AAT AAT ATT AAT TTT AAT ATT GAT GAT 2304 Gin Tyr Thr Glu Glu Glu Lys Asn Asn He Asn Phe Asn He Asp Asp 755 760 765
TTA AGT TCG AAA CTT AAT GAG TCT ATA AAT AAA GCT ATG ATT AAT ATA 2352 Leu Ser Ser Lys Leu Asn Glu Ser He Asn Lys Ala Met He Asn He 770 775 780
AAT AAA TTT TTG AAT CAA TGC TCT GTT TCA TAT TTA ATG AAT TCT ATG 2400 Asn Lys Phe Leu Asn Gin Cys Ser Val Ser Tyr Leu Met Asn Ser Met 785 790 795 800
ATC CCT TAT GGT GTT AAA CGG TTA GAA GAT TTT GAT GCT AGT CTT AAA 2448 He Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys 805 810 815
GAT GCA TTA TTA AAG TAT ATA TAT GAT AAT AGA GGA ACT TTA ATT GGT 2496 Asp Ala Leu Leu Lys Tyr He Tyr Asp Asn Arg Gly Thr Leu He Gly 820 825 830
CAA GTA GAT AGA TTA AAA GAT AAA GTT AAT AAT ACA CTT AGT ACA GAT 2544 Gin Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp 835 840 845
ATA CCT TTT CAG CTT TCC AAA TAC GTA GAT AAT CAA AGA TTA TTA TCT 2592 He Pro Phe Gin Leu Ser Lys Tyr Val Asp Asn Gin Arg Leu Leu Ser 850 855 860
ACA TTT ACT GAA TAT ATT AAG TAA 2616
Thr Phe Thr Glu Tyr He Lys * 865 870
(2) INFORMATION FOR SEQ ID NO : 26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 872 ammo acids
(B) TYPE: ammo acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:
Met Gin Phe Val Asn Lys Gin Phe Asn Tyr Lys Asp Pro Val Asn Gly 1 5 10 15
Val Asp He Ala Tyr He Lys He Pro Asn Ala Gly Gin Met Gin Pro 20 25 30
Val Lys Ala Phe Lys He His Asn Lys He Trp Val lie Pro Glu Arg 35 40 45
Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu 50 55 60
Ala Lys Gin Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr 65 70 75 80
Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu 85 90 95
Arg He Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser He Val 100 105 110 Arg Gly He Pro Phe Trp Gly Gly Ser Thr He Asp Thr Glu Leu Lys 115 120 125
Val He Asp Thr Asn Cys He Asn Val He Gin Pro Asp Gly Ser Tyr 130 135 140
Arg Ser Glu Glu Leu Asn Leu Val He He Gly Pro Ser Ala Asp He 145 150 155 160
He Gin Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175
Arg Asn Gly Tyr Gly Ser Thr Gin Tyr He Arg Phe Ser Pro Asp Phe 180 185 190
Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu 195 200 205
Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu 210 215 220
Leu He His Ala Gly His Arg Leu Tyr Gly He Ala He Asn Pro Asn 225 230 235 240
Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu 245 250 255
Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270
Phe He Asp Ser Leu Gin Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285
Lys Phe Lys Asp He Ala Ser Thr Leu Asn Lys Ala Lys Ser He Val 290 295 300
Gly Thr Thr Ala Ser Leu Gin Tyr Met Lys Asn Val Phe Lys Glu Lys 305 310 315 320
Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu 325 330 335
Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu He Tyr Thr Glu Asp 340 345 350
Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn 355 360 365
Phe Asp Lys Ala Val Phe Lys He Asn He Val Pro Lys Val Asn Tyr 370 375 380
Thr He Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn 385 390 395 400
Phe Asn Gly Gin Asn Thr Glu He Asn Asn Met Asn Phe Thr Lys Leu 405 410 415
Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg 420 425 430
Gly He He Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys 435 440 445
Ala Leu Asn Asp Leu Cys He Lys Val Asn Asn Trp Asp Leu Phe Phe 450 455 460 Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu 465 470 475 480
He Thr Ser Asp Thr Asn He Glu Ala Ala Glu Glu Asn He Ser Leu 485 490 495
Asp Leu He Gin Gin Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro 500 505 510
Glu Asn He Ser He Glu Asn Leu Ser Ser Asp He He Gly Gin Leu 515 520 525
Glu Leu Met Pro Asn He Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu 530 535 540
Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gin Glu Phe Glu 545 550 555 560
His Gly Lys Ser Arg He Ala Leu Thr Asn Ser Val Asn Glu Ala Leu 565 570 575
Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys 580 585 590
Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu 595 600 605
Gin Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr 610 615 620
Asp Lys He Ala Asp He Thr He He He Pro Tyr He Gly Pro Ala 625 630 635 640
Leu Asn He Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu 645 650 655
He Phe Ser Gly Ala Val He Leu Leu Glu Phe He Pro Glu He Ala 660 665 670
He Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr He Ala Asn Lys 675 680 685
Val Leu Thr Val Gin Thr He Asp Asn Ala Leu Ser Lys Arg Asn Glu 690 695 700
Lys Trp Asp Glu Val Tyr Lys Tyr He Val Thr Asn Trp Leu Ala Lys 705 710 715 720
Val Asn Thr Gin He Asp Leu He Arg Lys Lys Met Lys Glu Ala Leu 725 730 735
Glu Asn Gin Ala Glu Ala Thr Lys Ala He He Asn Tyr Gin Tyr Asn 740 745 750
Gin Tyr Thr Glu Glu Glu Lys Asn Asn He Asn Phe Asn He Asp Asp 755 760 765
Leu Ser Ser Lys Leu Asn Glu Ser He Asn Lys Ala Met He Asn He 770 775 780
Asn Lys Phe Leu Asn Gin Cys Ser Val Ser Tyr Leu Met Asn Ser Met 785 790 795 800
He Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys 805 810 815 Asp Ala Leu Leu Lys Tyr He Tyr Asp Asn Arg Gly Thr Leu He Gly 820 825 830
Gin Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp 835 840 845
He Pro Phe Gin Leu Ser Lys Tyr Val Asp Asn Gin Arg Leu Leu Ser 850 855 860
Thr Phe Thr Glu Tyr He Lys * 865 870
(2) INFORMATION FOR SEQ ID NO : 27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2574 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
( i i ) MOLECULE TYPE : DNA ( genomic )
( xi ) SEQUENCE DESCRIPTION : SEQ ID NO : 27 :
ATGCCGGTTA CCATCAACAA CTTCAACTAC AACGACCCGA TCGACAACAA CAACATCATC 60
ATGATGGAAC CGCCGTTCGC ACGTGGTACC GGTCGTTACT ACAAGGCTTT CAAGATCACC 120
GACCGTATCT GGATCATCCC GGAACGTTAC ACCTTCGGTT ACAAACCTGA GGACTTCAAC 180
AAGAGTAGCG GGATTTTCAA TCGTGACGTC TGCGAGTACT ATGATCCAGA TTATCTGAAT 240
ACCAACGATA AGAAGAACAT ATTCCTTCAG ACTATGATCA AGTTATTTAA TAGAATCAAA 300
TCAAAACCAT TGGGTGAAAA GTTATTAGAG ATGATTATAA ATGGTATACC TTATCTTGGA 360
GATAGACGTG TTCCACTCGA AGAGTTTAAC ACAAACATTG CTAGTGTAAC TGTTAATAAA 420
TTAATCAGTA ATCCAGGAGA AGTGGAGCGA AAAAAAGGTA TTTTCGCAAA TTTAATAATA 480
TTTGGACCTG GGCCAGTTTT AAATGAAAAT GAGACTATAG ATATAGGTAT ACAAAATCAT 540
TTTGCATCAA GGGAAGGCTT CGGGGGTATA ATGCAAATGA AGTTTTGCCC AGAATATGTA 600
AGCGTATTTA ATAATGTTCA AGAAAACAAA GGCGCAAGTA TATTTAATAG ACGTGGATAT 660
TTTTCAGATC CAGCCTTGAT ATTAATGCAT GAACTTATAC ATGTTTTACA TGGATTATAT 720
GGCATTAAAG TAGATGATTT ACCAATTGTA CCAAATGAAA AAAAATTTTT TATGCAATCT 780
ACAGATGCTA TACAGGCAGA AGAACTATAT ACATTTGGAG GACAAGATCC CAGCATCATA 840
ACTCCTTCTA CGGATAAAAG TATCTATGAT AAAGTTTTGC AAAATTTTAG AGGGATAGTT 900
GATAGACTTA ACAAGGTTTT AGTTTGCATA TCAGATCCTA ACATTAATAT TAATATATAT 960
AAAAATAAAT TTAAAGATAA ATATAAATTC GTTGAAGATT CTGAGGGAAA ATATAGTATA 1020
GATGTAGAAA GTTTTGATAA ATTATATAAA AGCTTAATGT TTGGTTTTAC AGAAACTAAT 1080
ATAGCAGAAA ATTATAAAAT AAAAACTAGA GCTTCTTATT TTAGTGATTC CTTACCACCA 1140
GTAAAAATAA AAAATTTATT AGATAATGAA ATCTATACTA TAGAGGAAGG GTTTAATATA 1200 TCTGATAAAG ATATGGAAAA AGAATATAGA GGTCAGAATA AAGCTATAAA TAAACAAGCT 1260
TATGAAGAAA TTAGCAAGGA GCATTTGGCT GTATATAAGA TACAAATGTG TAAAAGTGTT 1320
AAAGCTCCAG GAATATGTAT TGATGTTGAT AATGAAGATT TGTTCTTTAT AGCTGATAAA 1380
AATAGTTTTT CAGATGATTT ATCTAAAAAC GAAAGAATAG AATATAATAC ACAGAGTAAT 1440
TATATAGAAA ATGACTTCCC TATAAATGAA TTAATTTTAG ATACTGATTT AATAAGTAAA 1500
ATAGAATTAC CAAGTGAAAA TACAGAATCA CTTACTGATT TTAATGTAGA TGTTCCAGTA 1560
TATGAAAAAC AACCCGCTAT AAAAAAAATT TTTACAGATG AAAATACCAT CTTTCAATAT 1620
TTATACTCTC AGACATTTCC TCTAGATATA AGAGATATAA GTTTAACATC TTCATTTGAT 1680
GATGCATTAT TATTTTCTAA CAAAGTTTAT TCATTTTTTT CTATGGATTA TATTAAAACT 1740
GCTAATAAAG TGGTAGAAGC AGGATTATTT GCAGGTTGGG TGAAACAGAT AGTAAATGAT 1800
TTTGTAATCG AAGCTAATAA AAGCAATACT ATGGATAAAA TTGCAGATAT ATCTCTAATT 1860
GTTCCTTATA TAGGATTAGC TTTAAATGTA GGAAATGAAA CAGCTAAAGG AAATTTTGAA 1920
AATGCTTTTG AGATTGCAGG AGCCAGTATT CTACTAGAAT TTATACCAGA ACTTTTAATA 1980
CCTGTAGTTG GAGCCTTTTT ATTAGAATCA TATATTGACA ATAAAAATAA AATTATTAAA 2040
ACAATAGATA ATGCTTTAAC TAAAAGAAAT GAAAAATGGA GTGATATGTA CGGATTAATA 2100
GTAGCGCAAT GGCTCTCAAC AGTTAATACT CAATTTTATA CAATAAAAGA GGGAATGTAT 2160
AAGGCTTTAA ATTATCAAGC ACAAGCATTG GAAGAAATAA TAAAATACAG ATATAATATA 2220
TATTCTGAAA AAGAAAAGTC AAATATTAAC ATCGATTTTA ATGATATAAA TTCTAAACTT 2280
AATGAGGGTA TTAACCAAGC TATAGATAAT ATAAATAATT TTATAAATGG ATGTTCTGTA 2340
TCATATTTAA TGAAAAAAAT GATTCCATTA GCTGTAGAAA AATTACTAGA CTTTGATAAT 2400
ACTCTCAAAA AAAATTTGTT AAATTA ATA GATGAAAATA AATTATATTT GATTGGAAGT 2460
GCAGAATATG AAAAATCAAA AGTAAATAAA TACTTGAAAA CCATTATGCC GTTTGATCTT 2520
TCAATATATA CCAATGATAC AATACTAATA GAAATGTTTA ATAAATATAA TAGC 2574
(2) INFORMATION FOR SEQ ID NO: 28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2574 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS : double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:
ATGCCAGTTA CAATAAATAA TTTTAATTAT AATGATCCTA TTGATAATAA TAATATTATT 60
ATGATGGAGC CTCCATTTGC GAGAGGTACG GGGAGATATT ATAAAGCTTT TAAAATCACA 120
GATCGTATTT GGATAATACC GGAAAGATAT ACTTTTGGAT ATAAACCTGA GGATTTTAAT 180
AAAAGTTCCG GTATTTTTAA TAGAGATGTT TGTGAATATT ATGATCCAGA TTACTTAAAT 240 ACTAATGATA AAAAGAATAT ATTTTTACAA ACAATGATCA AGTTATTTAA TAGAATCAAA 300
TCAAAACCAT TGGGTGAAAA GTTATTAGAG ATGATTATAA ATGGTATACC TTATCTTGGA 360
GATAGACGTG TTCCACTCGA AGAGTTTAAC ACAAACATTG CTAGTGTAAC TGTTAATAAA 420
TTAATCAGTA ATCCAGGAGA AGTGGAGCGA AAAAAAGGTA TTTTCGCAAA TTTAATAATA 4 80
TTTGGACCTG GGCCAGTTTT AAATGAAAAT GAGACTATAG ATATAGGTAT ACAAAATCAT 540
TTTGCATCAA GGGAAGGCTT CGGGGGTATA ATGCAAATGA AGTTTTGCCC AGAATATGTA 600
AGCGTATTTA ATAATGTTCA AGAAAACAAA GGCGCAAGTA TATTTAATAG ACGTGGATAT 660
TTTTCAGATC CAGCCTTGAT ATTAATGCAT GAACTCATCC ACGTCCTCCA CGGTCTCTAC 720
GGTATCAAAG TAGACGACCT CCCGATCGTC CCGAACGAAA AAAAATTCTT CATGCAGAGC 780
ACCGACGCAA TCCAGGCAGA AGAACTCTAC ACCTTCGGTG GTCAGGACCC GAGCATCATC 840
ACCCCGAGCA CCGACAAAAG CATCTACGAC AAAGTCCTCC AGAACTTCCG TGGTATCGTC 900
GACCGTCTCA ACAAAGTCCT CGTCTGCATC AGCGACCCGA ACATCAACAT CAACATCTAC 960
AAAAACAAAT TCAAAGACAA ATACAAATTC GTCGAAGACA GCGAAGGTAA ATACAGCATC 1020
GACGTCGAGA GCTTCGACAA ACTCTACAAA AGCCTCATGT TCGGTTTCAC CGAAACCAAC 1080
ATCGCAGAAA ACTACAAAAT CAAAACCCGT GCAAGCTACT TCAGCGACAG CCTCCCGCCG 1140
GTCAAAATCA AAAACCTCCT CGACAACGAA ATCTACACCA TCGAAGAAGG TTTCAACATC 1200
AGCGACAAAG ACATGGAAAA AGAATACCGT GGTCAGAACA AAGCAATCAA CAAACAAGCT 1260
TACGAAGAAA TCAGCAAAGA ACACCTCGCA GTCTACAAAA TCCAGATGTG CAAAAGCGTC 1320
AAAGCACCGG GTATCTGCAT CGACGTTGAC AACGAAGACC TCTTCTTCAT CGCAGACAAA 1380
AACAGCTTCA GCGACGACCT CAGCAAAAAC GAACGTATCG AATACAACAC CCAGAGCAAC 1440
TACATCGAAA ACGACTTCCC GATCAACGAA CTCATCCTCG ACACCGACCT CATCAGCAAA 1500
ATCGAACTCC CGAGCGAAAA CACCGAAAGC CTCACCGACT TCAACGTTGA CGTCCCGGTC 1560
TACGAAAAAC AGCCGGCAAT CAAAAAAATC TTCACCGACG AAAACACCAT CTTCCAGTAC 1620
CTCTACAGCC AGACCTTCCC GCTAGATATA AGAGATATAA GTTTAACATC TTCATTTGAT 1680
GATGCATTAT TATTTTCTAA CAAAGTTTAT TCATTTTTTT CTATGGATTA TATTAAAACT 1740
GCTAATAAAG TGGTAGAAGC AGGATTATTT GCAGGTTGGG TGAAACAGAT AGTAAATGAT 1800
TTTGTAATCG AAGCTAATAA AAGCAATACT ATGGATAAAA TTGCAGATAT ATCTCTAATT 1860
GTTCCTTATA TAGGATTAGC TTTAAATGTA GGAAATGAAA CAGCTAAAGG AAATTTTGAA 1920
AATGCTTTTG AGATTGCAGG AGCCAGTATT CTACTAGAAT TTATACCAGA ACTTTTAATA 1980
CCTGTAGTTG GAGCCTTTTT ATTAGAATCA TATATTGACA ATAAAAATAA AATTATTAAA 2040
ACAATAGATA ATGCTTTAAC TAAAAGAAAT GAAAAATGGA GTGATATGTA CGGATTAATA 2100
GTAGCGCAAT GGCTCTCAAC AGTTAATACT CAATTTTATA CAATAAAAGA GGGAATGTAT 2160
AAGGCTTTAA ATTATCAAGC ACAAGCATTG GAAGAAATAA TAAAATACAG ATATAATATA 2220
TATTCTGAAA AAGAAAAGTC AAATATTAAC ATCGATTTTA ATGATATAAA TTCTAAACTT 2280 AATGAGGGTA TTAACCAAGC TATAGATAAT ATAAATAATT TTATAAATGG ATGTTCTGTA 2340
TCATATTTAA TGAAAAAAAT GATTCCATTA GCTGTAGAAA AATTACTAGA CTTTGATAAT 2400
ACTCTCAAAA AAAATTTGTT AAATTATATA GATGAAAATA AATTATATTT GATTGGAAGT 2460
GCAGAATATG AAAAATCAAA AGTAAATAAA TACTTGAAAA CCATTATGCC GTTTGATCTT 2520
TCAATATATA CCAATGATAC AATACTAATA GAAATGTTTA ATAAATATAA TAGC 2574

Claims

1 . A polypeptide comprising first and second domains, wherein said first domain is adapted to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and wherein said second domain is adapted (i) to translocate the polypeptide into a cell or (ii) to increase the solubility of the polypeptide compared to the solubility of the first domain on its own or (iii) both to translocate the polypeptide into a cell and to increase the solubility of the polypeptide compared to the solubility of the first domain on its own, said polypeptide being free of clostridial neurotoxin and free of clostridial neurotoxin precursor that can be converted into toxin by proteolytic action .
2. A polypeptide according to Claim 1 wherein said first domain comprises a clostridial toxin light chain.
3. A polypeptide according to Claim 1 wherein said first domain comprises a fragment or variant of a clostridial toxin light chain.
4. A polypeptide according to Claim 2 or 3 wherein the clostridial toxin is a botulinum toxin.
5. A polypeptide according to any preceding claim wherein the first domain exhibits endopeptidase activity specific for a substrate selected from one or more of SNAP-25, synaptobrevin/VAMP and syntaxin.
6. A polypeptide according to any preceding claim wherein said second domain comprises a clostridial toxin heavy chain HN portion.
7. A polypeptide according to any of Claims 1 -5 wherein said second domain comprises a fragment or variant of a clostridial toxin heavy chain HN portion.
8. A polypeptide according to Claim 6 or 7 wherein the clostridial toxin is a botulinum toxin.
9. A polypeptide according to any of Claims 1 -8 further comprising a third domain adapted for binding of the polypeptide to a cell, by binding of the third domain directly to a cell or by binding of the third domain to a ligand or to ligands that bind to a cell.
10. A polypeptide according to Claim 9 wherein said third domain is for binding the polypeptide to an immunoglobulin.
1 1 . A polypeptide according to Claim 10 wherein said third domain is a tandem repeat synthetic IgG binding domain derived from domain β of Staphylococcal protein A.
1 2. A polypeptide according to Claim 9 wherein said third domain comprises an amino acid sequence that binds to a cell surface receptor.
1 3. A polypeptide according to Claim 1 2 wherein said third domain is insulin-like growth factor-1 (IGF- 1 ) .
14. A polypeptide according to any preceding claim comprising a botulinum toxin light chain or a fragment or a variant of a botulinum toxin light chain and a portion designated HN of a botulinum toxin heavy chain.
1 5. A polypeptide according to Claim 14 wherein one or both of (a) the toxin light chain or fragment or variant of toxin light chain and (b) the portion of the toxin heavy chain are of botulinum toxin type A.
1 6. A polypeptide according to Claim 1 5 wherein the botulinum toxin type A light chain variant has at residue 2 a glutamate, at residue 26 a lysine and at residue 27 a tyrosine.
1 7. A polypeptide according to Claim 14 wherein one or both of (a) the toxin light chain or fragment or variant of toxin light chain and (b) the portion of the toxin heavy chain are of botulinum toxin type B.
1 8. A polypeptide according to any of Claims 1 - 1 3 comprising a botulinum toxin light chain or a fragment or a variant of a botulinum toxin light chain and at least 100 N-terminal amino acids of a botulinum toxin heavy chain.
1 9. A polypeptide according to Claim 1 8 comprising a botulinum toxin type B light chain, or a fragment or variant thereof, and 107 N-terminal amino acids of a botulinum toxin type B heavy chain.
20. A polypeptide according to Claim 1 5 or 1 6 comprising at least 423 of the N- terminal amino acids of botulinum toxin type A heavy chain.
21 . A polypeptide according to Claim 20 comprising a botulinum toxin type A light chain and 423 N-terminal amino acids of a botulinum toxin type A heavy chain.
22. A polypeptide according to Claim 20 comprising a botulinum toxin type A light chain variant wherein residue 2 is a glutamate, residue 26 is a lysine and residue 27 is a tyrosine, and 423 N-terminal amino acids of a botulinum toxin type A heavy chain.
23. A polypeptide according to Claim 1 7 comprising at least 41 7 of the N- terminal amino acids of botulinum toxin type B heavy chain.
24. A polypeptide according to Claim 23 comprising a botulinum toxin type B light chain and 41 7 N-terminal amino acids of a botulinum toxin type B heavy chain.
25. A polypeptide according to any of Claims 1 4-24 lacking a portion designated Hc of a botulinum toxin heavy chain.
26. A polypeptide comprising a botulinum toxin light chain and a fragment of a botulinum toxin heavy chain, said fragment being not capable of binding to cell surface receptors.
27. A polypeptide according to Claim 26 lacking an intact portion designated Hc of a botulinum toxin heavy chain.
28. A polypeptide according to any preceding claim comprising a variant of a clostridial toxin and further comprising a site for cleavage by a proteolytic enzyme, which cleavage site is not present in the native toxin.
29. A polypeptide according to Claim 28 comprising a variant of a clostridial toxin light chain and further comprising a site for cleavage by a proteolytic enzyme, which cleavage site is not present in the native toxin light chain.
30. A polypeptide according to Claim 28 or 29 comprising a variant of a clostridial toxin heavy chain HN portion and further comprising a site for cleavage by a proteolytic enzyme, which cleavage site is not present in the native toxin heavy chain HN portion.
31 . A polypeptide according to Claim 28, 29 or 30 obtainable by modification of a DNA encoding the polypeptide so as to introduce one or more nucleotides coding for the cleavage site.
32. A fusion protein comprising a fusion of (a) a polypeptide according to any of Claims 1 -31 with (b) a second polypeptide being a polypeptide or oligopeptide adapted for binding to an affinity matrix so as to enable purification of the fusion protein using said matrix.
33. A fusion protein according to Claim 32 wherein said second polypeptide is adapted to bind to a chromatography column, such as an affinity matrix of glutathione Sepharose.
34. A fusion protein according to Claim 32 or 33 wherein a specific protease cleavage site is incorporated between the first and second polypeptides, said protease site enabling proteolytic separation of first and second polypeptides.
35. A composition comprising a derivative of a clostridial toxin, said derivative retaining at least 10% of the endopeptidase activity of the botulinum toxin, said derivative further being non-toxic in vivo due to its inability to bind to cell surface receptors, and wherein the composition is free of any component, such as toxin or a further toxin derivative, that is toxic in vivo.
36. A composition according to Claim 35 or a polypeptide according to any of Claims 1 -31 or a fusion protein according to Claim 32, 33 or 34 for use as a positive control in a toxin assay.
37. A composition according to Claim 35 or a polypeptide according to any of Claims 1 -31 or a fusion protein according to Claim 32, 33 or 34 for use as a vaccine against clostridial toxin.
38. A composition according to Claim 35 or a polypeptide according to any of Claims 1 -31 or a fusion protein according to Claim 32, 33 or 34 for in vivo use.
39. A pharmaceutical composition comprising a composition according to Claim 35, a polypeptide according to any of claims 1 -31 or a fusion protein according to Claim 32, 33 or 34, in combination with a pharmaceutically acceptable carrier.
40. A nucleic acid encoding a polypeptide or a fusion protein according to any of Claims 1 -34.
41 . A nucleic acid encoding a polypeptide or a fusion protein according to Claim 40 and comprising nucleotides encoding residues 1 -448 of a botulinum toxin type A light chain.
42. A nucleic acid according to Claim 40 or 41 comprising nucleotides encoding residues 1 -423 of a botulinum toxin type A heavy chain HN domain.
43. A nucleic acid encoding a polypeptide or a fusion protein according to Claim 40 and comprising nucleotides encoding residues 1 -470 of a botulinum toxin type B light chain.
44. A nucleic acid encoding a polypeptide or a fusion protein according to Claim 40 or 43 comprising nucleotides encoding residues 1 -41 7 of a botulinum toxin type B heavy chain HN domain.
45. A nucleic acid according to any of Claims 40-44 comprising nucleotides encoding a restriction endonuclease cleavage site not present in native clostridial toxin sequence.
46. A nucleotide according to Claim 45 obtainable by modification of a nucleotide encoding a polypeptide or fusion protein according to any of claims 1 -34 so as to introduce said cleavage site.
47. A DNA according to any of claims 40-46.
48. A DNA selected from SEQ ID No:s 1 , 8, 1 0, 1 2, 14, 1 6, 1 8, 23 and 24.
49. A method of manufacture of a polypeptide according to any of Claims 1 -31 comprising expressing in a host cell a nucleic acid according to any of Claims 40- 48 and recovering the polypeptide.
50. A method of manufacture of a polypeptide according to any of Claims 1 -31 comprising expressing in a host cell a nucleic acid encoding a fusion protein according to Claim 32, 33 or 34, purifying the fusion protein by eluting the fusion protein through an affinity matrix adapted to retain the fusion protein and eluting through said matrix a ligand adapted to displace the fusion protein, and recovering the fusion protein.
51 . A method of manufacture according to Claims 49 or 50 in which the nucleic acid is DNA.
52. A cell expressing a polypeptide or fusion protein according to any of Claims
1 -34.
PCT/GB1997/002273 1996-08-23 1997-08-22 Recombinant toxin fragments WO1998007864A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
AU43895/97A AU723397B2 (en) 1996-08-23 1997-08-22 Recombinant toxin fragments
AT97942094T ATE294238T1 (en) 1996-08-23 1997-08-22 RECOMBINANT TOXIN FRAGMENTS
DK97942094T DK0939818T3 (en) 1996-08-23 1997-08-22 Recombinant textin fragments
EP97942094A EP0939818B1 (en) 1996-08-23 1997-08-22 Recombinant toxin fragments
JP1998510524A JP4273250B6 (en) 1996-08-23 1997-08-22 Recombinant toxin fragment
DE69733146T DE69733146T2 (en) 1996-08-23 1997-08-22 RECOMBINANT TOXIN FRAGMENTS
CA2264191A CA2264191C (en) 1996-08-23 1997-08-22 Recombinant toxin fragments
US09/255,829 US6461617B1 (en) 1996-08-23 1999-02-23 Recombinant toxin fragments
US10/241,596 US7192596B2 (en) 1996-08-23 2002-09-12 Recombinant toxin fragments
US11/077,550 US7674470B2 (en) 1996-08-23 2005-03-11 Recombinant toxin fragments
US11/644,010 US20070248626A1 (en) 1996-08-23 2006-12-22 Recombinant toxin fragments
US11/717,713 US7897158B2 (en) 1996-08-23 2007-03-14 Recombinant toxin fragments
US12/174,896 US8454976B2 (en) 1996-08-23 2008-07-17 Recombinant toxin fragments
US12/360,470 US8017134B2 (en) 1996-08-23 2009-01-27 Recombinant toxin fragments
US12/369,341 US8012491B2 (en) 1996-08-23 2009-02-11 Recombinant toxin fragments
US12/399,542 US8012479B2 (en) 1996-08-23 2009-03-06 Recombinant toxin fragments

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9617671.4 1996-08-23
GBGB9617671.4A GB9617671D0 (en) 1996-08-23 1996-08-23 Recombinant toxin fragments
GB9625996.5 1996-12-13
GBGB9625996.5A GB9625996D0 (en) 1996-08-23 1996-12-13 Recombinant toxin fragments
US78289396A 1996-12-27 1996-12-27

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US78289396A Continuation-In-Part 1996-08-23 1996-12-27
US78289396A Continuation 1996-08-23 1996-12-27

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/255,829 Continuation US6461617B1 (en) 1996-08-23 1999-02-23 Recombinant toxin fragments
US09242689 A-371-Of-International 1999-02-23

Publications (1)

Publication Number Publication Date
WO1998007864A1 true WO1998007864A1 (en) 1998-02-26

Family

ID=26309911

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/002273 WO1998007864A1 (en) 1996-08-23 1997-08-22 Recombinant toxin fragments

Country Status (10)

Country Link
US (7) US6461617B1 (en)
EP (1) EP0939818B1 (en)
AT (1) ATE294238T1 (en)
AU (1) AU723397B2 (en)
CA (1) CA2264191C (en)
DE (1) DE69733146T2 (en)
DK (1) DK0939818T3 (en)
GB (2) GB9617671D0 (en)
WO (1) WO1998007864A1 (en)
ZA (1) ZA977541B (en)

Cited By (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999017806A1 (en) * 1997-10-08 1999-04-15 The Speywood Laboratory Limited Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics
WO2000005252A1 (en) * 1998-07-22 2000-02-03 Agricultural Research Council Vaccine comprising a non-toxic immunogenic derivative of clostridium botulinum type d neurotoxin
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
WO2000061192A2 (en) * 1999-04-08 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment of pancreatitis
WO2001014570A1 (en) * 1999-08-25 2001-03-01 Allergan Sales, Inc. Activatable recombinant neurotoxins
WO2001021213A2 (en) * 1999-09-23 2001-03-29 Microbiological Research Authority Inhibition of secretion from non-neuronal cells
WO2001053336A1 (en) * 2000-01-19 2001-07-26 Allergan Sales, Inc. Clostridial toxin derivatives and methods for treating pain
WO2002036758A2 (en) * 2000-11-06 2002-05-10 United States Army Medical Research And Material Command Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
WO2002044199A2 (en) * 2000-11-29 2002-06-06 Allergan, Inc. Neurotoxins with enhanced target specificity
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6500436B2 (en) 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
WO2002040506A3 (en) * 2000-11-17 2003-03-27 Allergan Inc Modified clostridial neurotoxins with altered biological persistence
US6632440B1 (en) 1998-08-25 2003-10-14 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
US6641820B1 (en) 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6688311B2 (en) 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
WO2004024909A2 (en) * 2002-09-12 2004-03-25 Health Protection Agency Recombinant colstridium neurotoxin fragments
WO2004078202A1 (en) 2003-03-03 2004-09-16 Allergan, Inc. Clostridial neurotoxins for treating uterine disorders
US6821520B2 (en) 2000-02-15 2004-11-23 Allergan, Inc. Clostridial toxin therapy for Hashimoto's thyroiditis
US6831059B2 (en) 2000-10-20 2004-12-14 Allergan, Inc. Compositions and methods for treating gonadotrophin related illnesses
WO2005023309A2 (en) 2003-09-11 2005-03-17 Health Protection Agency Design of re-targeted toxin conjugates
WO2006010360A2 (en) * 2004-07-22 2006-02-02 Biotecon Therapeutics Gmbh Carrier for medicaments for obtaining oral bioavailability
US7037680B2 (en) * 1993-09-21 2006-05-02 The United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
WO2006047214A2 (en) 2004-10-21 2006-05-04 Igf Oncology, Llc Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer
WO2006059113A2 (en) 2004-12-01 2006-06-08 Health Protection Agency Fusion proteins comprising a non-cytotoxic protease, a targeting moiety, a protease cleavage site and a translocation domain
WO2006060044A1 (en) * 2004-08-02 2006-06-08 Allergan, Inc. Toxin compounds with enhanced membrane translocation characteristics
US7140371B2 (en) 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US7179474B2 (en) 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
US7208466B1 (en) 1999-03-31 2007-04-24 The Health Protection Agency Use of a lectin or conjugates for modulation of c-fibre activity
US7227010B2 (en) 1993-09-21 2007-06-05 United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
WO2007138339A2 (en) * 2006-06-01 2007-12-06 Syntaxin Limited Treatment of pain by use of a single chain polypeptide fusion protein
WO2007138336A2 (en) * 2006-06-01 2007-12-06 Syntaxin Limited Treatment of pain by single chain, polypeptide fusion protein
WO2008008805A2 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
WO2008008082A2 (en) * 2005-09-19 2008-01-17 Allergan, Inc. Clostridial toxin activatable clostridial toxins
AU2005227383B2 (en) * 1999-09-23 2008-08-21 Ipsen Bioinnovation Limited Inhibition of secretion from non-neuronal cells
US7419675B2 (en) 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
US7429386B2 (en) 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
EP1990059A2 (en) 2004-08-27 2008-11-12 Allergan, Inc. Methods for treating cancer
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7658933B2 (en) 2004-12-01 2010-02-09 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US7659092B2 (en) 2004-12-01 2010-02-09 Syntaxin, Ltd. Fusion proteins
US7674470B2 (en) 1996-08-23 2010-03-09 Health Protection Agency Recombinant toxin fragments
US7727538B2 (en) 1998-08-25 2010-06-01 Syntaxin Ltd. Methods and compounds for the treatment of mucus hypersecretion
US7740868B2 (en) 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
EP2204183A1 (en) 2002-02-08 2010-07-07 Allergan, Inc. Treatment of neuroblastoma
US7785606B2 (en) * 2004-11-22 2010-08-31 New York University Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
US7888469B2 (en) 2000-11-17 2011-02-15 Allergan, Inc. Post-translation modification and clostridial neurotoxins
CN102083451A (en) * 2008-06-12 2011-06-01 赛恩泰新公司 Suppression of cancers
US7993656B2 (en) 2006-07-11 2011-08-09 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
US8012491B2 (en) 1996-08-23 2011-09-06 Syntaxin, Ltd. Recombinant toxin fragments
US8128940B2 (en) 2005-03-15 2012-03-06 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
AU2005311086B2 (en) * 2004-12-01 2012-03-29 Allergan, Inc. Fusion proteins
WO2012156743A1 (en) 2011-05-16 2012-11-22 Syntaxin Limited Therapeutic fusion proteins
US8372405B2 (en) 2005-10-07 2013-02-12 Health Protection Agency Proteins with improved solubility and methods for producing and using same
US8399400B2 (en) 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8518417B1 (en) 2006-07-11 2013-08-27 Allergan, Inc. Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
EP2664343A2 (en) 2008-11-17 2013-11-20 Syntaxin Limited Suppression of cancer
WO2013180799A1 (en) 2012-05-30 2013-12-05 President And Fellows Of Harvard College Engineered botulinum neurotoxin
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
WO2014033441A1 (en) 2012-08-27 2014-03-06 Syntaxin Limited Fusion proteins and methods for treating, preventing or ameliorating pain
AU2012203055B2 (en) * 2004-12-01 2014-03-20 Allergan Inc. Fusion proteins
WO2014053651A1 (en) 2012-10-04 2014-04-10 Dublin City University Biotherapy for pain
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8790897B2 (en) 1998-08-25 2014-07-29 Syntaxin Ltd. Treatment of mucus hypersecretion
US8852603B2 (en) 1999-09-23 2014-10-07 Syntaxin Limited Inhibition of secretion from non-neuronal cells
US8980284B2 (en) 2010-01-25 2015-03-17 New York University Recombinant derivatives of botulinum neurotoxins engineered for trafficking studies and neuronal delivery
CN104870468A (en) * 2012-11-21 2015-08-26 突触融合蛋白有限公司 Methods for the manufacture of proteolytically processed polypeptides
US9170252B2 (en) 2012-10-23 2015-10-27 Ipsen Bioinnovation Limited Assay for assessment of endosomal transport
US9315549B2 (en) 2013-01-28 2016-04-19 New York University Treatment methods using atoxic neurotoxin derivatives
WO2016154534A1 (en) 2015-03-26 2016-09-29 President And Fellows Of Harvard College Engineered botulinum neurotoxin
WO2018002348A1 (en) 2016-07-01 2018-01-04 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
WO2018039506A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Engineered botulinum neurotoxin
WO2018050699A1 (en) 2016-09-16 2018-03-22 Ipsen Biopharm Limited Method for producing di-chain clostridial neurotoxins
WO2018060351A1 (en) 2016-09-29 2018-04-05 Ipsen Biopharm Limited Hybrid neurotoxins
WO2018075783A2 (en) 2016-10-20 2018-04-26 President And Fellows Of Harvard College In vitro and cell based assays for measuring the activity of botulinum neurotoxins
WO2018073288A1 (en) 2016-10-18 2018-04-26 Ipsen Biopharm Limited Cellular vamp cleavage assay
EP3470054A1 (en) 2017-10-11 2019-04-17 Hugel Inc. Microstructure formulation techniques for botulinum toxin
WO2019145577A1 (en) 2018-01-29 2019-08-01 Ipsen Biopharm Limited Non-neuronal snare-cleaving botulinum neurotoxins
WO2019162696A1 (en) 2018-02-26 2019-08-29 Ipsen Biopharm Limited Use of ultrasound to guide injection of non-cytotoxic protease
US10457927B2 (en) 2013-12-23 2019-10-29 Dublin City University Multiprotease therapeutics for chronic pain
WO2019224184A1 (en) 2018-05-21 2019-11-28 Ipsen Biopharm Limited Suppression of bone cancer-induced allodynia
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
EP3590956A1 (en) 2008-06-12 2020-01-08 Ipsen Bioinnovation Limited Suppression of neuroendocrine diseases
WO2020065336A1 (en) 2018-09-28 2020-04-02 Ipsen Biopharm Limited Clostridial neurotoxins comprising an exogenous activation loop
EP3650462A1 (en) 2015-10-02 2020-05-13 Ipsen Biopharm Limited Method for purifying clostridial neurotoxin
EP3660509A1 (en) 2018-11-29 2020-06-03 Abbio Inc. A cell-based method for determining an activity of botulinum toxin
WO2020115490A1 (en) 2018-12-05 2020-06-11 Ipsen Biopharm Limited Treatment of symptoms of traumatic brain injury
WO2020148542A1 (en) 2019-01-16 2020-07-23 Ipsen Biopharm Limited Sortase-labelled clostridium neurotoxins
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
EP3777837A1 (en) 2016-08-26 2021-02-17 Hugel Inc. Liquid formulation containing botulinum toxin and stabilizing agent, and preparation method therefor
WO2021064369A1 (en) 2019-09-30 2021-04-08 Ipsen Biopharm Limited Use of chlostridial neurotoxin variant for the treatment of neurological disorders
EP3822286A1 (en) 2015-01-09 2021-05-19 Ipsen Bioinnovation Limited Cationic neurotoxins
US11034947B2 (en) 2013-07-09 2021-06-15 Ipsen Bioinnovation Limited Cationic neurotoxins
WO2022153057A1 (en) 2021-01-15 2022-07-21 Ipsen Biopharm Limited Treatment of brain damage
WO2022200809A1 (en) 2021-03-26 2022-09-29 Ipsen Biopharm Limited Clostridial neurotoxins comprising an exogenous activation loop
WO2022208039A1 (en) 2021-03-30 2022-10-06 Ipsen Biopharm Limited Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders
WO2022208091A1 (en) 2021-03-30 2022-10-06 Ipsen Biopharm Limited Treatment of pain & inflammatory disorders
WO2023089338A1 (en) 2021-11-22 2023-05-25 Ipsen Biopharm Limited Treatment of visceral pain
WO2023105289A1 (en) 2021-12-06 2023-06-15 Dublin City University Methods and compositions for the treatment of pain
US11897921B2 (en) 2014-12-09 2024-02-13 New York University Propeptide fusion comprising a mutated clostridium botulinum neurotoxin and a VHH domain
WO2024069175A1 (en) 2022-09-28 2024-04-04 Ipsen Biopharm Limited Clostridial neurotoxins comprising an activating endosomal protease cleavage site
WO2024069176A1 (en) 2022-09-28 2024-04-04 Ipsen Biopharm Limited Clostridial neurotoxins comprising an activating exogenous protease cleavage site

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
US20060141572A1 (en) * 1993-09-21 2006-06-29 Smith Leonard A Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US20080249019A1 (en) * 1998-08-25 2008-10-09 Syntaxin, Ltd. Treatment of mucus hypersecretion
US7563874B2 (en) * 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
GB9824282D0 (en) * 1998-11-05 1998-12-30 Microbiological Research Agenc Delivery of superoxide dismutase to neuronal cells
US20080032931A1 (en) * 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
US20090018081A1 (en) * 1999-08-25 2009-01-15 Allergan, Inc. Activatable clostridial toxins
CA2392202C (en) * 1999-12-02 2012-02-28 Microbiological Research Authority Constructs for delivery of therapeutic agents to neuronal cells
US7368532B2 (en) * 1999-12-02 2008-05-06 Syntaxin Limited Constructs for delivery of therapeutic agents to neuronal cells
US20030219462A1 (en) * 2000-07-21 2003-11-27 Allergan Sales, Inc Clostridial neurotoxin compositions and modified clostridial neurotoxins
US7115399B2 (en) * 2001-07-31 2006-10-03 Allergan, Inc. Pinna reflex assay
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US20040115727A1 (en) * 2002-12-11 2004-06-17 Allergan, Inc., A Corporation Evolved clostridial toxins with altered protease specificity
US7341843B2 (en) * 2003-04-11 2008-03-11 Allergan, Inc. Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
US9103820B2 (en) * 2004-06-28 2015-08-11 Japan Science And Technology Agency Method for screening toxin neutralizing peptide, STX2 inhibiting peptide and verotoxin neutralizing agent
JP5089388B2 (en) 2004-09-01 2012-12-05 アラーガン、インコーポレイテッド Degradable clostridial toxin
US7700738B2 (en) * 2005-01-27 2010-04-20 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US8021859B2 (en) * 2005-03-15 2011-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
CA2619502C (en) * 2005-08-18 2012-11-20 Zimmer Gmbh Ultra high molecular weight polyethylene articles and methods of forming ultra high molecular weight polyethylene articles
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US7855268B2 (en) * 2006-06-01 2010-12-21 Allergan, Inc. Tolerogizing compositions comprising botulinum toxin type B peptides
US8598321B2 (en) 2007-03-22 2013-12-03 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US8664290B2 (en) * 2007-04-10 2014-03-04 Zimmer, Inc. Antioxidant stabilized crosslinked ultra-high molecular weight polyethylene for medical device applications
CN101918021A (en) * 2007-10-23 2010-12-15 阿勒根公司 Methods of treating urogenital-neurological disorders using modified clostridial toxins
EP2214696A1 (en) * 2007-10-23 2010-08-11 Allergan, Inc. Methods of treating chronic neurogenic inflammation using modified clostridial toxins
CA2712559C (en) * 2008-01-30 2015-03-31 Zimmer, Inc. Orthopedic component of low stiffness
KR101609894B1 (en) 2008-03-14 2016-04-08 알러간, 인코포레이티드 Immuno-Based Botulinum Toxin Serotype A Activity Assays
US9000131B2 (en) * 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
EP2364168A1 (en) 2008-12-04 2011-09-14 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
RU2535003C2 (en) 2008-12-10 2014-12-10 Аллерган, Инк. Pharmaceutical compositions of clostridia toxin
KR101923847B1 (en) 2009-03-13 2018-11-29 알러간, 인코포레이티드 Immuno-Based Retargeted Endopeptidase Activity Assays
MX2012006985A (en) 2009-12-16 2012-09-12 Allergan Inc Modified clostridial toxins comprising an integrated protease cleavage site-binding domain.
RU2569185C2 (en) 2010-01-25 2015-11-20 Аллерган, Инк. Method for intracellular conversion of single-stranded proteins into their double-stranded form
MX2012013381A (en) 2010-05-20 2013-02-21 Allergan Inc Degradable clostridial toxins.
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
US20130330369A1 (en) 2010-10-08 2013-12-12 Allergan, Inc. Reduction Of Antibody Response Against Botulinum Neurotoxin And Variants Thereof
JP2014510045A (en) 2011-02-08 2014-04-24 ハロザイム インコーポレイテッド Hyaluronan degrading enzyme composition and lipid preparation and its use for the treatment of benign prostatic hypertrophy
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
EP3626259A1 (en) 2016-09-13 2020-03-25 Allergan, Inc. Stabilized non-protein clostridial toxin compositions
US11439685B2 (en) 2020-05-22 2022-09-13 Trustees Of Boston University Formulations for treating a fibrotic disease
WO2021247475A1 (en) * 2020-06-02 2021-12-09 Trustees Of Boston University Production of soluble relaxin and relaxin analogs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012802A1 (en) * 1989-10-31 1996-05-02 Ophidian Pharmaceuticals, Inc. Vaccine and antitoxin for treatment and prevention of c. difficile disease

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4594336A (en) * 1982-09-28 1986-06-10 Institut Pasteur Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its application
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
WO1991009871A1 (en) 1989-12-22 1991-07-11 Seragen Incorporated Hybrid molecules having translocation region and cell-binding region
WO1992015327A1 (en) 1991-03-08 1992-09-17 Protein Design Labs, Inc. Recombinant double chain immunotoxins
WO1993004191A1 (en) 1991-08-15 1993-03-04 Neorx Corporation Noncytolytic toxin conjugates
WO1993015766A1 (en) 1992-02-10 1993-08-19 Seragen, Inc. Desensitization to specific allergens
GB9305735D0 (en) 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
GB9305919D0 (en) 1993-03-22 1993-05-12 Health Lab Service Board Botulinum toxin polypeptides and their use as vaccines
US7214787B1 (en) 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
US5962637A (en) 1994-06-03 1999-10-05 Microbiological Research Authority Toxin assay
US6967088B1 (en) 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
DE69731357T2 (en) 1996-03-23 2006-02-02 The Research Foundation For Microbial Diseases Of Osaka University, Suita FUNCTIONAL ANTIGEN FRAGMENT OF TETANUS TOXIN AND TETANUS VACCINE
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US8012491B2 (en) * 1996-08-23 2011-09-06 Syntaxin, Ltd. Recombinant toxin fragments
WO1998008540A1 (en) 1996-08-28 1998-03-05 Ophidian Pharmaceuticals, Inc. Multivalent vaccine for clostridium botulinum neurotoxin
US6444209B1 (en) 1996-10-28 2002-09-03 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US6822076B2 (en) 1998-05-13 2004-11-23 Biotecon Therapeutics Gmbh Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof
US8790897B2 (en) 1998-08-25 2014-07-29 Syntaxin Ltd. Treatment of mucus hypersecretion
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US20080249019A1 (en) 1998-08-25 2008-10-09 Syntaxin, Ltd. Treatment of mucus hypersecretion
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
US7563874B2 (en) * 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
GB9824282D0 (en) 1998-11-05 1998-12-30 Microbiological Research Agenc Delivery of superoxide dismutase to neuronal cells
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
GB9914861D0 (en) 1999-06-25 1999-08-25 Imperial College Tetanus toxin polypeptides
US6535580B1 (en) 1999-07-27 2003-03-18 Agere Systems Inc. Signature device for home phoneline network devices
US7132259B1 (en) 1999-08-25 2006-11-07 Allergan, Inc. Activatable recombinant neurotoxins
US20080032931A1 (en) * 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
US7740868B2 (en) * 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
GB9921592D0 (en) 1999-09-13 1999-11-17 Microbiological Res Authority Preparation of highly pure toxin fragments
US20080038274A1 (en) 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
US20030180289A1 (en) 1999-09-23 2003-09-25 Foster Keith Alan Inhibition of secretion from non-neuronal cells
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US7368532B2 (en) 1999-12-02 2008-05-06 Syntaxin Limited Constructs for delivery of therapeutic agents to neuronal cells
CA2392202C (en) * 1999-12-02 2012-02-28 Microbiological Research Authority Constructs for delivery of therapeutic agents to neuronal cells
US7138127B1 (en) * 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7273722B2 (en) 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US20020086036A1 (en) * 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US6787517B1 (en) 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
GB0112687D0 (en) 2001-05-24 2001-07-18 Microbiological Res Authority Pharmaceutical use of secreted bacterial effector proteins
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
AU2003237346A1 (en) 2002-05-31 2003-12-19 Thomas Jefferson University Compositions and methods for transepithelial molecular transport
GB0216865D0 (en) 2002-07-19 2002-08-28 Microbiological Res Authority Targetted agents for nerve regeneration
WO2004052277A2 (en) * 2002-12-05 2004-06-24 Wisconsin Alumni Research Foundation Anthrax antitoxins
US7341843B2 (en) * 2003-04-11 2008-03-11 Allergan, Inc. Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
GB0311961D0 (en) 2003-05-23 2003-06-25 Health Prot Agency Mass-based toxin assay and substrates therefor
GB0321344D0 (en) 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
JP5089388B2 (en) * 2004-09-01 2012-12-05 アラーガン、インコーポレイテッド Degradable clostridial toxin
US7785606B2 (en) 2004-11-22 2010-08-31 New York University Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
CA2595115C (en) * 2004-12-01 2014-01-21 Health Protection Agency Fusion proteins for treating, preventing or ameliorating pain
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
GB0426397D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
AU2005311098B2 (en) * 2004-12-01 2011-08-11 Allergan, Inc. Non-cytotoxic protein conjugates
US7659092B2 (en) 2004-12-01 2010-02-09 Syntaxin, Ltd. Fusion proteins
WO2006071877A2 (en) * 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
AU2006225116B2 (en) * 2005-03-15 2012-04-19 Allergan, Inc. Modified Clostridial toxins with altered targeting capabilities for Clostridial toxin target cells
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
WO2007047342A1 (en) * 2005-10-12 2007-04-26 Allergan, Inc. Assays of molecular or subcellular interactivity using depolarization after resonance energy transfer (daret)
EP1834962A1 (en) * 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGylated mtutated Clostridium botulinum toxin
GB0610867D0 (en) * 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
GB0610868D0 (en) * 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
WO2008008805A2 (en) * 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
JP2009543557A (en) * 2006-07-11 2009-12-10 アラーガン、インコーポレイテッド Modified clostridial toxin with enhanced translocation ability and altered targeting activity against clostridial toxin target cells
GB0815264D0 (en) * 2008-08-21 2008-09-24 Syntaxin Ltd Non-cytotoxic proteins
WO2010033913A1 (en) * 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
GB0903006D0 (en) * 2009-02-23 2009-04-08 Syntaxin Ltd Modified non-cytotoxic proteases
KR20120107926A (en) * 2009-08-14 2012-10-04 알러간, 인코포레이티드 Methods of treating cancer using opioid retargeted endpeptidases
WO2011091419A2 (en) * 2010-01-25 2011-07-28 New York Universiy Recombinant derivatives of botulinum neurotoxins engineered for trafficking studies and neuronal delivery

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012802A1 (en) * 1989-10-31 1996-05-02 Ophidian Pharmaceuticals, Inc. Vaccine and antitoxin for treatment and prevention of c. difficile disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BINZ T ET AL: "THE COMPLETE SEQUENCE OF BOTULINUM NEUROTOXIN TYPE A AND COMPARISON WITH OTHER CLOSTRIDIAL NEUROTOXINS", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 16, 5 June 1990 (1990-06-05), pages 9153 - 9158, XP002009348 *
KURAZONO H ET AL: "Minimal essential *domains* specifying toxicity of the *light* *chains* of tetanus toxin and botulinum neurotoxin type A.", J BIOL CHEM, JUL 25 1992, 267 (21) P14721-9, UNITED STATES, XP002047910 *
LI ET AL: "A SINGLE MUTATION IN THE RECOMBINANT LIGHT CHAIN OF TETANUS TOXIN ABOLISHES ITS PROTEOLYTIC ACTIVITY AND REMOVES THE TOXICITY SEEN AFTER RECONSTITUTION WITH NATIVE HEAVY CHAIN", BIOCHEMISTRY, vol. 33, no. 22, 1994, pages 7014 - 7020, XP002015938 *

Cited By (255)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037680B2 (en) * 1993-09-21 2006-05-02 The United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US7227010B2 (en) 1993-09-21 2007-06-05 United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US7897158B2 (en) 1996-08-23 2011-03-01 Syntaxin, Ltd Recombinant toxin fragments
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US8454976B2 (en) 1996-08-23 2013-06-04 Syntaxin Limited Recombinant toxin fragments
US7674470B2 (en) 1996-08-23 2010-03-09 Health Protection Agency Recombinant toxin fragments
US8017134B2 (en) 1996-08-23 2011-09-13 Syntaxin Limited Recombinant toxin fragments
US8012491B2 (en) 1996-08-23 2011-09-06 Syntaxin, Ltd. Recombinant toxin fragments
US8012479B2 (en) 1996-08-23 2011-09-06 Health Protection Agency Recombinant toxin fragments
WO1999017806A1 (en) * 1997-10-08 1999-04-15 The Speywood Laboratory Limited Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics
US7452543B2 (en) 1997-10-08 2008-11-18 Syntaxin Ltd. Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics
US7052702B1 (en) 1997-10-08 2006-05-30 Health Protection Agency Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics
WO2000005252A1 (en) * 1998-07-22 2000-02-03 Agricultural Research Council Vaccine comprising a non-toxic immunogenic derivative of clostridium botulinum type d neurotoxin
US7727538B2 (en) 1998-08-25 2010-06-01 Syntaxin Ltd. Methods and compounds for the treatment of mucus hypersecretion
US8790897B2 (en) 1998-08-25 2014-07-29 Syntaxin Ltd. Treatment of mucus hypersecretion
US6632440B1 (en) 1998-08-25 2003-10-14 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
US7208466B1 (en) 1999-03-31 2007-04-24 The Health Protection Agency Use of a lectin or conjugates for modulation of c-fibre activity
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
WO2000061192A3 (en) * 1999-04-08 2001-03-08 Allergan Sales Inc Methods and compositions for the treatment of pancreatitis
US7276473B2 (en) 1999-04-08 2007-10-02 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
WO2000061192A2 (en) * 1999-04-08 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment of pancreatitis
US6843998B1 (en) 1999-04-08 2005-01-18 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
US7897157B2 (en) 1999-08-25 2011-03-01 Allergan, Inc. Activatable clostridial toxins
JP2003507073A (en) * 1999-08-25 2003-02-25 アラーガン・セイルズ・インコーポレイテッド Activable recombinant neurotoxin
WO2001014570A1 (en) * 1999-08-25 2001-03-01 Allergan Sales, Inc. Activatable recombinant neurotoxins
US8273358B2 (en) 1999-08-25 2012-09-25 Allergan, Inc. Activatable clostridial toxins
US8211671B2 (en) 1999-08-25 2012-07-03 Allergan, Inc. Activatable recombinant neurotoxins
US8119370B2 (en) 1999-08-25 2012-02-21 Allergan, Inc. Activatable recombinant neurotoxins
AU777556B2 (en) * 1999-08-25 2004-10-21 Allergan, Inc. Activatable recombinant neurotoxins
US8071110B2 (en) 1999-08-25 2011-12-06 Allergan, Inc. Activatable clostridial toxins
US8003351B2 (en) 1999-08-25 2011-08-23 Allergan, Inc. Activatable recombinant neurotoxins
EP2267009A3 (en) * 1999-08-25 2011-04-20 Allergan, Inc. Activatable recombinant neurotoxins
US7985411B2 (en) 1999-08-25 2011-07-26 Allergan, Inc. Activatable recombinant neurotoxins
US7959933B2 (en) 1999-08-25 2011-06-14 Allergan, Inc. Activatable recombinant neurotoxins
EP2267008A3 (en) * 1999-08-25 2011-04-20 Allergan, Inc. Activatable recombinant neurotoxins
EP2264052A3 (en) * 1999-08-25 2011-04-20 Allergan, Inc. Activatable recombinant neurotoxins
EP2267010A3 (en) * 1999-08-25 2011-04-20 Allergan, Inc. Activatable recombinant neurotoxins
EP2267008A2 (en) 1999-08-25 2010-12-29 Allergan, Inc. Activatable recombinant neurotoxins
EP2267010A2 (en) 1999-08-25 2010-12-29 Allergan, Inc. Activatable recombinant neurotoxins
EP2267009A2 (en) 1999-08-25 2010-12-29 Allergan, Inc. Activatable recombinant neurotoxins
EP2264052A2 (en) 1999-08-25 2010-12-22 Allergan, Inc. Activatable recombinant neurotoxins
EP1206554B2 (en) † 1999-08-25 2010-10-20 Allergan, Inc. Activatable recombinant neurotoxins
US7749514B2 (en) 1999-08-25 2010-07-06 Allergan, Inc. Activatable clostridial toxins
US7740868B2 (en) 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
EP1700918A2 (en) 1999-08-25 2006-09-13 Allergan, Inc. Activatable recombinant neurotoxins
US7709228B2 (en) 1999-08-25 2010-05-04 Allergan, Inc. Activatable recombinant neurotoxins
US7132259B1 (en) 1999-08-25 2006-11-07 Allergan, Inc. Activatable recombinant neurotoxins
US7422877B2 (en) 1999-08-25 2008-09-09 Allergan, Inc. Activatable recombinant neurotoxins
US7419676B2 (en) 1999-08-25 2008-09-02 Allergan, Inc. Activatable recombinant neurotoxins
EP1700918A3 (en) * 1999-08-25 2007-09-05 Allergan, Inc. Activatable recombinant neurotoxins
JP2011184459A (en) * 1999-09-23 2011-09-22 Syntaxin Ltd Inhibition of secretion from non-neuronal cell
AU782457B2 (en) * 1999-09-23 2005-07-28 Ipsen Bioinnovation Limited Inhibition of secretion from non-neuronal cells
JP2003509476A (en) * 1999-09-23 2003-03-11 マイクロバイオロジカル リサーチ オーソリティ Inhibition of secretion from non-neuronal cells
EP2110142A2 (en) 1999-09-23 2009-10-21 Syntaxin Limited Inhibition of secretion from non-neuronal cells
WO2001021213A2 (en) * 1999-09-23 2001-03-29 Microbiological Research Authority Inhibition of secretion from non-neuronal cells
WO2001021213A3 (en) * 1999-09-23 2002-07-11 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
JP2014037429A (en) * 1999-09-23 2014-02-27 Syntaxin Ltd Inhibition of secretion from nonneural cell
AU2005227383B2 (en) * 1999-09-23 2008-08-21 Ipsen Bioinnovation Limited Inhibition of secretion from non-neuronal cells
AU2008241572B2 (en) * 1999-09-23 2011-01-27 Ipsen Bioinnovation Limited Inhibition of secretion from non-neuronal cells
US8852603B2 (en) 1999-09-23 2014-10-07 Syntaxin Limited Inhibition of secretion from non-neuronal cells
EP2110142A3 (en) * 1999-09-23 2013-02-27 Syntaxin Limited Inhibition of secretion from non-neuronal cells
JP2011074091A (en) * 1999-09-23 2011-04-14 Syntaxin Ltd Inhibition of secretion from non-neuronal cell
US6235289B1 (en) 1999-10-12 2001-05-22 Allergan Sales, Inc. Intraspinal methods for treating pain
US6333037B1 (en) 1999-10-12 2001-12-25 Allergan Sales Inc. Methods for treating pain with a modified neurotoxin
US6372226B2 (en) 1999-10-12 2002-04-16 Allergan Sales, Inc. Intraspinal botulinum toxin for treating pain
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US7833535B2 (en) 2000-01-19 2010-11-16 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7262291B2 (en) 2000-01-19 2007-08-28 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7736659B2 (en) 2000-01-19 2010-06-15 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7622127B2 (en) 2000-01-19 2009-11-24 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7780968B2 (en) 2000-01-19 2010-08-24 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7244436B2 (en) 2000-01-19 2007-07-17 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US8017131B2 (en) 2000-01-19 2011-09-13 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
WO2001053336A1 (en) * 2000-01-19 2001-07-26 Allergan Sales, Inc. Clostridial toxin derivatives and methods for treating pain
US7704512B2 (en) 2000-01-19 2010-04-27 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6500436B2 (en) 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7244437B2 (en) 2000-01-19 2007-07-17 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7413742B2 (en) 2000-01-19 2008-08-19 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7056729B2 (en) 2000-01-19 2006-06-06 Allergan, Inc. Botulinum neurotoxin-substance P conjugate or fusion protein for treating pain
US6641820B1 (en) 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US7425338B2 (en) 2000-01-19 2008-09-16 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6821520B2 (en) 2000-02-15 2004-11-23 Allergan, Inc. Clostridial toxin therapy for Hashimoto's thyroiditis
US7468189B2 (en) 2000-04-14 2008-12-23 Allergan, Inc. Neuropathic pain treatment method
US7361358B2 (en) 2000-04-14 2008-04-22 Allergan, Inc. Treatment of a facial pain by peripheral administration of a neurotoxin
US7276245B2 (en) 2000-04-14 2007-10-02 Allergan, Inc. Method for treating hyperalgesia by peripheral administration of a neurotoxin
US7294339B2 (en) 2000-04-14 2007-11-13 Allergan, Inc. Method for treating allodynia by peripheral administration of a neurotoxin
US7291344B2 (en) 2000-04-14 2007-11-06 Allergan, Inc. Method for treating phantom pain by peripheral administration of a neurotoxin
US7172763B2 (en) 2000-04-14 2007-02-06 Allergan, Inc. Post-operative pain treatment by peripheral administration of a neurotoxin
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6869610B2 (en) 2000-04-14 2005-03-22 Allergan Sales, Inc. Pain treatment by peripheral administration of a neurotoxin
US7067137B2 (en) 2000-04-14 2006-06-27 Allergan, Inc. Method for treating post herpetic neuralgia by peripheral administration of a neurotoxin
US7288260B2 (en) 2000-04-14 2007-10-30 Allergan, Inc. Method for treating pain by peripheral administration of a neuroptoxin
US7211262B2 (en) 2000-04-14 2007-05-01 Allergan, Inc. Burn pain treatment by peripheral administration of a neurotoxin
US6831059B2 (en) 2000-10-20 2004-12-14 Allergan, Inc. Compositions and methods for treating gonadotrophin related illnesses
WO2002036758A3 (en) * 2000-11-06 2004-02-19 Us Army Med Res Mat Command Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
WO2002036758A2 (en) * 2000-11-06 2002-05-10 United States Army Medical Research And Material Command Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US7888469B2 (en) 2000-11-17 2011-02-15 Allergan, Inc. Post-translation modification and clostridial neurotoxins
WO2002040506A3 (en) * 2000-11-17 2003-03-27 Allergan Inc Modified clostridial neurotoxins with altered biological persistence
US7893202B1 (en) 2000-11-17 2011-02-22 Allergan, Inc. Post-translational modifications and Clostridial neurotoxins
US8119767B2 (en) 2000-11-17 2012-02-21 Allergan, Inc. Post-translational modifications and clostridial neurotoxins
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
AU2002228684B2 (en) * 2000-11-29 2007-01-25 Allergan, Inc. Neurotoxins with enhanced target specificity
AU2002228684B9 (en) * 2000-11-29 2007-03-22 Allergan, Inc. Neurotoxins with enhanced target specificity
US8309686B2 (en) 2000-11-29 2012-11-13 Allergan, Inc. Neurotoxins with enhanced target specificity
WO2002044199A2 (en) * 2000-11-29 2002-06-06 Allergan, Inc. Neurotoxins with enhanced target specificity
WO2002044199A3 (en) * 2000-11-29 2003-11-06 Allergan Inc Neurotoxins with enhanced target specificity
US7456272B2 (en) 2000-11-29 2008-11-25 Allergan, Inc. Neurotoxins with enhanced target specificity
EP2204183A1 (en) 2002-02-08 2010-07-07 Allergan, Inc. Treatment of neuroblastoma
US7140371B2 (en) 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US6688311B2 (en) 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US7234469B2 (en) 2002-03-14 2007-06-26 Allergan, Inc. Surface topography method for determining effect of a botulinum toxin upon a muscle
US9006395B2 (en) 2002-09-12 2015-04-14 The Secretary Of State For Health Recombinant toxin fragments
WO2004024909A2 (en) * 2002-09-12 2004-03-25 Health Protection Agency Recombinant colstridium neurotoxin fragments
EP2280066A3 (en) * 2002-09-12 2011-05-11 Health Protection Agency Recombinant clostridium neurotoxin fragments
US20110028691A1 (en) * 2002-09-12 2011-02-03 The Health Protection Agency Recombinant toxin fragments
AU2003267559B2 (en) * 2002-09-12 2008-08-14 The Secretary Of State For Health Recombinant colstridium neurotoxin fragments
WO2004024909A3 (en) * 2002-09-12 2004-07-08 Health Prot Agency Recombinant colstridium neurotoxin fragments
WO2004078202A1 (en) 2003-03-03 2004-09-16 Allergan, Inc. Clostridial neurotoxins for treating uterine disorders
WO2005023309A3 (en) * 2003-09-11 2005-09-15 Health Prot Agency Design of re-targeted toxin conjugates
WO2005023309A2 (en) 2003-09-11 2005-03-17 Health Protection Agency Design of re-targeted toxin conjugates
AU2004269979B2 (en) * 2003-09-11 2009-12-10 Ipsen Bioinnovation Limited Design of re-targeted toxin conjugates
WO2006010360A3 (en) * 2004-07-22 2007-12-27 Biotecon Therapeutics Gmbh Carrier for medicaments for obtaining oral bioavailability
WO2006010360A2 (en) * 2004-07-22 2006-02-02 Biotecon Therapeutics Gmbh Carrier for medicaments for obtaining oral bioavailability
WO2006060044A1 (en) * 2004-08-02 2006-06-08 Allergan, Inc. Toxin compounds with enhanced membrane translocation characteristics
EP1990059A2 (en) 2004-08-27 2008-11-12 Allergan, Inc. Methods for treating cancer
US7429386B2 (en) 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
US7438921B2 (en) 2004-09-03 2008-10-21 Allergan, Inc. Buttock deformity treatment
US7179474B2 (en) 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
US8920777B2 (en) 2004-10-21 2014-12-30 Igf Oncology, Llc Toxins and radionuclides coupled to IGF-1 receptor ligands for treatment of cancer
EP1812082A2 (en) * 2004-10-21 2007-08-01 IGF Oncology, LLC Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer
WO2006047214A2 (en) 2004-10-21 2006-05-04 Igf Oncology, Llc Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer
EP1812082A4 (en) * 2004-10-21 2010-06-02 Igf Oncology Llc Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer
US8865186B2 (en) 2004-11-22 2014-10-21 New York University Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
US20120021002A1 (en) * 2004-11-22 2012-01-26 New York University Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
US8044188B2 (en) 2004-11-22 2011-10-25 New York University Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
US7785606B2 (en) * 2004-11-22 2010-08-31 New York University Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
WO2006059113A3 (en) * 2004-12-01 2006-09-28 Health Prot Agency Fusion proteins comprising a non-cytotoxic protease, a targeting moiety, a protease cleavage site and a translocation domain
US8187834B2 (en) 2004-12-01 2012-05-29 Syntaxin, Ltd. Non-cytotoxic protein conjugates
EP2335718A1 (en) 2004-12-01 2011-06-22 Health Protection Agency Non-cytotoxic protein conjugates
EP2292249A1 (en) 2004-12-01 2011-03-09 Health Protection Agency Non-cytotoxic protein conjugates
WO2006059113A2 (en) 2004-12-01 2006-06-08 Health Protection Agency Fusion proteins comprising a non-cytotoxic protease, a targeting moiety, a protease cleavage site and a translocation domain
AU2012203056B2 (en) * 2004-12-01 2014-03-20 Allergan Inc. Fusion proteins
EP2366399A1 (en) 2004-12-01 2011-09-21 Health Protection Agency Non-cytotoxic protein conjugates
EP2204182A1 (en) * 2004-12-01 2010-07-07 Health Protection Agency Non-cytotoxic protein conjugates
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8067200B2 (en) 2004-12-01 2011-11-29 Syntaxin Ltd. Fusion proteins
US7659092B2 (en) 2004-12-01 2010-02-09 Syntaxin, Ltd. Fusion proteins
US7658933B2 (en) 2004-12-01 2010-02-09 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US10619146B2 (en) 2004-12-01 2020-04-14 Ipsen Bioinnovation Limited Non-cytotoxic protein conjugates
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8124074B2 (en) 2004-12-01 2012-02-28 Syntaxin Limited Fusion proteins
US9139635B2 (en) 2004-12-01 2015-09-22 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US9474807B2 (en) 2004-12-01 2016-10-25 Ipsen Bioinnovation Limited Non-cytotoxic protein conjugates
US8124405B2 (en) 2004-12-01 2012-02-28 Syntaxin Limited Fusion proteins
AU2005311086B2 (en) * 2004-12-01 2012-03-29 Allergan, Inc. Fusion proteins
AU2012203055B2 (en) * 2004-12-01 2014-03-20 Allergan Inc. Fusion proteins
US9012195B2 (en) 2004-12-01 2015-04-21 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8940870B2 (en) 2004-12-01 2015-01-27 Syntaxin, Ltd. Fusion proteins
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8399400B2 (en) 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
US8372615B2 (en) 2004-12-01 2013-02-12 Syntaxin, Limited Fusion proteins
US8399401B2 (en) 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
US8956847B2 (en) 2004-12-01 2015-02-17 Syntaxin Limited Fusion proteins
US8128940B2 (en) 2005-03-15 2012-03-06 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7419675B2 (en) 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
WO2008008082A2 (en) * 2005-09-19 2008-01-17 Allergan, Inc. Clostridial toxin activatable clostridial toxins
WO2008008082A3 (en) * 2005-09-19 2008-05-15 Allergan Inc Clostridial toxin activatable clostridial toxins
EP2377881A3 (en) * 2005-09-19 2012-03-07 Allergan, Inc. Clostridial toxin activatable clostridial toxins
US7556817B2 (en) * 2005-09-19 2009-07-07 Allergan, Inc. Clostridial toxin activatable Clostridial toxins
EP2154151A3 (en) * 2005-09-19 2010-03-10 Allergan, Inc. Clostridial toxin activatable clostridial toxins
US7815917B2 (en) 2005-09-19 2010-10-19 Allergan, Inc. Botulinum neurotoxin serotype B activatable Botulinum neurotoxin serotype Bs
US8372405B2 (en) 2005-10-07 2013-02-12 Health Protection Agency Proteins with improved solubility and methods for producing and using same
WO2007138336A3 (en) * 2006-06-01 2008-12-11 Syntaxin Ltd Treatment of pain by single chain, polypeptide fusion protein
WO2007138336A2 (en) * 2006-06-01 2007-12-06 Syntaxin Limited Treatment of pain by single chain, polypeptide fusion protein
US9072736B2 (en) 2006-06-01 2015-07-07 Allergan, Inc. Treatment of pain
WO2007138339A3 (en) * 2006-06-01 2008-11-27 Syntaxin Ltd Treatment of pain by use of a single chain polypeptide fusion protein
US9243301B2 (en) 2006-06-01 2016-01-26 Allergan, Inc. Fusion proteins
CN101495135B (en) * 2006-06-01 2013-10-30 赛恩泰新公司 Treatment of pain by use of single chain polypeptide fusion protein
WO2007138339A2 (en) * 2006-06-01 2007-12-06 Syntaxin Limited Treatment of pain by use of a single chain polypeptide fusion protein
EP2038299A2 (en) 2006-07-11 2009-03-25 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
US7993656B2 (en) 2006-07-11 2011-08-09 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
US8518417B1 (en) 2006-07-11 2013-08-27 Allergan, Inc. Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
WO2008008805A3 (en) * 2006-07-11 2008-04-10 Allergan Inc Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
WO2008008805A2 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
CN102083451A (en) * 2008-06-12 2011-06-01 赛恩泰新公司 Suppression of cancers
EP3473643A1 (en) 2008-06-12 2019-04-24 Ipsen Bioinnovation Limited Fusion proteins for use in the treatemnt of cancer
EP3590956A1 (en) 2008-06-12 2020-01-08 Ipsen Bioinnovation Limited Suppression of neuroendocrine diseases
US10240138B2 (en) 2008-06-12 2019-03-26 Ipsen Bioinnovation Limited Polypeptides that bind to and inhibit secretion from growth hormone secreting cells
US10550377B2 (en) 2008-06-12 2020-02-04 Ipsen Bioinnovation Limited Suppression of prostate cancer using a targeted clostridial neurotoxin
EP3241560A1 (en) 2008-11-17 2017-11-08 Ipsen Bioinnovation Limited Suppression of cancer
EP2664343A2 (en) 2008-11-17 2013-11-20 Syntaxin Limited Suppression of cancer
US8980284B2 (en) 2010-01-25 2015-03-17 New York University Recombinant derivatives of botulinum neurotoxins engineered for trafficking studies and neuronal delivery
CN103649317A (en) * 2011-05-16 2014-03-19 辛它可辛有限公司 Therapeutic fusion proteins
US10704038B2 (en) 2011-05-16 2020-07-07 Ipsen Bioinnovation Limtied Therapeutic fusion proteins
CN103649317B (en) * 2011-05-16 2015-10-21 辛它可辛有限公司 Therapeutic fusion proteins
KR102032760B1 (en) 2011-05-16 2019-10-16 입센 바이오이노베이션 리미티드 Therapeutic fusion proteins
WO2012156743A1 (en) 2011-05-16 2012-11-22 Syntaxin Limited Therapeutic fusion proteins
US10081803B2 (en) 2011-05-16 2018-09-25 Ipsen Bioinnovation Limited Therapeutic fusion proteins
KR20140036239A (en) * 2011-05-16 2014-03-25 신택신 리미티드 Therapeutic fusion proteins
WO2013180799A1 (en) 2012-05-30 2013-12-05 President And Fellows Of Harvard College Engineered botulinum neurotoxin
US10844362B2 (en) 2012-05-30 2020-11-24 President And Fellows Of Harvard Engineered botulinum neurotoxin
EP3372239A1 (en) 2012-05-30 2018-09-12 President and Fellows of Harvard College Engineered botulinum neurotoxin
US9598685B2 (en) 2012-05-30 2017-03-21 President And Fellows Of Harvard College Engineered botulinum neurotoxin
US10190110B2 (en) 2012-05-30 2019-01-29 President And Fellows Of Harvard College Engineered botulinum neurotoxin
EP3246405A1 (en) 2012-08-27 2017-11-22 Ipsen Bioinnovation Limited Fusion proteins and methods for treating, preventing or ameliorating pain
WO2014033441A1 (en) 2012-08-27 2014-03-06 Syntaxin Limited Fusion proteins and methods for treating, preventing or ameliorating pain
US11248219B2 (en) 2012-08-27 2022-02-15 Ipsen Bioinnovation Limited Fusion proteins comprising a non-cytotoxic protease, a translocation domain, and a targeting moiety that binds a galanin receptor and methods for treating, preventing or ameliorating pain using such fusion proteins
WO2014053651A1 (en) 2012-10-04 2014-04-10 Dublin City University Biotherapy for pain
US9170252B2 (en) 2012-10-23 2015-10-27 Ipsen Bioinnovation Limited Assay for assessment of endosomal transport
CN104870468B (en) * 2012-11-21 2020-11-10 益普生生物创新有限公司 Method for producing proteolytically processed polypeptide
CN104870468A (en) * 2012-11-21 2015-08-26 突触融合蛋白有限公司 Methods for the manufacture of proteolytically processed polypeptides
US9315549B2 (en) 2013-01-28 2016-04-19 New York University Treatment methods using atoxic neurotoxin derivatives
EP3943105A2 (en) 2013-07-09 2022-01-26 Ipsen Bioinnovation Limited Cationic neurotoxins
US11034947B2 (en) 2013-07-09 2021-06-15 Ipsen Bioinnovation Limited Cationic neurotoxins
US10457927B2 (en) 2013-12-23 2019-10-29 Dublin City University Multiprotease therapeutics for chronic pain
US11897921B2 (en) 2014-12-09 2024-02-13 New York University Propeptide fusion comprising a mutated clostridium botulinum neurotoxin and a VHH domain
EP3822286A1 (en) 2015-01-09 2021-05-19 Ipsen Bioinnovation Limited Cationic neurotoxins
US11268080B2 (en) 2015-03-26 2022-03-08 President And Fellows Of Harvard College Engineered botulinum neurotoxin
WO2016154534A1 (en) 2015-03-26 2016-09-29 President And Fellows Of Harvard College Engineered botulinum neurotoxin
EP3981783A1 (en) 2015-03-26 2022-04-13 President And Fellows Of Harvard College Engineered botulinum neurotoxin
EP3650462A1 (en) 2015-10-02 2020-05-13 Ipsen Biopharm Limited Method for purifying clostridial neurotoxin
WO2018002348A1 (en) 2016-07-01 2018-01-04 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
US11117935B2 (en) 2016-08-24 2021-09-14 President And Fellows Of Harvard College Engineered botulinum neurotoxin
WO2018039506A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Engineered botulinum neurotoxin
EP3782605A1 (en) 2016-08-26 2021-02-24 Hugel Inc. Liquid formulation containing botulinum toxin and stabilizing agent, and preparation method therefor
EP3777837A1 (en) 2016-08-26 2021-02-17 Hugel Inc. Liquid formulation containing botulinum toxin and stabilizing agent, and preparation method therefor
WO2018050699A1 (en) 2016-09-16 2018-03-22 Ipsen Biopharm Limited Method for producing di-chain clostridial neurotoxins
WO2018060351A1 (en) 2016-09-29 2018-04-05 Ipsen Biopharm Limited Hybrid neurotoxins
WO2018073288A1 (en) 2016-10-18 2018-04-26 Ipsen Biopharm Limited Cellular vamp cleavage assay
WO2018075783A2 (en) 2016-10-20 2018-04-26 President And Fellows Of Harvard College In vitro and cell based assays for measuring the activity of botulinum neurotoxins
US11306347B2 (en) 2016-10-20 2022-04-19 President And Fellows Of Harvard College In vitro and cell based assays for measuring the activity of botulinum neurotoxins
US11788069B2 (en) 2016-10-20 2023-10-17 President And Fellows Of Harvard College In vitro and cell based assays for measuring the activity of botulinum neurotoxins
EP3470054A1 (en) 2017-10-11 2019-04-17 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
WO2019145577A1 (en) 2018-01-29 2019-08-01 Ipsen Biopharm Limited Non-neuronal snare-cleaving botulinum neurotoxins
WO2019162696A1 (en) 2018-02-26 2019-08-29 Ipsen Biopharm Limited Use of ultrasound to guide injection of non-cytotoxic protease
WO2019224184A1 (en) 2018-05-21 2019-11-28 Ipsen Biopharm Limited Suppression of bone cancer-induced allodynia
WO2020065336A1 (en) 2018-09-28 2020-04-02 Ipsen Biopharm Limited Clostridial neurotoxins comprising an exogenous activation loop
EP3660509A1 (en) 2018-11-29 2020-06-03 Abbio Inc. A cell-based method for determining an activity of botulinum toxin
EP3825689A2 (en) 2018-11-29 2021-05-26 Hugel Inc. A cell-based method for determining an activity of botulinum toxin
WO2020115490A1 (en) 2018-12-05 2020-06-11 Ipsen Biopharm Limited Treatment of symptoms of traumatic brain injury
WO2020148542A1 (en) 2019-01-16 2020-07-23 Ipsen Biopharm Limited Sortase-labelled clostridium neurotoxins
WO2021064369A1 (en) 2019-09-30 2021-04-08 Ipsen Biopharm Limited Use of chlostridial neurotoxin variant for the treatment of neurological disorders
WO2022153057A1 (en) 2021-01-15 2022-07-21 Ipsen Biopharm Limited Treatment of brain damage
WO2022200809A1 (en) 2021-03-26 2022-09-29 Ipsen Biopharm Limited Clostridial neurotoxins comprising an exogenous activation loop
WO2022208039A1 (en) 2021-03-30 2022-10-06 Ipsen Biopharm Limited Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders
WO2022208091A1 (en) 2021-03-30 2022-10-06 Ipsen Biopharm Limited Treatment of pain & inflammatory disorders
WO2023089338A1 (en) 2021-11-22 2023-05-25 Ipsen Biopharm Limited Treatment of visceral pain
WO2023105289A1 (en) 2021-12-06 2023-06-15 Dublin City University Methods and compositions for the treatment of pain
WO2024069175A1 (en) 2022-09-28 2024-04-04 Ipsen Biopharm Limited Clostridial neurotoxins comprising an activating endosomal protease cleavage site
WO2024069176A1 (en) 2022-09-28 2024-04-04 Ipsen Biopharm Limited Clostridial neurotoxins comprising an activating exogenous protease cleavage site

Also Published As

Publication number Publication date
US8454976B2 (en) 2013-06-04
DK0939818T3 (en) 2005-08-29
AU723397B2 (en) 2000-08-24
US20050244435A1 (en) 2005-11-03
US8017134B2 (en) 2011-09-13
US20020044950A1 (en) 2002-04-18
GB9625996D0 (en) 1997-01-29
CA2264191A1 (en) 1998-02-26
DE69733146D1 (en) 2005-06-02
ZA977541B (en) 1998-05-27
US20090246827A1 (en) 2009-10-01
US20070248626A1 (en) 2007-10-25
AU4389597A (en) 1998-03-06
DE69733146T2 (en) 2006-03-09
CA2264191C (en) 2012-01-17
JP4273250B2 (en) 2009-06-03
JP2001502890A (en) 2001-03-06
EP0939818A1 (en) 1999-09-08
US20070184070A1 (en) 2007-08-09
ATE294238T1 (en) 2005-05-15
GB9617671D0 (en) 1996-10-02
US6461617B1 (en) 2002-10-08
US20090274708A1 (en) 2009-11-05
US20090148888A1 (en) 2009-06-11
EP0939818B1 (en) 2005-04-27
US7897158B2 (en) 2011-03-01
US7674470B2 (en) 2010-03-09
US8012479B2 (en) 2011-09-06

Similar Documents

Publication Publication Date Title
US6461617B1 (en) Recombinant toxin fragments
CA2498502C (en) Recombinant clostridial toxin fragments with proteolytic activation
US8012491B2 (en) Recombinant toxin fragments
KR100338894B1 (en) Vaccine compositions
EP0833919B1 (en) Type f botulinum toxin and use thereof
WO1995030016A1 (en) Methods for peptide synthesis and purification
Wang et al. Preparation of a peptide vaccine against GnRH by a bioprocess system based on asparaginase
JP4273250B6 (en) Recombinant toxin fragment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997942094

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2264191

Country of ref document: CA

Ref country code: CA

Ref document number: 2264191

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 510524

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09242689

Country of ref document: US

Ref document number: 09255829

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997942094

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1997942094

Country of ref document: EP